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3. ABBREVIATIONS
AIDS acquired immunodeficiency syndrome
ALL acute lymphoblastic leukemia
ALT alanine aminotransferase




CAEBV chronic active EBV infection






CTL cytotoxic T lymphocyte
CyA cyclosporin A
DLI donor lymphocyte infusion
EA early antigen
EBER Epstein-Barr-encoded RNA




GAPDH glyceraldehyde 3-phosphate dehydrogenase
GVHD graft-versus-host disease
HHV-6 human herpesvirus 6
HHV-7 human herpesvirus 7
HIV human immunodeficiency virus
HD Hodgkin’s lymphoma
HPV human papilloma virus
IFA immunofluorescence assay
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IHD ischemic heart disease
IL interleukin
ITAM immunoreceptor tyrosine-based activation motif
LCL lymphoblastoid cell line
LMP latent membrane protein





PBS phosphate buffered saline
PBST phosphate buffered saline-Tween
PCR polymerase chain reaction
PNA peptide nucleic acid
PTLD post-transplant lymphoproliferative disorder
QPCR real-time quantitative polymerase chain reaction
RNA ribonucleic acid
SCT stem cell transplantation
SOT solid organ transplantation
TBI total body irradiation
UNCT undifferentiated carcinoma of nasopharyngeal type
VCA viral capsid antigen
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4. SUMMARY
Serological diagnosis of Epstein-Barr virus (EBV) infections is classically based on detection of
heterophile antibodies and on measurement of antibody reactivity for various EBV antigens.
Characteristic of EBV primary infection are positive viral capsid antigen (VCA) IgM and IgG and
lack of Epstein-Barr virus nuclear antigen (EBNA)-1 antibodies. During convalescence, VCA IgM
antibodies usually disappear and the EBNA-1 becomes detectable, while VCA IgG persists for life.
Avidity of VCA IgG separates primary and secondary infections both in immunocompetent and
immunocompromised individuals. Reactivations of EBV have been encountered among
immunocompromised hosts such as organ transplant recipients or patients with human
immunodeficiency virus (HIV) infection but also among immunocompetent individuals.
Serological diagnosis of herpes virus infections is hampered by concurrent expression of IgM for
heterologous members of this virus family. In serological diagnosis of mononucleosis it is quite
common to encounter EBV IgM-positive patients with high-avidity VCA IgG antibodies indicating
past immunity. To assess the frequency of such diagnostic findings and to understand their etiology,
we used specific EBV IgG, IgM and IgG avidity tests among immunocompetent or immuno-
suppressed patients with well-documented cytomegalovirus (CMV) primary infection. Among
EBV-seropositive patients with CMV primary infection, a large proportion (23%) showed antibody
profiles of EBV reactivation. In contrast, EBV primary infections did not appear to induce
immunoreactivation of CMV.
We also wanted to clarify the viral etiology of malignancies occurring after heart transplantation.
During the years 1985 and 1999 a total of 249 cardiac transplantations were performed at the
Helsinki University Central Hospital. Twenty recipients were diagnosed as having a malignant
tumor. We determined the presence of EBV by an in situ hybridisation assay (see below) and
manifest CMV infections by immunochemical quantitation. Half of the lymphomas expressed EBV
RNA. The majority of the patients with EBV positive lymphomas had a history of post-transplant
CMV infection. The result suggests that CMV might have a contributory role in the development of
EBV-associated lymphomas.
Epstein-Barr virus associated post-transplant lymphoproliferative disease (PTLD) is a life
threatening complication of allogeneic stem cell or solid organ transplantation. Following organ
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transplantation the incidence rate of this syndrome varies according to the type of graft and the
immunosuppressive regimen. One of our goals was to evaluate the incidence of symptomatic EBV
infections after organ transplantation and to improve the diagnosis of PTLD. First, we set up an in
situ hybridisation assay for detection of EBV RNA in tissue sections. Second, we set up in 1999
– to our knowledge first in Finland for any microbial pathogen – a quantitative EBV-DNA-PCR
(qPCR), and assessed its diagnostic value by using ordinary serum samples.
Diagnosis of PTLD after stem-cell transplantation has been demanding to many reasons:
conventional serology is not useful, tissue biopsies are needed for the in situ hybridisation assay,
lack of specific clinical signs or symptoms and rapid progression of the disease. We determined the
incidence of fatal PTLD among 257 allogenic stem cell transplantations (SCT) performed in
Finland during 1994-1999. The patients in studies III and IV are also included in the larger patient
material in study VI. The post-morten analysis revealed 18 cases of PTLD. From a subset of the
PTLD cases identified (12/18) and a series of corresponding stem-cell recipient controls (36),
consecutive samples of serum were studied by EBV qPCR. All the PTLD patients were positive for
EBV-DNA with progressively rising copy numbers. In most PTLD patients EBV-DNA became
detectable 70 days after SCT or 23 days before death; i.e. earlier than symptoms which appeared 15
days before death. Among SCT control group, EBV-DNA occurred only sporadically and EBV-
DNA levels remained relatively low (below 21x103 per ml). We concluded that qPCR for EBV-
DNA in serum is a highly sensitive (100%) and specific (96%) diagnostic approach. Intensely
immunosuppressed stem-cell recipients are at a great risk of developing PTLD and can now be
monitored for EBV-DNA as an indicator for pre-emptive treatment of this life-threatening disease.
Subsequently, the relationship between the occurrence of EBV-associated PTLD and the intensity
of immunosuppression was determined. All the patients who developed PTLD had been given anti-
thymocyte globulin (ATG) either for treatment of steroid-resistant acute graft-versus-host disease
(GVHD) or as a part of conditioning (all patients receiving an unrelated donor transplant). In
conclusion, in transplantations from an HLA-identical donor with a non-T-cell depleted graft, the
risk of PTLD correlated strongly with the intensity and quality of the immunosuppressive treatment.
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Furthermore, we wanted to find out how often and how severely do EBV related complications
exist after liver transplantation in Finland; 105 adult liver transplant recipients were retrospectively
monitored for EBV infections by EBV qPCR of sequential plasma samples (1284) obtained during
the first year after transplantation, and also for CMV, human herpesvirus-6 and -7. EBV DNA was
detected in fourteen patients (13%) during the first 12 months; 4% of the plasma specimens
contained EBV DNA. Most EBV reactivations occurred concomitantly with the betaherpes viruses.
All the EBV DNAemias with low copy number subsided quickly. The peak viral loads of 13
patients were relatively low (below 6.6x103 per ml). No clinical signs or symptoms could be
attributed to these EBV-DNAemias. Although most EBV reactivations were harmless, fatal PTLD
was diagnosed in one patient. In conclusion, as liver transplantations are concerned, EBV PTLD is a
rare but hazardous disease. Also among liver transplant recipients EBV qPCR seems to be essential
for the diagnosis of PTLD. During PTLD treatment, follow-up of EBV DNA levels is highly useful
for guidance of therapy decisions.
Finally, we wanted to determine the number and clinical significance of EBV infections among a
large cohort of allogenic, unselected stem cell transplant (SCT) recipients. Of the 406 SCT
performed in Helsinki during 1988-1999, 5479 consecutive samples of serum were retrospectively
studied by quantitative EBV PCR, and the clinical data were reviewed. Patients in study III and IV
are part of this analysis. Overall, EBV DNA in at least one serum sample was seen in 57 (14.0%)
patients, of whom 22 (5.4%) showed progressively rising and ultimately high (>50 000) levels of
EBV DNA (median 54 million copies/ml). In addition, 16 (4.0%) patients showed EBV DNA in
low copy numbers (median 5370 /ml) shortly before death. Among the SCT survivors, transient
EBV-DNAemias (median 6300 /ml), apparently corresponding to asymptomatic EBV infections
were seen in 19 (4.7%) patients. Thereby, low-level EBV-DNA positivity in serum occurs relatively
frequently after SCT and may subside without specific treatment. However, high molecular copy
numbers (>50 000) predict the development of PTLD very strongly, are not spontaneously
reversible, and warrant immediate treatment. In molecular diagnosis, the first criterion is the EBV
DNA level: low (<50 000 copies/ml) or high (>50 000 copies/ml). If this EBV DNA level is
50 000, the patient can be classified as having life-threatening EBV infection. If this initial EBV
DNA level is <50 000, the rapidity of the increase in the DNA levels is considered, according to the
mean value of the derivatives of the log-transformed EBV DNA values. If this value exceeds 3.6,
the patient is at a high risk of having life-threatening EBV infection.
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5. INTRODUCTION
Infection by Epstein-Barr virus (EBV) occurs in approximately 95% of the world’s adult
population. After primary infection, the virus persists lifelong in circulating B-lymphocytes and free
virus is intermittently detectable in saliva (Gerber et al., 1972). In developing countries, primary
infection usually occurs during the first few years of life and is often asymptomatic. However, in
developed populations, primary infection is often delayed until adolescence or adulthood, in many
cases producing the characteristic clinical features of infectious mononucleosis, including sore
throath, fever, malaise, lymphadenopathy, and mild hepatitis (Henle et al., 1968).
EBV was the first human virus implicated in oncogenesis. EBV has been implicated in the
pathogenesis of lymphoid and epithelial malignancies including endemic Burkitt’s lymphoma,
undifferentiated nasopharyngeal carcinoma, Hodgkin’s lymphoma, the immunodeficiency-related
non-Hodgkin’s lymphomas, post-transplant lymphoproliferative disease (PTLD), some T cell
lymphomas, and more recently certain cancers of the stomach and smooth muscle (Burkitt, 1962;
zur Hausen et al., 1970; Hanto et al., 1981 and 1982; Strauss et al., 1993; Baumforth et al., 1999).
In 1964, Epstein and his co-workers identified herpes-virus like particles by EM in a cell line
established from a Burkitt’s lymphoma biopsy (Epstein et al., 1964). Subsequently, it was shown
that sera from patients with Burkitt’s lymphoma had much higher antibody titres to EBV antigens
than did controls (Klein et al., 1966; Epstein 1973; Henle et Henle, 1979). The detection of EBV
DNA in Burkitt’s lymphoma and nasopharyngeal carcinoma tumour cells, and the experimental
production in 1973 of lymphomas in cotton top marmosets and owl monkeys exposed to EBV,
strongly suggests that this virus has oncogenic potential in both human and non-human primates
(Miller et al., 1977). Lehtinen et al. (1993) have reported elevated EBV early antigen (EA) and
EBV nuclear antigen (EBNA) antibody levels associated with increased risk of malignant
lymphoma. These elevated antibody responses may be due to destruction of neoplastic EBV
positive B-cells and/or activation of latent EBV infection early in the lymphomagenesis. Although
the EBV genome can be detected in malignant cells, a causative role of EBV in many of these
tumors has not been firmly established.
The precise mechanisms by which EBV transforms cells are only now being elucidated. The virus
appears to adopt different forms of latent infection in different types of tumors. Specific patterns of
latent EBV gene expression are characteristic of the different EBV-associated malignancies.
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Polymorphic non-Hodgkins’s lymphomas which arise in organ transplant recipients, frequently
express the full complement of EBV latent genes (Young et al., 1989). Of these latent genes, latent
membrane protein 1 (LMP1) has been shown to act as a constitutively activated receptor and to
cause aberrant cellular signalling. This illustrates the complex relation between the virus and the
host cell. Another important factor influencing EBV gene expression is the immune response: viral
latent proteins to which immunodominant cytotoxic lymphocyte responses are directed, the Epstein-
Barr virus nuclear antigen 3 (EBNA3) family of proteins, are downregulated in virus-associated
tumors arising in immunocompetent individuals (Murray et al., 2001). Epstein-Barr virus nuclear
protein 1 (EBNA1), an essential protein for the maintenance of EBV infection, has evolved to evade
immunosurveillance by preventing the protein being processed through the MHC class I pathway
(Murray et al., 2001). Studies of the function the EBV latent genes have revealed the ability of these
proteins to target specific cell signalling pathways.
The importance of the immune system in suppressing EBV mediated B cell growth and division is
underscored by the frequent development of EBV associated lymphoproliferative disease in various
immunosuppressive states. The prototypic EBV induced lymphoproliferative disorder arises as a
result of the iatrogenic immunosuppression of organ transplant recipients, although similar
disorders occur in some of the inherited immunodeficiencies and in patients with acquired
immunodeficiency syndrome (AIDS). Lymphoproliferations that arise after iatrogenic
immunosuppression for transplant recipients are almost always of B cell origin, and are known as
post-transplant lymphoproliferative disease or disorders (PTLD). PTLDs are extremely
heterogenous, ranging from polyclonal hyperplasia to aggressive, non-Hodgkin’s lymphoma (Hanto
et al., 1982; O’Reilly et al., 1997; Faye et al., 2005). PTLD may involve virtually any organ system,
including the central nervous system, bone marrow, intestine and lungs.
The association of EBV with malignancy has been characterized by analysis of the terminal repeat
sequences in DNA extracts (Raab-Traub et al., 1986). The linear genomes produced during lytic
infection carry variable numbers of direct tandem 500bp repeats at each end. When the termini of
EBV genome fuse, the number of terminal repeats incorporated is variable and is a property of the
resulting circular episome. This number of terminal repeats appears to be stable through the
multiple rounds of latent replication during cellular proliferation. The demonstration of a single
fused terminal fragment in tumour tissue suggests that the virus has been present through all stages
during monoclonal proliferation of tumour cells and supports the etiological role of EBV in
tumorigenesis (Raab-Traub et al., 1986).
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6. REVIEW OF THE LITERATURE
6.1 HISTORY
In 1958, Denis Burkitt, a British surgeon working in Uganda, described a common cancer affecting
children in regions of equatorial Africa. Burkitt wrote and spoke widely about the unusual
epidemiologic and clinical features of this lymphoma (Burkitt, 1962, 1963 and 1966). The climatic
and geographical distribution of Burkitt’s lymphoma, as it came to be known, led Burkitt to suggest
that a virus might be responsible. After this, Epstein-Barr virus (EBV) was discovered in 1964 by
electron microscopy of cells cultured from Burkitt’s lymphoma tissue by Epstein, Achong, and Barr
(Epstein et al., 1964). Four years later, EBV was found to be the cause of heterophile-positive
infectious mononucleosis (Henle et al., 1968). EBV DNA was detected in tissues from patients with
nasopharyngeal carcinoma in 1970 (zur Hausen et al., 1970). Since then, EBV was found to be
associated with non-Hodgkin’s lymphoma and oral hairy leukoplakia in patients with the acquired
immunodeficiency syndrome (AIDS) (Zieglar et al., 1982; Greenspan et al., 1985). A couple of
years later, EBV was found to be associated with T-cell lymphomas and Hodgkin’s lymphoma
(Jones et al., 1988; Mueller al, 1989).
6.2 CLASSIFICATION
Epstein-Barr virus (EBV) belongs to the herpesvirus family. EBV is a member of the genus
Lymphocryptovirus, which belongs to the gamma herpesvirinae. The gamma herpesvirus subfamily
includes both the gamma 1, or Lymphocryptovirus, and gamma 2, or Rhadinovirus, genera (Kieff et
Rickinson, 2001). EBV is the only human Lymphocryptovirus, and the Kaposi’s sarcoma-associated
herpesvirus is the only human Rhadinovirus (Chang et al., 1994; Kieff et Rickinson, 2001). Many
Old World primate species have their own endemic Lymphocryptovirus, and some New World
primate species also have endemic Lymphocryptoviruses (Kieff et Rickinson, 2001). EBV was the
first lymphocryptovirus to be discovered (Epstein et al, 1964). The other Lymphocryptoviruses have
been named according to their natural host species. The Lymphocryptoviruses are structurally
similar to each other (in genome structure and gene organization) (Kieff et al., 1991 and 2001).
The gamma herpesvirus subfamily classification was established on the basis of similarity in
biologic properties. EBV and Kaposi’s sarcoma-associated herpesvirus have particularly limited
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host ranges and both are associated with human malignancies (Kieff et Rickinson, 2001). These and
other gamma herpesviruses also establish latent infection in lymphocytes, but also beta
herpesviruses such as human herpesvirus 6 (HHV-6), human herpesvirus 7 (HHV-7), and
cytomegalovirus (CMV) latently infect lymphocytes. Taxonomists have renamed EBV as human
herpesvirus 4 (HHV-4). However, most authors still use the name EBV (Kieff et Rickinson, 2001).
6.3 VIRUS AND GENOME STRUCTURE
Kieff and his collegues have described the structure of EBV (Fundamental Virology, 1991 and
Virology 2001): EBV has (1) a toroid-shaped protein core wrapped with DNA (Figure I), (2) a
nucleocapsid with 162 capsomeres, (3) a protein tegument between the nucleocapsid and the
envelope and (4) an outer envelope with external glycoprotein spikes (Kieff et al., 1991). The major
EBV capsid proteins are of 160, 47 and 28kd. The glycoprotein gp350/220 predominates on the
outer envelope (Dolyniuk et al., 1976; Thorley-Lawson et al., 1979). The EBV genome is composed
of linear, douple-stranded 184-kbp DNA; and regions of the EBV genome have become known by
their position on a BamHI restriction endonuclease map of the genome. The characteristic features
of EBV and other lymphocryptoviridae include according to Kieff and his collegues (1991 and
2001): (1) a single overall format and gene arrangement (Given et al., 1978; Dambaugh et al, 1980;
Raab-Traub et al., 1980), (2) tandemly reiterated 0.5-kbp terminal direct repeats (TRs) (Hayward et
al, 1977; Given et al, 1979; Kintner et al. 1979), and (3) tandemly reiterated 3-kbp internal direct
repeats (IRls) (Given D et al., 1979; Hayward et al., 1980; Cheung et al., 1981), which divide the
genome into two largely unique sequence domains (short and long; US and UL). US and UL have
almost all of the genome coding capacity. Although, largely unique DNA, US and UL include
perfect and imperfect tandem DNA repeats, most of which are within ORS (Kieff et Rickinson,
2001).
The reiteration frequency of the EBV tandem perfect repeats becomes variable during viral DNA
replication, with the average number of repeats being identical to the parent genome (Kieff et
Rickinson, 2001). When EBV infects a cell, the genome becomes an episome with a characteristic
number of tandem repeats, dependent on the number in the parental genome, with variation during
viral DNA replication and the unique cleavage and joining events of the single infecting viral
genome (Kieff et Rickinson, 2001). If the infection is nonpermissive for viral replication and
permissive for latent infection, each EBV episome in progeny infected cells will have the same
number of tandem repeats as the parent cell (Kieff et Rickinson, 2001). The number of tandem
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repeats is therefore useful in determining whether a group of latently infected cells arose from a
single common progenitor cell or from multiple cells (Brown et al., 1986; Raab-Traub et al., 1986).
EBV isolates differ in their tandem reiteration frequency. Individual isolates tend to have a constant
number of repeats (Dambaugh et al, 1980; Heller et al., 1981; Raab-Traub et al., 1986; Katz et al,
1988; Kieff et al., 1991). EBV was the first herpesvirus whose genome was completely cloned
(Dambaugh et al., 1980; Raab-Traub et al, 1980) and sequenced (Baer et al., 1984).
Figure I. A toroid form.
6.4 THE MAJOR EBV-OUTER ENVELOPE GLYCOPROTEIN, gp350/220
The major EBV outer-envelope glycoprotein, gp350/220, is the EBV ligand for CD21 (Wells et al.,
1982; Nemerow et al., 1987; Tanner et al., 1987). Gp350 and gp220 are transplated from an
abundant late-replication-cycle EBV mRNA, part of which is spliced in frame to give the mRNA
for the smaller, 220kd, glycoprotein (Biggin et al., 1984; Beisel et al., 1985; Whang et al., 1987).
CD21 is the only B-lymphocyte surface protein which binds to gp350/220 (Tanner et al., 1987).
Soluble gp350/220 can saturate B-lymphocyte receptors and block virus infection, indicating an
essential role for the gp350/220-interaction in virus adsorption (Tanner et al., 1988; Nemerow et al.,
1989). The peptide EDPGFFNVE, which is contained in gp350/220 and C3d (the complement
component which binds to CD21), at least partially mediates the binding of C3d or gp350 to CD21,
since synthetic peptides containing this sequence bind to CD21 and block EBV infection (Nemerow
et al., 1989; Tanner et al., 1987 and 1988).
EBV gp350/220 not only mediates EBV absorption, but also mediates initial penetration (Tanner et
al., 1987). Multiple gp350/220 molecules on the EBV outer envelope cross-link B-lymphocyte
plasma membrane CD21, resulting in patching and capping of CD21 and surface immunoglobulin
(Tanner et al., 1987). Surface cross-linking of CD21 causes normal B-lymphocyte to enlarge and
clump but does not increase cell RNA or DNA synthesis (Tanner et al., 1987). After capping, EBV
undergo polar endocytosis into smooth membrane vesicles (Nemerow and Cooper, 1984; Tanner et
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al., 1987). The EBV envelope presumably fuses with the vesicle membrane, releasing the
nucleocapsids into the cytoplasm (Kieff and Liebowitz, 1991). Gp350/220 may play some role in
the EBV envelope vesicle membrane fusion, since gp350 has a domain which could be
amphopathic (Beisel et al., 1985; Tanner et al., 1987). However, the EBV gH homolog, gp85, is the
second most abundant envelope glycoprotein and probably plays a key role in EBV envelope
vesicle membrane fusion (Edson et Thorley-Lawson, 1981 and 1983; Strnad et al., 1983; Heineman
et al., 1988). Monoclonal antibodies to gp85 do not affect virus adsorption but do inhibit EBV
envelope and cell membrane fusion (Miller and Hutt-Fletcher, 1988). Most EBV neutralizing
antibody response is directed to gp350/220 (Thorley-Lawson et Poodry, 1982).
6.5 ESTABLISHMENT OF LATENCY OR INITIATION OF VIRUS REPLICATION
By analogy with other DNA viruses which replicate in the nucleus, the cytoskeleton is likely to
mediate EBV capsid transport to the nucleus (Dales and Chardonet, 1973). Genome circularization
either precedes or coincides with earliest virus gene expression. Cell transcription factors probably
determine if latent or lytic infection ensues. B-lymphocyte-specific transcription factors may be
necessary for latent or lytic cycle EBV promoter activity (Farrel et al., 1983).
The usual outcome of B-lymphocyte infection with EBV is persistent latent infection and
transformation of cell growth to perpetual proliferation. The effect on cell growth is rapid and
efficient (Henderson et al., 1977; Sudgen et Mark, 1977; Mark et Sugden, 1982). There are
probably sequential changes in cell growth after initial infection (Moss et al., 1984). EBV induces
RNA synthesis, immunoglobulin secretion, expression of several B-cell activation markers, DNA
synthesis and cell division (Kintner et Sugden, 1981; Thorley-Lawson et al., 1982; Gordon et al.,
1984; Amen et al., 1986). EBV-infected B lymphocytes produce autostimulartory substances which
promote cell growth in vitro (Gordon et al., 1984). Autocrine growth stimulation may contribute to
the proliferation of B lymphocytes latently infected with EBV in vitro as well as to EBV
transformation of B lymphocytes in vivo (Kieff et Liebowitz, 1991).
6.5.1 ZEBRA PROTEIN
The switch from the latent to the lytic life cycle of the virus is controlled by two immediate-early
proteins: ZEBRA (also called EB1 and Zta), encoded by the BZLF1 gene and Rta, encoded by the
BRLF1 gene (Countryman et al., 1985 and 1987; Hardwick et al., 1988; Rooney et al., 1989;
Feederle et al., 2000). Both transcription factors are expressed simultaneously following induction
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of the lytic cycle (Takada et Ono, 1989; Sinclair et al., 1991; Gradoville et al., 2002). Each protein
activates a separate class of EBV lytic cycle genes, and together the two proteins synergize to
activate a third class of lytic cycle genes (Ragoczy et Miller, 1999). Some early lytic genes, such as
BMRF1, are activated in synergy by ZEBRA and Rta. However, ZEBRA suppresses Rta’s ability to
activate a late gene, BLRF2. El-Guindy and Miller (2004) showed that this repressive activity is
dependent on the phosphorylation state of ZEBRA. ZEBRA plays an indispensable role in driving
the lytic cycle of EBV.
ZEBRA is a sequence-specific DNA binding protein that forms a homodimer via its pseudo-
leucine-zipper dimerization domain. ZEBRA recognizes canonical AP-1 sites well as a spectrum of
7-bp sequences termed ZEBRA response elements (ZREs) (Lehman et al., 1998). ZEBRA triggers
the switch from the latent to the lytic state by binding to ZREs in promoters of viral and cellular
genes and activating their transcription (Farrell et al., 1989; Flemington et Speck, 1990).
Transcriptional activation of responsive genes by ZEBRA requires that the viral protein interacts
with several cellular proteins. The protein directly interacts with TATA binding protein and
components of the TFIIA complex via its activation domain. The activation domain of ZEBRA
stabilizes the TFIIA-TFIID complex and recruits the TFIIB complex, which further stabilizes the
preinitiation complex (Chi et al., 1995). The transcriptional activity of ZEBRA is also dependent on
the ability of ZEBRA to recruit CREB binding protein, a transcriptional coactivator that possesses
intrinsic histone acetyltransferase activity (Adamson et Kenney, 1999; Zerby et al., 1999).
ZEBRA is also indispensable for lytic viral DNA replication. The protein binds to multiple motifs
in oriLyt, (Hammerschmidt et Sugden, 1988; Lieberman et Berk, 1990; Schepers et al., 1993). The
minimum lytic viral DNA replication machinery in EBV consists of ZEBRA plus six EBV-encoded
replication proteins (Fixman et al., 1992). ZEBRA physically interacts with three of these proteins:
the viral DNA polymerase (BALF5), the DNA polymerase processivity factor (BMRF1) via its
DNA binding domain, and the helicase-primase complex (BBLF4-BSLF1:BBLF2/3) via its
activation domain (Zhang et al., 1996; Gao et al., 1998; Baumann et al., 1999). The latter
interactions suggest that ZEBRA might recruit and stabilize the replisome on oriLyt.
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6.6 LYTIC INFECTION
6.6.1 EARLY LYTIC INFECTION
Lytic replication differs from the latent amplification in that multiple rounds of replication are
initiated within oriLyt and the replication process is dependent on EBV-encoded proteins
(Hammerschmidt et Sugden, 1988; Fixman et al., 1995; Tsurami et al., 2005). A two-stage model
has been proposed for the oriLyt-mediated EBV DNA replication (Schepers et al., 1996). Essential
EBV replication genes were identified by Fixman and colleagues (1995) and this allowed
identification of seven essential core EBV replication genes (BZLF1, BALF5, BMRF, BMRF1,
BALF2, BBLF4, BSLF1, BBLF2/3). These genes are necessary for oriLyt-specific DNA replication
(Fixman et al., 1995; Tsurami et al., 2005).
At least 30 EBV mRNAs are early mRNAs and almost 30 EBV mRNAs are late mRNAs (Hummel
et Kieff, 1982; Bankier et al., 1983; Baer et al., 1984; Hudson et al., 1985; Gibson et al., 1986;
Sample et al., 1986; Biggin et al., 1987). Early and late mRNAs are intermingled through most of
the EBV genome (Kieff et Liebowitz, 1991). Frequently, different promoters initiate nested
transcripts which begin with different open-reading frames and terminate at the same
poyadenylation site so that the longest mRNA includes all of the shorter mRNAs and reading
frames 3’ to the primary reading frame. Some early and late genes are spliced whereas others are
not (Kieff et Liebowitz, 1991). The function of quite many EBV genes was first guessed from
comparison of predicted amino acid sequences of other herpesvirus proteins of known function
(Kieff et Liebowitz, 1991).
Among the EBV early genes identified by their homology to early genes of other herpesviruses are
several which are linked to DNA replication. These include DNA polymerase (BALF5), major
DNA-binding protein (BALF2), ribonucleotide reductase (BORF2 and BARF1), thymidine kinase
(BXLF1), and alkaline exonuclease (GLF5) (Hummel et Kieff, 1982; Nikas et al., 1986; Kieff et
Liebowitz, 1991; Tsurumi et al., 1998). These genes are distributed through the long EBV US
domain (Kieff et Liebowitz, 1991). The EBV DNA polymerase has been extensiviely purified and
is 117kd in size (Roubal et al., 1981; Kallin et al., 1985). Partially purified DNA polymerase was
associated with several other EBV nuclear proteins, including the 50-kd protein encoded by
BMRF1 (Li et al., 1987; Kieff et Rickinson, 2001; Johannsen et al., 2004). The EBV, varizella
zoster virus (VZV) and herpes simplex virus (HSV) ribonucleotide reductases have extensively
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homology (Gibson et al., 1984). The large subunit of EBV ribonucleotide reductase is 85kd and is
confined to multiple, discrete regions in the cytoplasm of productively infected cells (Nikas et al.,
1986; Goldschmidts et al., 1987). The large subunit is a delayed early protein which accumulates in
cells approximately 4hr after the BMRF1 nuclear early protein (Pearson et al., 1983; Goldschmidts
et al., 1987). Methanol fixation of cells destroys the immunologic reactivity of the large subunit,
suggesting that it may be a major component of the restricted early antigen complex (Kieff et
Liebowitz, 1991).
In addition to the two immediate-early proteins BZLF1 and BRFL1, two EBV early proteins –
BSMLF1 and BMRF1 – may trans-activate other early EBV genes (Kieff et Liebowitz, 1991; Kieff
et Rickinson, 2001). Both are quite abundant early nuclear proteins (Pearson et al., 1983; Cho et al.,
1985; Wong et Levine, 1989; Fixman et al., 1995). BSLMF1 is a trans-activator of gene expression
which acts synergistically with BZLF1 or BRLF1 in inducing higher-level expression in transient
expression assays (Lieberman et al., 1986; Wong et Levine, 1986; Oguro et al., 1987; Chavier et al.,
1989; Chevallier et al., 1986 and 1989; Kieff et Liebowitz, 1991). BSMLF1 increases cytoplasmic
transport of unspliced mRNAs (Ruvolo et al., 1998; Boyle et al., 1999). BSMLF1 has been
suggested to be a trans-activator of translation. Soon after induction of the lytic cycle, viral DNA is
amplified to yield monomeric plasmid progeny DNA. The BZLF1 protein acts as an immediate-
early trans-activator and also as an oriLyt-binding protein (Schepers et al., 1996; Tsurumi et al.,
2005).
One abundant EBV early protein is the 135-kd, single-stranded DNA-binding protein, BALF2
(Hummel et Kieff, 1982). This protein has primary amino acid sequence homology to the major
HSV DNA-binding protein, ICP8, which appears to function in DNA replication (Kieff et
Liebowitz, 1991; Kieff et Rickinson, 2001). A second RNA that is less abundant encodes the 18-kd
protein BHRF1, which has extensive homology with Bcl-2 (Austin et al., 1988; Pearson et al.,
1987; Henderson et al., 1993; Kieff et Rickinson, 2001).
The three proteins encoded by the BBLF4, BSLF1 and BBLF2/3 genes form a tight complex and
are predicted to act as helicase, primase and helicase-primase associated proteins, respectively, have
sequence homology to the herpes simplex virus type 1 UL5, UL52 and UL8 genes (Fixman et al.,
1995; Tsurami et al., 2005). It has been suggested that all products of the EBV replication genes
(BALF5, BMRF1, BALF2, BBLF4, BSLF1 and BBLF2/3, except for the BZLF1 protein) work
together at replication forks to synthesise leading and lagging strands of the EBV genome (Tsurumi,
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2001; Tsumi et al., 2005). EBV DNA replication genes are dependent on expression of the BZLF1,
BRLF1, and BSMLF1 transactivators (Kieff et Rickinson, 2001). EBV DNA replication also
requires topoisomerase 1 and 2 activity (Kawanishi, 1993). The redistribution of BZLF1 and
BMRF1 gene products to the same nuclear site may identify the site at which viral DNA is
replicated (Takaki et al., 1984; Kieff et Rickinson, 2001).
6.6.2 VIRAL DNA REPLICATION
EBV DNA replication appears to be biphasic and a two-stage model has been proposed (Pfuller et
Hammerschmidt, 1996). With induction of lytic EBV replication, the episome copy number
increases, suggesting that circular episomal DNA replication is a precursor to subsequent DNA
replication (Shaw, 1985). The BZLF1 protein binds to the oriLyt. In the late phase of the viral
productive cycle, the EBV genome is amplified 100- to 1000-fold (Tsurumi et al., 2005).
Essential EBV replication genes are BZLF1, BALF5, BMRF1, BALF2, BBLF4, BSLF1, BBLF2/3.
The BZLF1 protein functions as an oriLyt-binding protein and an immediate-early transactivator
(Schepers et al., 1996; Tsurumi et al., 2005). The product of the BZLF1 gene is also known as Zta,
ZEBRA and EB1. Expression of BZLF1 alone is sufficient to trigger the entire lytic cascade
(Countryman et Miller, 1985; Rooney et al., 1989; Amon et Farrell, 2005). The BALF5 gene
encodes the DNA Pol catalytic subunit and the BMRF1 gene encodes the DNA Pol accessory
subunit (Tsurumi et al., 1993, 1994 and 2005). A single-stranded DNA-binding protein is encoded
by the BALF2 gene (Tsurumi et al., 1997 and 1998). The three proteins encoded by the BBLF4,
BSLF1 and BBLF2/3 genes form a complex and are predicted to act as helicase, primase and
helicase-primase associated proteins, respectively (Yokoyama et al., 1999; Fujii et al., 2000). All
except for the BZLF1 protein work together at replication fork (Tsurumi, 2001). The specific
interactions between the six viral replication proteins are essential for EBV DNA replication.
Two EBV DNA segments (DL and DR left and right duplications of DNA with oriLyt activity)
which have strong early promoter activity function as origins of lytic-infection viral DNA
replication (Hammerschmidt et Sugden, 1988). Most likely initiation of the lytic EBV DNA
replication involves the formation of an initiation complex, which consists of two essential
upstream and downstream domains. The former contains several BZLF1 binding sites, and the latter
includes binding sites for several cellular proteins (Tsurumi et al., 2005). The first step would be the
binding of the BZFL1 protein and two transcription factors, ZBP-89 and Sp1, to oriLyt to form an
initial complex (Tsurumi et al., 2005). ZBP-89 and Sp1 are known to stimulate replication
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(Baumann et al., 1999). The interaction of the BZLF1 protein with the BBLF4/BSLF1/BBLF2/3
complex is in line with its recruitment of the viral helicase-primase complex to oriLyt (Gao et al.,
1998; Tsurumi et al., 2005). Also, BZLF1 protein can interact with both BALF5 and BMRF1
proteins (Zhang et al., 1996; Baumann et al., 1999). The BALF2 ssDNA-binding protein then
interacts with the BZLF1-BBLF4/BSLF1/BBLF2/3 complex (Gao et al., 1998).These proteins
together would have the potential to open up the duplex DNA in the origin region and synthesise
RNA primers (Tsurumi et al., 2005). The interaction between the EBV Pol holoenzyme and the
BBLF4/BSLF1/FFLF2/3 complex may be crucially important in initiation of DNA synthesis (Fujii
et al., 2000; Tsurumi et al., 2005).
The BALF5 Pol catalytic and BMRF1 Pol subunits function as the Pol holoenzyme, presumably
synthesising both leading and lagging strands (Tsurumi et al., 2005). The BALF2 protein binds
ssDNA templates and facilitates movement of the EBV DNA Pol holoenzyme on the ssDNA
template. The EBV helicase and primase complex may then bind to the lagging strand at the fork,
translocate in the 5’-to-3’ direction and synthesise the RNA primer (Tsurumi et al., 2005). The
BALF5 Pol catalytic subunit interacts with each component of the BBLF4/BSLF1/BBLF2/3
complex (Fujii et al., 2000). Thus, the six viral replication proteins appear to all work at the
replication fork as the replication machinery (Tsurami et al., 2005).
EBV productive DNA replication occurs at discrete sites in nuclei, called replication compartments
(Tsurumi et al., 2005). BZLF1 oriLyt binding proteins show a diffuse pattern of distribution in the
nuclei in immediate early stages of induction and then become associated with the replicating EBV
genome with granular spots in the replication compartments throughout the phase for lytic infection
(Tsurumi, et al., 2005). Almost all abundantly expressed BMRF1 proteins bind to DNA indicating
that they not only act at viral replication forks as a Pol processive factor, but are also widely
distributed on newly synthesised EBV genomic DNA (Tsurumi et al., 2005).
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6.6.3 LATE LYTIC INFECTION
Conserved herpesvirus genes are known to encode five capsid proteins, five envelope proteins, and
10 tegument proteins (Gompels et al., 1988; Davison et Taylor, 1987). Accordingly, EBV BcLF1,
BDLF1, BFRF3, BORF1, and BBRF1 ORFs are likely to encode the major, minor, and smallest
capsid proteins (MCP, mCP, and sCP, respectively), mCP-binding protein (mCPBP) and the portal
protein (Johannsen et al., 2004). The antibodies against viral capsid antigen (VCA) complex are the
important serodiagnostic markers of EBV infection. Then, the tegument proteins are encoded by the
EBV BPLF1, BOLF1, BVRF1, BGLF1, BGLF4, BGLF2, BBRF2, BSRF1, BGLF3, and BBLF1
ORFs (Hummel et Kieff, 1982; Vroman et al., 1985; Russo et al., 1996; Davison et al., 2002; de
Jesus et al., 2003; Johannsen et al., 2004). EBV BNRF1 and BLRF2 probably encode -
herpesvirus-unique tegument proteins (Hummel et Kieff, 1982; Baer et al., 1984; Cameron et al.,
1987; Serio et al., 1996; Johannsen et al., 2004). The EBV homologues of gB (BALF4), gH
(BXLF2), and gL (BKRF2) have been detected by specific antibodies in EB virions. Furthermore,
EBV BLLF1, BZLF2, and BDLF3 ORF-specific antibodies have detected EBV-unique gp350,
gp42, and gp150 (Hutt-Fletcher et Lake, 2001; Johannsen et al., 2004). EBV BMRF2-encoded
protein may also be found in virus envelopes because an RGD (arginine-glycine-aspartic acid)
motif that may function as a ligand for an integrin receptor (Tugizov et al., 2003).
The known EBV glycoprotein genes are BLLF1 (gp350/220) BALF4 (gB or gp110), BXLF2 (gH or
gp85), BKRF2, BZLF2 (gp42), BILF2 (gp55/80 or gp78), BDLF3 (gp150), BLFR1 (gp15), BBRF3
(gp84/113) and BILF1 (gp64) (Biggin et al., 1984; Hummel et al., 1984; Beisel et al., 1985; Gong et
al., 1987; Heineman et al., 1988; Oba et al., 1988; Mackett et al., 1990; Nuebling et Mueller-
Lantzsch, 1991; Hutt-Fletcher et al., 2001; Kieff et Rickinson, 2001; Johannsen et al., 2004). At
least two other EBV genes, BHRF1 and BMRF2, probably encode glycoproteins. BILF2, in a
recombinant vacciniavirus expression system, was expressed as a glycoprotein named as gp78 or
gp55/80 (Mackett et al., 1990; Kieff et Rickinson, 2001; Johannsen et al., 2004). The BILF2
glycoprotein corresponds to an abundant glycoprotein in purified virus preparantions (Kieff et
Rickinson, 2001). However, antibody to BILF2 fails to neutralize virus infectivity (Mackett et al.,
1990). BDLF3 cDNA analysis confirms that BDLF3 mRNA is not spliced (Heineman, 1987).
BDLF3 (gp150) is a highly glycosylated protein of only 26-kd expressed late in EBV replication
(Heineman, 1987; Johannsen et al., 2004). BALF4 is collinearly homologus to HSV-1 glycoprotein
B (gB), which is a major virion and infected cell-surface glycoprotein (Pellet et al., 1985; Emini et
al., 1987; Gong et al., 1987). BALF4 encodes two late mRNAs. The BALF4 3-kb mRNA translates
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a 93-kd protein, EBV glycoprotein B (gB or gp110), which is glycosylated to 110 kd (Gong et al.,
1987 and 1990). Mature EB virions have a small amount of full-length EBV gB (gp110) and, which
is one of the most abundant late EBV proteins (Hutt-Fletcher et Lake, 2001). The intracellular
distribution of EBV gB (gp110) closely parallels that of an endoplasmic reticulum resident protein
(Gong et Kieff, 1990). Light or electron microscopy localizes EBV gB (gp110) to the inner and
outer nuclear membrane and to cytoplasmic membranes frequently surrounding enveloped virus.
Despite EBV gB (gp110)s presence in the inner nuclear membrane through which nucleocapsids
bud to acquire their initial envelope, EBV gB (gp110) cannot be demonstrated in enveloped
intracellular or extracellular virus (Gong et al., 1987 and 1990). Thus EBV gB (gp110) is a very
abundant viral glycoprotein present in the cell nucleus and in the endoplasmic reticulum, but is not
a major structural protein of the virion. EBV gB appears to be the critical component for EBV
glycoprotein-mediated cell fusion (McShane et Longnecker, 2004).
In contrast to EBV gB (gp110), two other EBV glycoproteins EBV gH (gp85) and gp350/220, are
found on the virus and in the plasma membrane of lytically infected cells (Dolyniuk et al., 1976;
Strnad et al., 1979; Thorley-Lawson, 1979; Thorley-Lawson et al., 1979, 1980 and 1982; Hoffman
et al., 1980; Mueller-Lantzsch et al., 1980; North et al., 1980; Morgan et al., 1983 and 1984;
Hummel et al., 1984; Beisel et al., 1985; Heineman et al., 1988; Oba et al., 1988; Gong et al., 1990;
Johannsen et al., 2004). EBV gH (gp85) is encoded by BXLF2, which has significant collinear
homology to HSV-1 gH (McGeoch et Davison, 1986; Heineman, 1987; Oba et al., 1988), whereas
gp350/220 is encoded by BLLF, which has only a small region of distant homology to HSV-1 gC
(Beisel et al., 1985; Tanner et al., 1987). EBV gH (gp85) is a relatively minor virus component
which appears to be important in fusion between virus and cell membranes (Miller et Hutt-Fletcher,
1988), whereas gp350/220 is the dominant external virus glycoprotein which mediates virus binding
to the B-lymphocyte receptor, CD21 (see above). EBV gH (gp85) expressed in NIH 3T3 cells
localizes to the internal cytoplasmic and nuclear membranes, whereas gp350/220 localizes to the
Golgi apparatus and plasma membrane (Heineman et al., 1987; Whang et al., 1987) .This suggests
that EBV gH (gp85) may require another virus protein to bring it to the plasma membrane of
lytically infected lymphocytes, where it is characteristically found, whereas gp350/220 appears to
possess the signals necessary for efficient intracellular transport, Golgi processing, and plasma-
membrane insertion. Gp350/220 is not only the most abundant viral protein in the lytically infected
cell plasma membrane, but it is also one of the most abundant late viral proteins and the most
abundant protein on the outer surface of the virus (Kieff et Liebowitz, 1991). Most of the human
EBV neutralizing antibodies and significant immune T cell reactivity are directed against
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gp350/220 (Thorley-Lawson et Poodry, 1982; Ulaeto et al., 1988). Gp350/220 is therefore an
essential component of any prospective EBV vaccine.
Early EM observations of lymphocytes lytically infected with EBV revealed the presence of
nucleocapsids in the cytoplasm (Kieff et Rickinson, 2001). It has been hypothesised that the virus
probably acquires an initial envelope as it buds through the nuclear membrane, that de-envelopment
occurs within cytoplasmic vesicles resulting in release of nucleocapsids into the cytoplasm (Kieff et
Rickinson, 2001). Re-envelopment occurs at the plasma membrane, where the virus acquires a
definitive envelope rich in gp350/220 and gH/gL. Late in infection, as the cell deteriorates, partially
enveloped or initially enveloped virus may be released in substantial quantity (Kieff et Rickinson,
2001). Overview of EBV lytic cycle is presented in Figure II.
Figure II. Overview of EBV lytic cycle presented by Amon and Farrell (Rev Med Virol 15:149-
156, 2005). The lytic cycle can be induced with anti-IgG, which cross-links the B cell receptor to mimic antigen
binding. Immediate early, early and late genes are expressed in sequential order. Late gene expression is prevented by
inhibitors of lytic DNA replication such as acyclovir. Copyright ®John Wiley & Sons Limited. Reproduced with
permission.
6.7 EBV TYPES: EBV1 AND EBV2 (EBV A AND B)
Two EBV types, EBV-1 and EBV-2 (or type A and B, respectively) have been identified in most
human populations (Bornkamm et al., 1980; Dambaugh et al., 1980; Heller et al., 1981; Dambaugh
et al., 1984; Zimber et al., 1986; Young et al., 1987; Rowe et al., 1989). These were initially defined
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on the basis or divergence within the coding region for EBV-determined nuclear antigen 2 (EBNA-
2), a viral gene expressed during latent infection that is crucial for B-cell immortalization (Rabson
et al., 1982; Dambaugh et al., 1984; Adldinger et al., 1985; Skare et al., 1985; Hammerschmidt et
Sugden, 1989). The major differences between EBV-1 and EBV-2 genomes are in the latent
infection cycle genes EBNA-2 (Dambaugh et al., 1984; Adldinger et al., 1985), EBNA leader
protein (EBNA-LP or also known as EBNA5) (Dambaugh et al., 1984; Sample J et al., 1986),
EBNA-3A, -3B, and -3C (also known as EBNA-3, EBNA-4 or EBNA-6) (Rowe et al., 1989) and in
the EBERs (Arrand et al., 1989). Further distinction between EBV isolates can be made on the basis
of mutations affecting different regions of the genome (Walling et al., 1994; Walling et Raab-
Traub, 1994; Gratama et Ernberg, 1995).
The two families vary in their geographic distribution, tissue tropism, and biologic behaviour. Type
1 EBV is ubiquitous, while type 2 is commonly isolated only in parts of Africa endemic for malaria
and Burkitt’s lymphoma (Zimber et al., 1986; Young et al., 1987). EBV-1 can infect oropharyngeal
epithelial cells and peripheral blood lymphocytes, while type 2, when found in healthy Westerners,
is seen in the oropharynx and only rarely in the peripheral blood (Sixbey et al., 1989; Sculley et al.,
1988 and 1990). EBV-1 efficiently immortalizes B cells, while EBV-2 immortalizes B cells far less
effectively in vitro, and these B cells are less hardy in culture than those infected by type 1
(Rickinson et al., 1987).
Many studies have shown an increased incidence of oropharyngeal and peripheral blood infection
by EBV-2 in various immunocompromised populations. A higher rate of EBV-2 infection is found
in equatorial Africa, and this may be related to the generalized depression in T-cell function and
intense polyclonal B-cell stimulation commonly seen in this part of the world (Sixbey et al., 1989).
In the West, patients debilitated by age and illness have been found to harbour EBV-2 (Boyle et al.,
1993). Also, an increased incidence of EBV-2 has been shown in patients with acquired
immunodeficiency syndrome (AIDS) (Sculley et al., 1988; Sixbey et al., 1989) EBV-2 infection
also appears to be more common in immunocompromised patients with some lymphoid neoplasms,
such as AIDS-associated non-Hodgkin’s lymphomas (Boyle et al., 1991; Borisch et al., 1992).
Interestingly, Buissom and colleagues (1994) reported changes in the dominant EBV type during
human immunodeficiency virus (HIV) infection: EBNA-2 serotyping and genotyping showed that
HIV-infected patients were highly infected by EBV-2, and that the dominant strain was mostly
retained. However, during a follow-up study, a change in the dominant viral strain was observed in
two patients (Buissom et al., 1994). It has been shown that up to one third of cardiac transplant
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patients carry EBV type 2 in their peripheral blood, a much higher figure than the 3% observed in
the general population (Sculley et al., 1990; Kyaw et al., 1992). However, despite the
immunocompromised state of the hosts, solid-organ transplant recipients with post-transplant
lymphoproliferative disorders (PTLD) frequently harbored EBV type 1 (Frank et al., 1995).
Falk and colleagues (1997) reported direct identification of EBV types and virants in clinical
samples by PCR. Both types and multiple variants of each type were found with a much higher
frequency from saliva samples of HIV-carrying individuals compared with healthy individuals or
immunocompetent patients with infectious mononucleosis: 74% HIV-1 positive individuals
secreted EBV in saliva, of these 48% were positive for EBV type 1, 23% were positive for both
type 1 and type 2 EBV, and 29% were positive for type 2 alone (Falk et al., 1997). Both type 1 and
2 were detected in the B-lymphocytes from one healthy individual, and one individual had two
variants of type 1 EBV (Falk et al., 1997). Type 1 EBV alone was detected in mouthwash samples
from six patients with infectious mononucleosis (Falk et al., 1997). It seems that an intact immune
response to the virus prevents superinfection by exogenous virus. Superinfection is probably a
regular threat, because the virus is ubiquitous, and symptom-free virus carriers frequently secrete
biologically active virus (Falk et al., 1997). Nevertheless, multiple virus variants have been
identified among isolates from approximately 15% of healthy carriers (Gratama et al., 1994). In one
case, 14 different variants were identified in the same individual. In some cases, these variants were
the result of changes in only one EBNA-protein. Falk and colleagues (1997) suggested that these
variants arise because of recombination between endogenous EBV genomes during latency, or more
likely, during lytic multiplication in the oropharynx. Superinfection appears to be rare in healthy
donors. Interestingly, a recent study by Tierney and colleagues (2006) shows that patients with
infectious mononucleosis frequently harbour different EBV strains. Tierney and colleagues (2006)
studied blood and throat wash samples from 14 patients with infectious mononucleosis; most
patients carried two or more EBV type 1 strains, one patient carried 2 EBV type 2 strains, and one
patient carried both virus types.
In contrast, for immunosuppressed individuals, several studies have shown dual carriage of type 1
and type 2, as well as the presence of multiple variants (Gratama et Ernberg, 1995). In cases where
the molecular weights of most EBNAs varied, it is likely that the presence of several variants in the
same patient is due to superinfection because of breakdown of immunological barriers (Falk et al.,
1997). In immunosuppressed patients, this may also relate to increased replication of endogenous
EBV because of a less tightly controlled immunoregulation of latency. This in turn may speed up
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generation of new variants by recombination between endogenous and superinfecting viral genomes
(Falk et al., 1997).
The complete EBV2 genome, for strain AG876, was sequenced by Dolan and colleagues (2006).
Comparison with the published EBV1 sequence demonstrated that the two sequences are collinear
and, outside the known diverged alleles, generally very close (Dolan et al., 2006). The EBNA1 gene
was identified as another diverged locus, although its variation is believed not to correlate with
EBV type. Overall, genomic comparisons indicated that the two EBV types should be considered as
belonging to the same virus species (Dolan et al., 2006).
6.8 EBV INFECTION
Infection of humans with EBV usually occurs by contact with oral secretions. Oropharyngeal
epithelium is permissive for virus replication (Sixbey et al., 1983 and 1984). Nearly all seropositive
persons intermitently shed the virus in saliva (Gerber et al., 1972; Yao et al., 1985). Because two
studies have reported EBV in male and female genital secretions, direct spread of virus during
sexual intercourse is possible (Sixbey et al., 1986; Israele et al., 1991). Crawford and colleagues
(2002) found a highly significant association between sexual intercourse and EBV seropositivity,
with correlation with increasing numbers of sex partners. These data suggest that sexual contact, or
a factor closely associated with it, is an important factor in acquisition of EBV during the teenage
years (Crawford et al., 2002). However, it is very difficult to distinguish between this and
transmission of virus by kissing or orogenital contact during sexual intercourse, and therefore, an
indirect association remains a possibility (Crawford et al., 2002). Recently, Thomas and colleagues
(2006) investigated the risk of sexual transmission; low levels of virus detected in genital secretions
compared to saliva suggest that this is not a major transmission route. There is a four to six weeks’
incubation period before the clinical symptoms of infectious mononucleosis appear (Rickinson et
Kieff, 2001).
Earlier studies indicated that the virus replicates in epithelial cells in the oropharynx (Sixbey et al.,
1984), and B lymphocytes are infected at early stage of disease (Allday et al., 1988). Other studies
have suggested that B cells in the oropharynx may be the primary site of infection
(Anagnostopoulos et al., 1995; Niedobitek et al., 1997) (Figure III). Histologic studies could not
identify any viral infection of tonsillar epithelium but did detect small numbers of lytically infected
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B-lymphoid cells, usually near the crypt epithelium (Weiss et Mohared, 1989; Anagnostopoulos et
al., 1995; Rickinson et Kieff 2001).
Figure III (Cohen, NEJM 343:481-492, 2000). Model of EBV infections in humans. In the
oropharynx, EBV directly infects B cells or epithelial cells, which in turn infect B cells. During primary infection, the
EBV-infected B cells undergo a lytic cycle with production of virus, or express the full complement of latent viral
proteins. The infection is limited by natural killer cells and cytotoxic T cells. Beyond convalescence, EBV is present in
the peripheral blood in latently infected memory B cells that express latent membrane protein (LMP) 2 and possibly
EBV nuclear antigen (EBNA) 1. The EBV carrying memory B cells can undergo EBV reactivation. Some latently
infected cells undergo lytic replication in the oropharynx, resulting in shedding of virus into the saliva or infection of
epithelial cells with release of virus. Reproduced with permission.
6.9 LATENT INFECTION
Early in the course of primary infection, EBV establishes latent infection in B lymphocytes. These
resting memory B cells are the site of EBV persistence within the body (Babcock et al., 1998). Once
infected, the B cells carry the viral genome in their nuclei. The viral genome of non-replicating
EBV exists in closed circles, called episomes. The observation that EBV can be eradicated in bone
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marrow-transplant recipients who have received therapy that ablates their hematopoietic cells, but
not their oropharyngeal cells, provides further evidence that B cells are the site of EBV persistence
(Gratama et al., 1988). In normal adults, from one to 50 B cells per million are latently infected with
EBV, and the number of these latently infected cells remains stable over years (Birx et al., 1986;
Babcock et al., 1998).
EBV enters B cells by interaction of the major viral glycoprotein gp350/220 with the complement
receptor (CR2/CD21), which is the receptor for complement component C3d. The viral
glycoproteins gp25 (gL) and gp42/38 that form a complex with viral gp85 (gH). This complex
mediates an interaction between EBV and major histocompatibility complex (MHC) class II
molecules, which serve as a co-receptor for virus entry into B cells (Knox et al., 1995; Murray et
al., 2001). Crosslinking of CD 21 activates B lymphocytes and causes some immediate effects:
tyrosine kinase (Lck) activation and calcium mobilisation, increased mRNA synthesis, homotypic
cell adhesion, blast transformation, surface CD 23 expression and interleukin 6 production (Murray
et al., 2001). Once the viral genome has been uncoated and transferred to the nucleus,
circularisation and transcription from the Wp promoter begin a cascade of events leading to
expression of all the latent genes. The EBV nuclear antigen (EBNA) leader protein (EBNA-LP) and
EBNA2 are the first proteins to be detected and these are sufficient to advance the cells to early G1
phase (Murray et al., 2001). The proliferation of EBV infected cells depends on high cell density
and on the autocrine production of cytokines. Later, EBV+ cells are less dependent upon autocrine
growth mechanisms. Following that, the virus establishes a latent infection in memory B cells, and
this is characterised by limited expression of virus latent genes (Murray et al., 2001).
It was believed earlier, that EBV exists in the peripheral blood within the IgD- memory B-cell pool,
(Babcock et al., 1998). However, Ehlin-Henriksson and colleagues (2003) have shown that B-
lymphocyte subpopulations are equally susceptible to Epstein-Barr virus infection, irrespective of
immunoglobulin isotype expression. EBV gene expression in these cells is restricted to latent
membrane protein 2A (LMP2A), EBERs, BamHI A RNAs and in some cases EBNA1 (Tierney, et
al., 1994; Miyashita et al., 1997; Babcock et al., 1998; Chen et al., 1999). This narrowing of viral
gene expression after primary infection is consistent with the reversion of infected cells from an
activated lymphoblast to a resting memory B-cell phenotype (Rickinson et Kieff, 2001). It has been
suggested that the most EBV-infected B-cells in the blood are EBNA1 and LMP2A mRNA
negative and these transcripts might be detectable only in such cells that have recently left the
lymphoid tissue environment (Babcock et al., 1999; Rickinson et Kieff, 2001). This implies the
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existence of a circulating pool of EBV-positive cells in which all viral antigen expression is limited
to the EBERs and possibly the BamHI A RNAs (Rickinson et Kieff, 2001).
Analysis of lymphoid tissues suggests that the proportion of B cells that carry the virus is very low,
comparable to levels in the blood (Anagnostopoulos, 1995; Babcock et al., 1998; Rickinson et
Kieff, 2001). It has been reported that in some cases EBER-positive centroblasts, EBNA2-negative,
but occasionally expressing LMP1, are detectable within germinal centres (Araujo, et al., 1999).
This is consistent with RT-PCR analysis that has detected LMP1, LMP2A, and EBNA1 mRNAs
both in the germinal center B cell and in the memory B cell compartments of tonsillar lymphocytes
(Babcock et al., 2000). These represent reactivations from the pre-existing memory cell pool rather
than de novo infections because such transcripts were consistently present in tonsils without
evidence of virus replication (Rickinson et Kieff, 2001). A subset of healthy tonsils contain EBV +
naive B cells and these cells express the latency III programme and show an activated phenotype
(Joseph et al., 2000). These cells presumably are either eliminated by virus-specific cytotoxic T
lymphocytes (CTLs) or differentiate to memory B cells, which then leave the tonsil. Some of these
memory B cells will pass through mucosal lymphoid tissue and terminally differentiate into plasma
cells, whereupon they might enter the lytic cycle (Murray et al., 2001). Interestingly, latency III
infection was found only in tonsils in which virus replication was occurring to provide a source of
progeny virus for de novo infections (Babcock et al., 2000). It seems that reactivations from the
latently infected memory B-cells and de novo infections may be occurring simultaneously in the
lymphoid tissues of virus carriers (Rickinson et Kieff, 2001).
6.10 EBV INFECTION OF EPITHELIAL CELLS
Epithelial cells generally do not express CD21, suggesting that EBV enters these tissue cells by
other cellular receptors. Various human epithelial cells can be infected in vitro either by direct
contact with high-titre virus supernatant or by mixed culture with EBV producing cells. Sixbey and
colleagues (1983) have shown in vitro evidence for direct infection by EBV and replication of the
virus in cultured normal human epithelial cells. In vivo epithelial cells might be infected by virtue
of their close proximity to lytically infected B cells resident near or within epithelial tissues
(Murray et al., 2001). Virus made by epithelial cells lacking MHC class II (E-EBV) contains
increased levels of gp42 and is more infectious for B cells compared with virus made in B cells (B-
EBV) (Murray et al., 2001). B-EBV was equally infectious for epithelial cells than was E-EBV.
These data suggest that primary EBV infection of epithelial tissues could lead to the production of
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virus with a particular tropism for B cells. Virus produced by B cells near to epithelia could more
readily infect epithelial tissues with subsequent release of virus into saliva (Murray et al., 2001).
EBV is not usually detectable in normal epithelial tissues, including desquamated oropharyngeal
cells and tonsillar epithelium from infectious mononucleosis patients (Niedobitek et al., 2000), and
normal epithelium adjacent to EBV+ undifferentiated nasopharyngeal carcinoma (Sam et al., 1993)
and gastric carcinomas (Gulley et al., 1996). Nevertheless, the virus can be detected in pre-invasive
undifferentiated nasopharyngeal carcinoma (Pathmanathan et al., 1995) and dysplastic gastric
epithelium (Gulley et al., 1996), suggesting that EBV might be an early trigger in the pathogenesis
of these lesions. EBV can also be detected in oral hairy leukoplakia, a benign lesion of the oral
epithelia characterised by intense lytic infection (De Souza et al., 1989).
6.11 EBV LATENT PROTEINS
Four types of latent gene expression have been described. In healthy individuals, the virus persists
episomally in resting memory B cells. Of the ~100 viral proteins, only LMP-2 is expressed. In
addition, the small polyadenylated viral RNAs designated as EBERs 1 and 2 are also produced.
This type of latency has been designated type 0 (Thompson et al., 2004). The other three types of
latency are characteristic for a heterogenous group of malignancies. Latency I, II, and III are based
on patterns of expression of the EBV genome (Thompson et al., 2004).
When peripheral blood lymphocytes from chronic virus carriers are cultured, the few EBV positive
B cells give rise to spontaneous outgrowths of EBV-transformed immortalised cell lines, known as
lymphoblastoid cell lines (LCLs) (Rickinson et al., 1984). Every cell in an LCL carries multiple
copies of circular extrachromosomal viral DNA (episomes) and produces several latent proteins,
including six nuclear antigens (EBNAs 1, 2, 3A, 3B and 3C, and EBNA-LP) and three latent
membrane proteins (LMPs 1,2A and 2B) (Kieff, 1996). Transcripts from the BamHI A region are
also detected, although whether these encode proteins remains controversial (Brooks et al., 1993).
LCLs also show abundant expression of the small non-polyadenylated RNAs EBERs 1 and 2. They
contribute to oncogenesis by confering resistence to apoptosis and causing induction of interleukin-
10, which acts as an autocrine growth (Nanbo et Takada, 2002). EBERs serve as excellent targets
for detection of EBV in tumours (Murray et al., 2001). This pattern of latent EBV gene expression
is referred to as Latency III (Lat III) and it is characteristic of LCLs, most post-transplant
lymphomas and AIDS-related proliferative disorders (Niedobitek et al., 1997; Murray et al., 2001).
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Latency I is characteristic of Burkitt’s lymphoma (Sbih-Lammali et al., 1996). In Latency I only
EBNA1, the EBERs and the BamA transcripts are regularly produced. Latency II is observed in
EBV-associated Hodgkin’s lymphoma, T-cell non-Hodgkin’s lymphoma and undifferentiated
nasopharyngeal carcinoma (Cesarman et al., 1999; Murray et al., 2001). In Latency II the EBERs,
EBNA1 and BamA are expressed together with LMP1 and LMP2.
The Latency III pattern of EBV gene expression seen in lymphoblastoid cell lines (LCLs) is
associated with high-level expression of the B-cell activation markers CD23, CD30, CD39 and CD
70 and of the cellular adhesion molecules leukocyte-function-associate molecule 1 (LFA-1;
CD11a/18), LFA-3 (CD 58) and intercellular adhesion molecule 1 (ICAM-1; CD54) (Roowe et al.,
1987). These markers are also expressed in high levels when the cells are activated into short-term
growth by antigenic or mitogenic stimulation, suggesting that EBV-induced immortalisation can be
elicited through the same cellular pathways that drive physiological B-cell proliferation. The ability
of EBNA2, EBNA3C and LMP1 to induce LCL-like changes implicates these viral proteins as key
factors of the immortalisation process (Wang et al, 1987). The expression of EBV latency factors is
shown in Table I.
Expression of EBV latency factors in disease
Latency
pattern EBNA-1 EBNA-2 EBNA-3 LMP-1 LMP-2 EBER Disease
Type 1 + - - - - + Burkitt’s lymphoma
Type 2 + - - + + + Nasopharyng . ca,
Hodgkin’s disease
T-cell lymphoma
Type 3 + + + + + + Mononucleosis
PTLD,XLP, (LCL )
Type 0 +/- - - - + + Healthy carrier
Table I. Expression of EBV latency factors in diseases associated with EBV.
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Figure IV. The Epstein-Barr virus (EBV) genome presented by Murray and Young (2001).
Diagram showing the location and transcription of the EBV latent genes on the double-stranded
viral DNA episome. The origin of plasmid replication (oriP) is shown in orange. The large solid blocks (in purple)
represent coding exons for each of the latent proteins and the arrows indicate the direction in which they are transcribed:
the latent proteins include the six nuclear antigens (EBNAs 1, 2, 3A, 3B and 3C, and EBNA-LP) and the three latent
membrane proteins (LMPs 1, 2A, 2B). EBNA-LP is transcribed from variable numbers of repetitive exons. LMP2A and
LMP2B are composed of multiple exons located either side of the terminal repeat (TR) region, which is formed during
the circularisation of the linear DNA to produce the viral episome. The orange arrows at the top represent the highly
transcribed non-polyadenylated RNAs EBER1 and EBER2. The outer long arrowed red line represents EBV
transcription during a form of latency known as latency III, where all the EBNAs are transcribed from either Cp or Wp
promoter; the different EBNAs are encoded by individual mRNAs generated by differential splicing of the same long
primary transcript. The inner shorter arrowed blue line represents the EBNA1 transcript originating from the Qp
promoter during Lat I and Lat II. Transcripts form the BamA region can be detected during latent infection, but no
protein arising from this region has been definitively identified. Shown here are the locations of the BARF0 and BARF1
coding regions. Reproduced with permission.
36
6.12 FUNCTION OF THE EBV LATENCY PRODUCTS
EBNA1
EBV transforms normal human B-cells into continuously growing lymphoblastoid cell lines (Henle
et al., 1967). All transformed cells express the EBV-determined nuclear antigen, EBNA, detected
by anticomplement immunofluorescence (Reedman et Klein, 1973). EBNA1 was identified by
immunoblotting and radioimmunoelectrophoresis in four EBV-positive but not in three EBV
negative cell lines, utilizing four EBV-positive human sera in comparison with two EBV-negative
human sera (Strnad et al., 1981). The production of sequence specific antisera conclusively showed
that the BamHI K fragment encodes a polypeptide that varies in size between 70 and 92 kd in
different EBV-carrying cell lines (Hennessy et Kieff, 1983; Dillner et al., 1984).
EBNA1 is a DNA-binding protein that is required for the replication and maintenance of the
episomal EBV genome (Yates et al., 1985). The plasmid origin of viral replication is dependent on
the binding of EBNA1 to oriP (Yates et al, 1985). EBNA1 regulates negatively its own expression
(Nonkwelo et al., 1996). EBNA1 acts as a transcriptional transactivator and upregulates Cp and the
LMP1 promoter (Kieff, 1996). The EBNA1 protein contains a glycine-glycine-alanine (Gly-Gly-
Ala) repeat sequence, which varies in size in different EBV isolates (Kieff, 1996). This domain is a
cis-acting inhibitor of MHC, class I-restricted presentation and appears to function by inhibiting
antigen processing via the ubiquitin-proteasome pathway (Levitskaya et al., 1995). EBNA1 might
also have a direct role in oncogenesis (Wilson et al., 1996).
EBNA2
In the immunoblotting study of EBNA1 was detected an additional polypeptide of 81K (Strnad et
al., 1981; Hennesy et Kieff, 1983). This protein was further characterized by immunofluorescence
and designed as EBNA-2 (Dillner et al., 1985). EBNA-2 was found to be associated with the
BamHI WYH region of EBV DNA (Dillner et al., 1985). EBNA2 protein is crucial for the
transformation process (Ernberg, 1986). EBNA 2 is a transcriptional activator of both cellular and
viral genes, and upregulates the expression of certain B-cell antigens: CD21, CD12, as well as
LMP1 and LMP2 (Wang et al., 1987; Kieff, 1996). EBNA2 interacts with a ubiquitous DNA-
binding protein RBP-J and this is partly responsible for targeting EBNA2 to promoters (Grossman
et al., 1994). The RBP-J homologue in Drosophila is involved in signal transduction from the
Notch receptor; a pathway that is important in cell fate determination in Drosophila and has been
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implicated in the development of T cell tumours in humans (Artavanis-Tsakonas et al., 1995).
EBNA2 can functionally replace the intracellular region of Notch (Sakai et al., 1998). The c-myc
oncogene is also a transcriptional target of EBNA2 – important for EBV-induced B-cell
proliferation (Kaiser et al., 1999).
EBNA3 family
Dillner and colleagues reported (1986) the existence of a third antigen of the EBNA complex,
designated as EBNA-3 (also known as EBNA3A). EBNA3A (EBNA-3) and EBNA3C (also known
as EBNA-6) are essential for B-cell transformation in vitro (Robertson, 1997). In was shown that
four virally determined nuclear antigens were expressed in EBV transformed cells and the fourth
antigen was designated as EBNA-4 (also known as EBNA3B) (Kallin et al., 1985). EBNA3B is a
transformation-associated EBV nuclear antigen that has been shown to contain multiple HLA-A11-
restricted epitopes with different immunogenicities. A high prevalence of EBNA3B (EBNA-4)
mutations has been proposed as mechanism of escaping the CTL response in certain HLA types
(Gavioli et al., 1992 and 1993; de Campos-Lima et al., 1993). EBNA3B (EBNA-4) induces
expression of vimentin and CD40 (Silins et al., 1994). EBNA3C (EBNA-6) can induce the
upregulation of both cellular (CD21) and viral (LMP1) gene expression (Allday et al, 1994), and
represses the Cp promoter (Radkov et al., 1997). EBNA3C (EBNA-6) might interact with the
retinoblastoma protein, pRB, to promote transformation (Parker et al., 1996). EBNA2 and EBNA3
proteins work together to precisely controlling RBP-J activity, thereby regulating the expression of
cellular and viral promoters (Robertson ES, 1997).
EBNA-LP (EBNA-5)
EBNA leader protein or EBNA-LP (also known as EBNA-5) is encoded by the leader of each of the
EBNA mRNAs and encodes a protein of variable size depending on the number of BamHI W
repeats contained by a particular EBV isolate (Dillner et al., 1986; Wang et al., 1987). EBNA-LP
(EBNA-5) is required for the efficient outgrowth of LCLs (Allan et al., 1994). Transient
transfection of EBNA-LP (EBNA-5) and EBNA2 into primary B cells induces G0 to G1 transition
(Sinclair et al., 1994). EBNA-LP (EBNA-5) can cooperate with EBNA2 in upregulating
transcriptional targets of EBNA2, including LMP1 (Nitsche et al., 1997). EBNA-LP (EBNA-5) is a
nuclear phosphoprotein, tightly associated with the nuclear matrix and often localized to distinct
nuclear bodies (Petti et al., 1990; Kitay et al., 1996). In vitro biochemical studies have demonstrated
an interaction of EBNA-LP (EBNA-5) with both retinoblastoma protein (pRb) and p53 (Szekely et
al., 1993). It was recently shown that, EBNA-LP, but not other EBNAs, interacts with the p14ARF-
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protein, a regulator of the p53 pathway and antagonizes p14ARF-induced cell death (Kashuba et al.,
2003).
LMP1
The mRNA coding for the latent membrane protein (LMP) is the most abundant EBV-specific
mRNA in latently infected cells. A monospecific anti-LMP serum was produced by Hennessy and
colleagues (1984) and the LMP was identified on immunoblots. EBV encodes two integral
membrane proteins, latent membrane protein 1 and 2 (LMP1 and LMP2). LMP1 acts as an
oncogene, and expression of this protein in transgenic mice results in B-cell lymphomas (Wang et
al., 1985; Kulwichit et al., 1998). LMP1 induces a signaling response in cells that mimics a
constitutively active form of the B-cell-surface-molecule CD40 (Uchida et al., 1999).
At least four signalling pathways, NF-B, JNK/AP-1, p38/MAPK and JAK/STAT, have been
identified in the function of LMP1 (Huen et al., 1995; Eliopoulos et al., 1998 and 1999; Gires et al.,
1999; Murray et al., 2001). Within the C-terminus of LMP1 are at least two activating regions,
CTAR1 and CTAR2. CTAR1 is essential for EBV-mediated transformation of primary B cells.
CTAR2 is required for long-term growth of EBVpositive B cells (Izumi et al., 1997; Murray et al.,
2001). LMP1 activates JNK cascade via CTAR2 alone (Eliopoulos et al., 1999) whereas activation
of the p38/MAPK pathway is mediated by both CTAR1 and CTAR2 (Eliopoulos et al., 1999;
Murray et al., 2001). Aggregation of LMP1 within the plasma membrane is a critical for signalling
(Gires et al., 1997). LMP1’s interaction with the TRAF molecules is important for association of
LMP1 with the cytoskeleton (Higuchi et al., 2001; Murray et al., 2001).
The cloning and sequencing of the gene encoding LMP1 from EBV isolates from Chinese or
Taiwanese cases of undifferentiated nasopharyngeal carcinoma revealed several mutations (Hu et
al., 1991). These so-called de1LMP1 variants show increased tumorgenicity in vitro (Li et al.,
1996). This de1LMP1 variant can also be detected in some T-cell lymphomas, Hodgkin’s
lymphomas, patients with infectious mononucleosis and lymphoblastoide cell lines from healthy
controls. Healthy virus carriers have been found to have a similar frequency of these mutations as




The gene encoding LMP2 yields two distinct proteins: LMP2A and LMP2B. The structures of these
proteins are similar: both have 12 transmembrane domains and a 27 amino acid cytoplasmic C-
terminus (Murray et al., 2001). LMP2A has also a 119 amino acid cytoplasmic N-terminal domain.
LMP2A aggregates in patches within the plasma membrane of latently infected B cells (Longnecker
et al., 1990). Neither LMP2A nor LMP2B is essential for B-cell transformation (Fruehling et al.,
1997; Longnecker, 2000). The LMP2A N-terminal domain contains eight tyrosine residues, two of
which (Y74 and Y85) form an immunoreceptor tyrosine-based activation motif (ITAM) (Fuehling
et al., 1997). When phosphorylated, the ITAM present in the B-cell receptor mediates lymphocyte
proliferation and differentiation (Murray et al., 2001). LMP2A interacts with these protein tyrosine
kinases through its phosphorylated ITAM and this association negatively regulates protein tyrosine
kinase activity (Fruehling et al., 1997). LMP2A ITAM is responsible for blocking B-cell receptor-
stimulated Ca2+ mobilisation, tyrosine phosphorylation and activation of EBV lytic cycle in B cells
(Miller et al., 1995; Murray et al., 2001).
Expression of LMP2A in the B cells of transgenic mice abrogates normal B-cell development,
allowing immunoglobulin-negative cells to colonise peripheral lymphoid organs (Caldwell et al.,
1998; Murray et al., 2001). This suggests that LMP2A can drive the proliferation and survival of B
cells in the absence of signalling through the B-cell receptor (Caldwell et al., 1998). These data
support a role of LMP2 in modifying the normal programme of B-cell development to favour the
maintenance of EBV latency and to prevent inappropriate activation of the EBV lytic cycle
(Caldwell et al., 1998; Murray et al., 2001). A modulatory role for LMP2B in regulating LMP2A
function has been suggested (Scholle et al., 1999). The consistent expression of LMP2A in
Hodgkin’s lymphoma and nasopharyngeal carcinoma suggests an important function for this protein
in oncogenesis but this remains to be shown (Murray et al., 2001). LMP2 also recruits Nedd4-like
ubiquitin protein ligases; this might contribute to a block in B-cell signalling (Ikeda et al., 2000).
Moreover, LMP2A can transform epithelial cells (Scholle et al., 2000).
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EBV-ENCODED RNAS 1 AND 2 (EBERS 1 AND 2)
EBV-encoded RNAs 1 and 2 (EBERs 1 and 2) are nonpolyadenylated, uncapped, noncoding RNAs
of 167 and 172 nucleotides, respectively (Baumforth et al., 1999; Thompson et al., 2004). They are
expressed abundantly (104-105 copies per cell) in nearly all EBV-infected cells (Arrand et Rumo,
1982; Howe et al., 1986 and 1989). Oral hairy leukoplakia and some hepatocellular carcinomas are
the exceptions; EBERs are not expressed (Gilligan et al., 1990; Niedobitek et al., 1991, Sugawara et
al., 1999). EBERs 1 and 2 (in addition to the two LMPs) are expressed in all forms of latency
(Murray et al., 2002). EBERs have been implicated in the induction of autocrine growth factors,
especially interleukin (IL)-10, and in maintaining the malignant phenotype of Burkitt’s lymphoma
cells, all of which supports a potential role for these RNAs in oncogenesis (Komano et al., 1999 and
2001; Nanbo et Takada, 2002; Thompson et al., 2004). Furhermore, it has been demonstrated that
EBERs confer resistance to interferon (IFN)--induced apoptosis by inhibition of douple-stranded
(ds) RNA-activated protein kinase (PRK), which is the key mediator of the antiviral effect of IFN-
(Nanbo et Takada, 2002).
6.13 EBV EARLY ANTIGENS (EAs)
During the productive cycle the EBV genome must be linear, and an opening of the episome
initiates disruption of latency. Thereafter a few immediate early proteins take part in transactivation
of the viral genome (Croen, 1981; Kieff et Liebowitz, 1991). After this, the viral enzymes which are
necessary for DNA-replication appear (Kieff et Liebowitz, 1991). These enzymes probably
comprise the EBV early antigens (EA). EA is a plethora of immediate-early and early viral proteins,
including the BZLF1 immediate early and the abundantly expressed BALF2, BHRF1, BMRF1, and
BMLF1 early proteins (Rickinson et Kieff, 2001). On the basis of the localisation in the cell, the EA
antigens are divided into two components (Henle et al., 1971). The diffuse antigen (EA-D) is
present in both the nucleus and cytoplasm of the infected cell. The restricted component (EA-R) is
confined to the cytoplasm, and disappears if the cells are fixed in alcohol (Miller, 1990; Kieff et
Liebowitz, 1991; Linde et al., 1992).
EA can be induced in cells which are permissive for EBV replication, and in non-permissive cells.
In permissive cells, the induction is followed by replication of EBV DNA and synthesis of
structural proteins for assembly of virus progeny (Kieff et Liebowitz, 1991). The host cell provided
the facilities necessary for replication, while the virus directs the DNA and protein synthesis of the
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cell towards its own purposes. The host cell protein synthesis is not shut down and the cell does not
die immediately. However, the initiation of the EBV productive cycle causes the cell to die
eventually by the changes induced by EBV, or by the attack from the immune system (Lince et al.,
1992). The components of the mature EBV are assembled in the nucleus of the infected cell. The
virus probably attains its envelope from the nuclear membrane. Eventually, mature viruses bud out
from the cell.
6.14 IMMUNE RESPONSE TO EBV
Infection with EBV results in both humoral and cellular immune responses. During EBV primary
infection, three antibodies (-IgG, -IgM and -IgA) are produced against EBV viral capsid antigen
(VCA), two antibodies (-IgG and -IgA) are produced in response to early antigen D (EA-D), one
antibody (-IgG) in response to early antigen R (EA-R) and three antibodies (-IgG, -IgM and -IgA)
to membrane antigen (MA) (Linde, 1996; Rickinson et Kieff, 2001). Each of these antigens is a
composite of several distinct viral proteins. EBNA is a complex of six distinct nulear proteins,
EBNA1, 2, 3A, 3B, 3C, and –LP, while antibodies to EBNA1 are most frequently detected by the
conventional anti-EBNA assay (Rickinson et Kieff, 2001). EA is a complex of immediate-early and
early viral proteins (BZLF1, BALF2, BHRF1, BMRF1 and BMLF1 proteins) (Rickinson et Kieff,
2001). Much of VCA reactivity is diffuse cytoplamic fluorescence against virus-encoded
nucleocapsid components (BcLF1, BFRF3, BLRF2, and the glycoprotein gp110), which are
expressed in late lytically infected cells (Rickinson et Kieff, 2001). Most MA reactivity is directed
against gp 350, the most abundant viral protein on the surface of lytically infected cells and on the
viral envelope (Rickinson et Kieff, 2001). Anti-MA levels in serum correlate with virus
neutralazing activity (Rickinson et Kieff, 2001).
First, during infectious mononucleosis appear IgM, IgG and IgA antibodies to VCA expressed in
lytically-infected cells. These antibodies are almost always present in relatively high titres (Linde,
1992). Antibodies to EA-D are found in around 80% of infectious mononucleosis cases. The
serological reactivity against the two dominant EBNA proteins, EBNA1 and EBNA2, changes with
time after EBV primary infection (Linde, 1992). Antibodies to EBNA2 appear before EBNA1
antibodies. Up to one year after the primary infection, the EBNA1:EBNA2 titre ratio may be <1,
but therafter this ratio is normally >1 (Miller et al., 1985; Henle et al., 1987). The VCA IgG
antibodies are detected throughout life in healthy persons carrying EBV. IgM antibodies to VCA
disappear within one to three months, and EA-D antibodies are replaced by EA-R antibodies
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(Linde, 1992). EA-R antibodies reach their maximum between three and six months after EBV
primary infection, and may persist in low titres in healthy individuals. Functionally important are
antibodies to MA, which appear during the lytic cycle, but these antibodies are seldom measured
routinely (Neel et al., 1984). These virus neutralizing antibodies are of low titer and predominantly
of IgM class at first, while IgG titers rising relatively late (Rickinson et Kieff, 2001). A transient
IgA response to MA is also detectable (Sixbey et Yao, 1992). Antibody responses to the latent
membrane proteins (LMP1 or LMP2) have not been seen during infectious mononucleosis but these
antibodies are only detectable in a small proportion of healthy carriers with the most sensitive
assays (Frech et al., 1990; Meij et al., 1999; Rickinson et Kieff, 2001).
Virus-neutralizing antibodies (anti-MA antibodies) are capable to prevent generalized spreading of
the virus (Rickinson et Kieff, 2001). However, the cellular immune response is more important than
the humoral for restricting EBV infection. Natural killer cells and CD4+ and CD8+ cytotoxic T
cells control EBV-infected B cells during primary infection (Rickinson et al., 1997). In infectious
mononucleosis, up to 40 percent of CD8+ T cells are targeted towards one replicative EBV protein
sequence, whereas two percent are targeted to one latent EBV protein sequence (Callan et al.,
1998). After recovery, HLA-restricted cytotoxic T cells are important in controlling EBV latency,
and CD8+ T cells are equally targeted towards replicative and latent antigens (Tan et al., 1999).
EBV induces a strong cytotoxic T lymphocyte (CTL) response to multiple antigens. However, a
great deal of the cytotoxic-T-cell response is targeted towards the EBNA-3 proteins (Cohen, 2000).
EBV may escape immune surveillance in vivo in several ways (Chu et al., 1999): 1) by altering the
amino acid sequence within epitopes recognized by virus specific cytotoxic T lymphocytes (CTLs);
2) via down-regulation of the peptide transporters, thus restricting the loading of MHC class I
molecules with peptides derived from intracellular antigens (Niedermann et al., 1995); 3) via down-
regulation of CTL immunodominant EBV proteins of EBNA3A, EBNA3B, EBNA3C (EBNA-3, -4,
and -6) as in some EBV-associated malignancies, such as Hodgkin’s lymphoma (Pallesan et al.,
1991; Deacon et al., 1993; Grasser et al., 1994) or, 4) via strong CTL response by certain dominant
HLA alleles, such as B8, which mounts a strong response to an EBNA-3 epitope (Burrows et al.,
1994) or B27, which mounts a strong response to an EBNA-6 epitope (Brooks et al., 1993) or A11,
which mounts a strong response to an EBNA-4 epitope (Gavioli et al., 1993). EBNA3B (EBNA-4)
is a transformation-associated EBV nuclear antigen that has been shown to contain multiple HLA-
A11-restricted epitopes with different immunogenicities (Chu et al., 1999). A high prevalence of
EBNA3B (EBNA-4) mutations has been proposed as a mechanism of escaping the CTL response in
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certain HLA types (Gavioli et al., 1992 and 1993; de Campos-Lima, 1993; Chu et al., 1999).
Epidemiological studies have shown that mutation of the antigenically determined epitope of
EBNA3B (EBNA-4) may play an important role in the development of EBV-associated
malignancies (Chu et al., 1999). EBV encodes several important proteins that show sequence and
functional homology to diverse human proteins (see below).
EBNA-1 has been shown to block its own degradation (Levitskaya et al., 1997). Since viral proteins
are normally broken down by proteasomes to peptides for presentation to cytotoxic T cells, the
ability of EBNA-1 to inhibit its degradation allows the protein to avoid triggering the activation of
cytotoxic T cells. EBV encodes proteins that inhibit apoptosis (see below). EBV LMP1 up-regulates
the expression of several cellular proteins that inhibit apoptosis, including bcl-2 and A20 (Kulwichit
et al., 1998). EBV infected Burkitt’s lymphoma cells down-regulate the expression of several
proteins that are important for killing by cytotoxic T cells. These include the transporter proteins
associated with antigen processing that convey viral peptides from the cytoplasm to the
endoplasmic reticulum for antigen presentation, the cellular adhesion molecules that allow the cells
to contact with each other and the MHC class 1 molecules that allow cytotoxic T cells to recognize
virus-infected cells (Khanna et al., 1999).
6.15 HUMAN PROTEIN HOMOLOGUES
BCRF1 AND IL-10
Interleukin-10 (IL-10) plays a critical role in EBV biology. EBV BCRF1 protein shows 84%
sequence homology to human interleukin-10 (IL-10) (Vieira et al., 1991). BCRF1 protein is often
termed as viral IL-10 (vIL-10). Human IL-10 has been described as a potent immunosuppressive
sytokine: IL-10 inhibits activation and effector function of T cells, monocytes, and macrophages.
Human IL-10 is otherwise a potent growth and activation factor for B cells and also protects some
B cells from apoptosis (Moore et al., 1990 and 1991; Miyazaki et al., 1993; Thompson et al., 2004).
The BCRF1 protein (viral IL-10) mimics the activity of interleukin-10 by inhibiting interferon-
(gamma) synthesis by human peripheral blood mononuclear cells in vitro (Hsu et al., 1990). The
BCRF1 protein (viral IL-10) is thought to play a role in the establishment of latent infection by
suppression of the host immune system (Thompson et al., 2004). The BCRF1 protein (viral IL-10)
is expressed late in the productive cycle and exhibits many properties ascribed to human IL-10 (de
Waal Malefyt et al., 1991; Miyazaki et al., 1993; Swaminathan et al., 1993; Mahot et al., 2003). The
viral transcription factor EB1, which is the main inducer of the EBV productive cycle, also activates
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transcription of the human IL-10 gene and secretion of human IL-10 (Mahot et al., 2003).
Therefore, an increase in IL-10 production occurs during latency and early and late during
productive cycle (Mahot et al., 2003). This might favour the survival of EBV-infected cells.
BDLF2 AND CYCLIN B1
On the basis of amino acid sequence alignment, homology between the BDLF2 protein and human
cyclin B1 has been suggested, although functional homology between these two proteins has yet to
be confirmed (Hayes et al., 1999). Human cyclin B1 regulates the G2-M transition in the cell
division cycle by activating particular cyclin-dependent protein kinases. Not so much is known
about BDLF2 (Thompson et al., 2004). It has been detected in oral hairy leukoplakia but not in
other diseases characterized by latent infections. It has been suggested to be a gene expressed late
during the lytic cycle and BDLF2 may have a role in protecting the cell from immune elimination
and programmed cell death (Hayes et al., 1999).
BHRF1, BALF1 AND BCL-2
Interestingly, EBV encodes two Bcl-2 homologues BHRF1 and BALF1. BHRF1, an early lytic
cycle antigen, shows partial (25%) sequence homology to the human protein Bcl-2, a cellular anti-
apoptotic protein (Henderson et al., 1993). In addition to structural homologue, BHRF1 is also
fuctionally homologous to Bcl-2. BHRF1 may enhance cell survival, allowing oncogenic mutations
to accumulate; it may also permit the production of a maximum number of virions through the
inhibition of apoptosis (Oudejans et al., 1995; Thompson et al., 2004). Some EBV-positive
lymphomas have been found to be positive for BHRF1 transcripts and latent BHRF1 transcripts
have been detected in T cell lymphomas and in EBV-transformed tightly latent B-cell lines in vitro
(Austin et al., 1988; Oudejans et al., 1995; Xu et al., 2001; Howell et al., 2005). EBV encodes also
the other protein, BALF1, which has structural homology to Bcl-2 and is likely to have similar anti-
apoptotic effects (Marshall et al., 1999; Bellows et al., 2002).
BARF-1 AND INTRACELLULAR ADHESION MOLECULE 1
The EBV BARF-1 protein shows some homology to the intracellular adhesion molecule 1, as well
as to the human colony stimulating factor 1 receptor (Wei et al., 1994; Strockbine et al., 1998).
BARF-1 is involved in immune suppression by either functioning as a soluble receptor for colony-
stimulating factor 1 (which normally enhances the expression of interferon- by monocytes) or by
occupying intracellular adhesion molecule 1 receptors on T lymphocytes without leading to the
proper stimuli necessary for T-cell activation (Wei et al., 1994; Sbih-Lammali et al., 1996; Cohen et
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al., 1999; Thompson et al., 2004). Because interferon- and interferon- inhibit the outgrowth of
EBV-infected cells in vitro, the BCRF1 and BARF1 proteins may help the virus to evade the host’s
immune system during acute EBV infection or reactivation (Cohen, 2000).
6.16 CLINICAL SYNDROMES ASSOCIATED WITH EBV
6.17 INFECTIOUS MONONUCLEOSIS
EBV primary infection of young adults causes infectious mononucleosis. EBV is present in the
saliva of most persistently infected individuals and is generally thought to be spread by close oral
contact. However, there have been several reports of EBV in genital secretions, suggesting the
possibility of sexual transmission between adults (Sixbey et al., 1986; Israele et al., 1991; Crawford
et al., 2002). Recently, Thomas and colleagues (2006) investigated the risk of sexual transmission;
low levels of virus detected in genital secretions compared to saliva suggest that this is not a major
transmission route. The findings of small quantities of cell-associated virus suggest a latent
infection, thus EBV is probably in the B lymphocyte rather than in the epithelial cell component of
the secretions (Thomas et al., 2006).
The symptoms of infectious mononucleosis are thought to be caused by T cell activation and
cytokine production (Foss et al., 1994; Andersson, 1996). Williams and colleagues (2004)
suggested that T cells expressig CD244 and surface lymphocyte activation marker (SLAM) are
responsible for the clinical features of mononucleosis but the control of activation is maintained by
parallel increased expression of SLAM-associated protein (SAP). Over 50 percent of patients have
the triad of fever, lymphadenopathy and pharyngitis. Spleno- and hepatomegaly, and palatal
petechiae are each present in more than 10 percent. Less common complications are spleen rupture,
hemolytic anemia, thrombocytopenia, aplastic anemia, myocarditis, hepatitis, Guillain-Barre
syndrome, and CNS infection. Most infants and children are asymptomatic or have nonspecific
symptoms (Henke et al., 1950; Straus et al., 1993).
Most patients with infectious mononucleosis have leukocytosis with an absolute increase in the
number of peripheral mononuclear cells, heterophile antibodies, elevated serum aminotransferase
levels, and atypical lymphocytes. These are predominantly T lymphoblasts of CD8+ subset but
include some CD4+ T cells and also activated natural killer (NK)-like cells with the CD16 or CD56
markers (Rickinson et Kieff, 2001). Most of the symptoms of infectious mononucleosis are
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attributed to the proliferation and activation of T cells in response to infection. Up to a few percent
of the peripheral blood B cells may be infected with EBV in infectious mononucleosis. Activation
of B cells results in production of polyclonal antibodies, heterophile antibodies and occasionally
cold agglutinins, cryoglobulins, antinuclear antibodies, or rheumatoid factor (Cohen, 2000).
Serodiagnosis of EBV primary infection is based on measurement of antibody reactivity for various
EBV antigens, including viral capsid antigen (VCA), the early antigens (EA), and members of the
Epstein-Barr virus nuclear antigen (EBNA) family. Characteristic for EBV primary infection are
positive VCA IgM and IgG results and lack of EBNA-1 antibodies (Henle et al., 1974). Avidity of
VCA IgG or EA IgG separates primary and secondary infections (De Ory et al., 1993; Andersson et
al., 1994; Vetter et al., 1994; Gray et al., 1995; Weissbrich, 1998; Korhonen et al., 1999).
Serodiagnosis of EBV primary infection by the diagnostic laboratory of the Helsinki University
Hospital campus (first University of Helsinki; now HUSLAB) is based on positive VCA IgM
together with VCA (or corresponding) IgG of low avidity.
The treatment of infectious mononucleosis consists of good supportive care, including adequate
hydration; nonsteroidal anti-inflammatory drugs or acetaminophen for fever and myalgias; and
(possibly) gargling with a two percent lidocaine (Xylocaine®) solution to relieve pharyngeal
discomfort (Ebell, 2004). A meta-analysis of five randomized controlled trials involving 339
patients found that patients who took acyclovir had less oropharyngeal shedding at the end of
therapy, but this treatment did not provide significant clinical benefit (Torre et al., 1999). Based on
clinical experience and case reports, corticosteroids are recommended in patients with significant
pharyngeal edema that threatens respiratory function (Ebell, 2004).
The risk of splenic rupture is estimated at 0.1 percent, based on a retrospective series of 8116
patients (Farley et al., 1992). Because of this, the patients are recommended to avoid athletics for at
least three or four weeks after disease (Ebell, 2004). Several studies have examined the long-term
outcomes of infectious mononucleosis. Between nine and 22 percent of patients reported persistent
fatigue or hypersomnia six months after infectious mononucleosis (Candy et al., 2002).
After mononucleosis individuals have a four-fold increased risk for Hodgkin’s lymphoma (Munoz
et al., 1978). Hjalgrim and colleagues (2000) studied the risk of Hodgkin’s lymphoma after
infectious mononucleosis by population-based cohorts of 38562 infectious mononucleosis patients
in Denmark and Sweden and concluded the risk to be specific: The standardized incidence ratio for
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Hodgkin’s lymphoma remained elevated for up to two decades after mononucleosis, but decreases
with time. The standardized incidence ratio for Hodgkin’s lymphoma tended to increase with at the
time of diagnosis of mononucleosis (Hjalgrim et al., 2000). Following infectious mononucleosis,
the standardized incidence ratio for Hodgkin’s lymphoma at ages 15-34 years was 3.49, which was
statistically significantly higher than the standardized incidence ratio for any other age group
(Hjalgrim et al., 2000).
6.18 CHRONIC ACTIVE EBV INFECTION
In 1948, Isaacs described a prolonged clinical course of infectious mononucleosis lasting from
months to years (Isaacs, 1948). During the late 1970s and early to middle 1980s, several groups
described a protracted illness usually preceded by infectious mononucleosis but with persistent
fatigue, headaches, myalgia, lymphadenopathy, and intermitted or low-grade fever (Tobi et al.,
1982; Hellmann et al., 1983; Dubois et al., 1984; Jones et al., 1985; Straus et al., 1985).
Unexpectedly, unusual profiles of antibodies to EBV were common in this syndrome. Specifically,
the titres of viral capsid antigen (VCA) and early antigen (EA) IgG antibodies were substantially
higher in patients compared to controls. Because of these serological patterns and clinical
symptoms, it was proposed that the syndrome arose from a chronic EBV infection.
Chronic active EBV infection is a rare disorder that has been defined by the presence of three
features: severe illness of more than six month’s duration that begins as a primary EBV infection or
that is associated with abnormal EBV serology; histologic evidence of organ disease and
demonstration of EBV antigens or EBV DNA in tissue (Straus, 1988). There are often extreme
elevations of virus-specific antibody titers. Chronic active EBV infection is a heterogeneous EBV-
related disorder, ranging from a mild/moderate form to a rapidly lethal disorder. The mild to
moderate form is more common in Western countries, while the lethal form is more common in
Japan (Jones et al., 1987; Ishira et al., 1995; Kimura et al., 2001). In 1978, Virelizier and colleagues
described a case of severe type of chronic active EBV infection (Virelizier et al., 1978). The
affected girl had a chronic disease chracterized by fever, lymphadenopathy, interstitial pneumonitis,
thrombocytopenia and polyclonal hypergammaglobulinemia. She had extremely high antibody titres
against VCA and EA. Subsequently, in 1984, Joncas and colleagues described a similar type of
chronic active EBV infection (Joncas et al., 1984).
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The lethal form of chronic active EBV infection is characterized by multiple organ failure,
hemophagocytic syndrome and development of lymphomas. The following clinical features are
common: symptoms persisting for at least six months and associated with (1) either intermittent or
persistent fever, lymphadenophathy, and hepatosplenomegaly, (2) a tendency for pancytopenia and
polyclonal gammopathy, and (3) no apparent manifestation of a serious underlying disease
(Virelizier et al., 1978; Joncas et al., 1984; Schooley et al., 1986; Kawa-Ha et al., 1987; Miller et
al., 1987; Jones et al., 1988; Kikuta et al., 1988; Ishira et al., 1989). Pneumonitis is another clinical
manifestation reported in the literature (Virelizier et al., 1978; Schooley et al., 1986). Other
symptoms, such as debilitating fatigue, sore throath, lymph node tenderness and pain, headache,
myalgia and arthralgia, are also encountered. Allogeneic stem cell transplantation is considered the
only potentially curative treatment for the lethal form of chronic active EBV infection (Teshima et
al., 1996; Imashuku et al., 1997; Takami et al., 1998; Fujii et al., 2000; Okamura et al., 2000).
Chronic active EBV infection has two distinct clinical classifications depending on whether T cells
or NK cells are predominantly infected cell type in the peripheral blood (Kimura et al., 2001). T
cell-type infections are characterised by high fever, anemia, hepatomegaly, lymphadenopathy and
high titers of EBV-antibodies. In contrast, NK cell-type infections exhibit large granular
lymphocytosis, hypersensitivity to mosquito bites and high IgE levels (Kimura et al., 2001 and
2003, Kimura, 2006).
EBV infects T or NK cells in many severe cases, and it is believed that these cells escape immune
surveillance because of the lack of EBV-specific immunity (Kuzushima, 1996; Kimura et al., 1995;
Tsuge et al., 2001). However, the exact pathogenesis is not known. In one study, in most of the
patients with chronic active EBV infection, EBV-specific CD8+ T cells were not detected (Sugaya
et al., 2004). Indeed, low frequencies of EBV-specific CD8+ T cells may be one of the
immunological features of chronic active EBV infection (Sugaya et al., 2004).
6.19 X-LINKED LYMPHOPROLIFERATIVE DISEASE
X-linked lymphoproliferative disease is an inherited disease of males unable to restrict EBV
infection (Purtilo et al., 1977). The mutated gene on the X chromosome has been identified as SAP
(signaling lymphocyte activation molecule [SLAM]-associated protein), also known as SH2D1A or
DSHP (Sayos et al., 1998). This gene encodes a protein located on the surface of T cells, which
interacts with two other proteins: SLAM, present on T and B cells, and 2B4, present on T cells and
natural killer cells (Sayos et al., 1998; Tangye et al., 1999). The absence of a functional SAP in
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patients with X-linked lymphoproliferative disease is thought to impair the normal interaction of T
and B cells, resulting in unregulated growth of EBV-infected B cells (Purtilo et al., 1977 and 1979).
X-linked lymphoproliferative disease is associated with a high morbidity; and the overall outcome
is poor (Purtilo et al., 1979). If the risk patients are identified, regular immunoglobulin replacement
therapy has been given to protect them from EBV or other viral infections (Gaspar et al., 2002).
However, in a number of cases, this has not prevented the development of the disease (Okano et al,
1990). At present, the only curative treatment is allogeneic stem cell transplantation (Vowels et al.,
1993; Pracher et al., 1994; Seemayer et al., 1995; Gross et al, 1996).
During the acute phase of X-linked lymphoproliferative disease, treatment is difficult as
demonstrated by the high mortality rate. Treatment using antivirals (aciclovir / ganciclovir /
foscarnet), high-dose immunoglobulin, immunosuppressive agents, and IFN- have been
disappointing (Okano et al, 1990 and 1991). With the identification of the XLP gene, gene therapy
is a forthcoming option.
6.20 CANCERS ASSOCIATED WITH EBV
6.21 NASOPHARYNGEAL CARCINOMA
Nasopharyngeal carcinoma is prevalent in Southern China, in Northern Africa and among Alaskan
Inuits. Nasopharyngeal carcinoma has three etiologic factors, including genetic susceptibility,
chemical carcinogens, and EBV infection (Chan et al., 2004). In Southern China nasopharyngeal
carcinoma is the third most common malignancy and the incidence rate varies between 15 and 50
per 100 000 (Ho, 1978; Zeng et al., 1982; Chan et al., 2002). Nasopharyngeal carcinoma is
associated with the HLA A2-B46 haplotype in the Chinese population, with two alleles in linkage
disequilibrium, whereas HLA A2 and A11 in non-Chinese patients are protective against
nasopharyngeal carcinoma (Hildesheim et al., 2002). Nasopharyngeal carcinoma occurs
sporadically in the United States and Western Europe. Nearly 100 percent of anaplastic or poorly
differentiated nasopharyngeal carcinomas contain EBV genomes and express EBV proteins (Cohen,
2000). The EBV genome is present in the transformed cells but not in the lymphocytes of the tumor.
Clonal EBV genomes are found in the early preinvasive dysplastic lesions or carcinoma in situ,
indicating that EBV infection precedes the development of nasopharyngeal carcinoma
(Pathmanathan et al., 1995).
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Nasopharyngeal carcinomas are epithelial neoplasms. Three histopathological types are recognized
in the World Health Organization (WHO) classification (Shanmugaratnam et al., 1993). Type I is
squamous cell carcinoma with varying degrees of differentiation. Type II is non-keratinizing
carcinoma and type III can be considered undifferentiated carcinoma of the nasopharyngeal type.
The histological types may be of prognostic significance (Chan et al., 2002). The most common
presenting symptom is cervical lymphadenopathy, followed by nasal, aural and neurological
symptoms (Chan et al., 2002).
Patients with nasopharyngeal carcinoma often have elevated titers of IgA antibody to EBV
structural proteins (Cohen, 2000). Measurement of EBV-specific IgA is useful in early screening
for nasopharyngeal carcinoma in southern China (de The G et al., 1986). An increase in EBV-
specific antibody titers after therapy is associated with a poor prognosis, whereas a declining or
constant level is a favourable sign (Halprin et al., 1986). The quantity of EBV DNA detected in
blood correlates with the stage and prognosis of the disease (Wei et al., 2005). Radiotherapy with
concomitant chemotherapy has increased survival, and improved techniques (such as intensity-
modulated radiotherapy), early detection of recurrence, and application of appropriate surgical
salvage procedures have contributed to improved therapeutic results (Chan et al., 2002; Wei et al.,
2005). Screening of high-risk individuals in endemic regions together with developments in gene
therapy and immunotherapy might improve the outcome further (Wei et al., 2005).
6.22 BURKITT’S LYMPHOMA
In 1958, Dennis Burkitt described a disorder associated with jaw tumors in African children
(Burkitt, 1958). In 1961, the neoplasm was identified as a form of malignant lymphoma, and
became an entity called Burkitt’s lymphoma (O’Conor, 1961). Burkitt’s lymphoma is a high-grade
malignant lymphoma of small, noncleaved B cells. In equatorial Africa, Burkitt’s lymphoma is
associated with Plasmodium falciparum malaria (Cohen et al., 2000). Over 90 percent of these
endemic cases are associated with EBV (Lenoir et al., 1984). Infection with malaria is thought to
diminish the T-cell control of proliferating EBV-infected B cells and enhance their proliferation.
Not more than 25% of sporadic Burkitt’s lymphomas are EBV DNA positive and express the EBV
nuclear antigen-1 (EBNA1) and nuclear RNAs (EBER) (Gutierrez et al. 1992; Niedobitek et al.,
1995; Lehtinen, 1987; Lehtinen et Lehtinen, 1998; Subar et al., 1998).
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Burkitt’s lymphoma cells contain a chromosomal translocation involving chromosomes 8 and 14,
22 or 2 (Taub et al., 1982; Dalla-Favera et al., 1982; Leder et al., 1983; Klein et Klein 1985;
Manilov et al., 1986). These translocations result in positioning of the c-myc oncogene
(chromosome 8) near the immunoglobulin heavy-chain (chromosome 14) or light-chain
(chromosome 2 or 22) constant regions, leading to deregulation of the c-myc gene expression. The
dysregulated expression of c-myc results in increased complex formation between the myc protein
and a DNA-binding max protein which by transcriptional activation enables progression of the cell
cycle and lymphoproliferation (Inghirami et al., 1990; Sanlund et al., 1996; Henriksson et Luscher,
1996). In addition to the EBV positivity of Burkitt’s lymphoma, similar geographical gradient exists
in the distribution of the chromosome 8 breakpoints: far upstream of c-myc in endemic Burkitt’s
lymphoma, immediate 5’ of c-myc in Latin American, and within the transcriptional unit in
sporadic Burkitt’s lymphoma (Barriga et al., 1988; Gutierrez et al., 1992).
Tissues from patients with Burkitt’s lymphoma in Africa usually contain EBV DNA and express
only one EBV protein, EBNA-1. The form of latency characteristic of Burkitt's lymphoma is often
referred to as latency I. As in nasopharyngeal carcinoma, clonal EBV genomes are found in
Burkitt’s lymphoma, indicating that it arises from a single EBV-infected cell (Cohen et al., 2000).
Interestingly, anti-VCA and anti-EA(R) antibody titers in the serum of patients with endemic
Burkitt’s lymphoma are considerably higher than controls and anti-VCA antibody titers are raised
even before the clinical onset of the tumor (Henle et al., 1969; de The G et al., 1978; Geser et al.,
1982; Rickinson et Kieff, 2001).
Although current literature is limited by a lack of randomized trials, Burkitt's lymphoma appears to
be curable in a high proportion of cases if treated with aggressive multiagent chemotherapy
regimens (Bociek, 2005). The use of autologous stem cell transplantation appears to benefit the
patients with chemotherapy-sensitive relapses. The role of allogeneic stem cell transplantation for
this disease remains uncertain (Bociek, 2005).
6.23 HODGKIN’S LYMPHOMA
Hodgkin’s lymphoma is an uncommon malignant tumor of the lymphatic system where the Reed–
Sternberg giant cells that are characteristic for Hodgkin’s lymphoma, replace the normal lymphoid
structure. EBV DNA has been detected in about 40 to 60 percent of patients with Hodgkin’s tumors
in the United States. At the cellular level, EBV-encoded RNA (EBER), latent membrane protein
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(LMP) and the Epstein-Barr nuclear antigen (EBNA) have been localized in the Reed–Sternberg
(RS) cells of the diseased patients (Grasser et al., 1994; Armstrong et al., 1998; Sleckman et al.,
1998). The viral genomes are monoclonal (Weiss et al., 1989; Jarret et al., 1991; Gulley et al.,
1994). Elevated levels of EBV antibodies have been observed in patients with Hodgkin’s lymphoma
even before diagnosis (Hesse et al., 1977; Mueller et al., 1989). Conclusive evidence of the causal
relationship of EBV infection and infectious mononucleosis in Hodgkin’s lymphoma was obtained
from longitudinal cohort and case-control studies (Rosdahl et al., 1974; Kvåle et al., 1979; Mueller
et al., 1989; Lehtinen, 1989; Hjalgrim et al., 2000).
EBV positivity in lymphoma tissue is discerned in ~70% of mixed cellularity Hodgkin’s lymphoma,
>95% of lymphocyte-depleted Hodgkin’s lymphoma, and in 10–40% of cases of nodular sclerosis;
the lymphocyte-predominant Hodgkin’s lymphoma subtype is almost always EBV negative
(Chapman et al., 1998; Thompson et al., 2004). Geographic variations of EBV positivity have also
been studied; EBV positivity in Hodgkin’s lymphoma is found in 65% of cases in Japan, 67% of
cases in Mexico, 94% of cases in Peru, 92% of cases in Kenya, 41% of cases in Italy, and ~50% of
cases in the United States (Zarate-Osorno et al., 1995; Chang et al., 1996; Leoncini et al., 1996;
Tomita et al., 1996; Thompson et al., 2004). Free circulating EBV DNA is often present in the
plasma of patients with Hodgkin’s lymphoma. Musacchio and colleagues recently reported (2006)
EBV DNA present in the plasma of 91% of patients with EBV-associated Hodgkin’s lymphoma,
and in all patients with HIV-associated disease. EBV DNA prevalence was higher in patients with
advanced disease, irrespective of HIV status.
Patients with Hodgkin’s lymphoma have an excellent prognosis with modern chemotherapy
even if the disease is far advanced at diagnosis (Josting et al., 2002; Schmitz et al., 2005).
The impact of EBV on clinical outcome is still controversial. Kwon and colleagues (2006) reported
both EBER and LMP1 positivities were associated with longer progression-free survival in patients
younger than 25 years of age. However, reverse trends were noticed in older patients. Keegan and
colleagues (2005) reported that EBV presence was associated with better survival in young patients
(<15 years old). In adults aged 15 to 44 EBV did not affect the outcome. In older adults (45 to 96
years) EBV presence was associated with poorer survival for patients with nodular sclerosis
(Keegan et al., 2005).
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6.24 NON-HODGKIN’S LYMPHOMA IN IMMUNOCOMPETENT INDIVIDUALS
EBV can also infect lymphoid cells other than B-cells. Several types of non-B-cell, non-Hodgkin’s
lymphoma are associated with EBV: nasal T/natural killer (NK)-cell lymphoma and
angioimmunoblastic lymphadenopathy are the most directly associated with EBV (Jones et al.,
1988; Weiss et al., 1992; Thompson et al., 2004). Nasal T/NK-cell lymphoma is characterized by
progressive necrotic lesions in the nasal cavity, nasopharynx and palate (Jaffe et al., 1996). It has
been called angiocentric lymphoma, lethal midline granuloma, or polymorphic reticulosis (Harris et
al., 1994). Nasal T/NK lymphoma cells have several unique genotypic and phenotypic features.
These features include an absence of T-cell antigens, expression of natural killer cell marker CD 56,
and absence of T-cell receptor gene rearrangement (Harabuchi et al., 1990; Weiss et al., 1992;
Kwong et al., 1997; Baumforth et al., 1999; Thompson et al., 2004). EBV is strongly associated
with these lymphomas, almost all cases are positive for EBV (Harabuchi et al., 1990; Ho et al.,
1990; Weiss et al., 1992; Kanavaros et al., 1993; Nagata et al., 2001; Thompson et al., 2004). Nasal
T/NK-cell lymphoma is a relative rare disease associated with quite a poor prognosis and it is more
prevalent in Asia than in Europe and in the United States (Lipford et al., 1988; Frierson et al., 1989;
Ratech et al., 1989; Ho et al., 1990; Nakamura et al., 1997; Cheung et al., 1998; Nagata et al.,
2001).
Angioimmunoblastic lymphadenopathy is a T-cell lymphoma in which expanding B-cell clones are
often present beside the T-cell clones. EBV infection is mainly seen in the B lymphocytes and B
immunoblasts, although the virus also occurs in rare neoplastic and nonneoplastic T cells (Weiss et
al., 1992; Thompson et al., 2004). The presence of EBV in only a subpopulation of cells suggests
that EBV infection is secondary to malignancy or that the viral genome has been lost from the
malignant cell (Thompson et al., 2004). EBV-positive B cells have also been observed growing in
peripheral T-cell lymphomas (Ho et al., 1998); EBV might be activated in latently infected B cells
by the neoplastic T cells, and/or the EBV-positive B cells might play a role in maintaining the
malignant T-cell process (Hojo et al., 1995; Ho et al., 1999; Thompson et al., 2004).
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6.25 POST-TRANSPLANT LYMPHOPROLIFERATIVE DISEASE
Post-transplant lymphoproliferative disease (PTLD) forms a wide spectrum of disorders
complicating immunosuppressive conditions of various forms. An increased incidence of
lymphomas in immunosuppressed transplant recipients was first recognized in 1969, and further
studies demonstrated that 90% of PTLDs are Epstein-Barr virus positive (Penn et al., 1969; Paya et
al., 1999). The development of PTLD is linked to a deficient EBV-specific cellular immune
response. In solid organ transplant recipients, this deficiency is caused by imunosuppression
administered to prevent graft rejection; in hematopoietic stem cell transplant recipients, it is caused
by high-dose chemotherapy and/or radiation administered as part of the conditioning regimen,
manipulation of the graft to deplete T cells or immunosuppression to prevent graft-versus-host
disease (GVHD).
There is no universally accepted definition of PTLD (Loren et al., 2003). The term generally refers
to a spectrum of B-cell hyperproliferative states, and includes benign conditions such as infectious
monucleosis-like illness, polyclonal lymphoid hyperplasia, and monoclonal malignancies such as
B-cell (and occasionally T cell) lymphomas (Nalesnik et al., 1996; Baumforth et al., 1999; Loren et
al., 2003). Recommendations for a formal classification of PTLD were established by two
international consensus groups and published in 1999 (Paya et al., 1999). According to these
guidelines, the term PTLD may encompass the full range of EBV-related lymphoproliferative
states, including benign processes (Loren et al., 2003). However, when not otherwise specified,
PTLD should refer to the neoplastic end of the PTLD spectrum (Loren et al., 2003). According to
the WHO classification, PTLD can be classified into: (1) early lesions, generally represented by
EBV driven polyconal lymphoproliferations and (2) true monoclonal diseases, including
polymorphic PTLD and monomorphic PTLD; the latter further distinguished into Burkitt
lymphoma/Burkitt-like lymphoma, diffuse large B-cell lymphoma and Hodgkin’s lymphoma (Jaffe
et al., 2001; Capello et al., 2005). Neoplasia should be defined by two of the following three
characteristics: (1) destruction of the underlying lymph node architecture; (2) monoclonality
(regardless of morphology); (3) evidence of EBV infection in the neoplastic cells (Loren et al.,
2003).
PTLD may present with a diverse spectrum of clinical symptoms and signs, underscoring the need
for a high index of suspicion in making the diagnosis. Although the highest incidence occurs in the
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first year after transplantation, cases have been reported as late as nine years after transplantation
(Gottschalk et al., 2005). Symptoms and signs are similar to those seen during EBV primary
infection and include fever, sweats, generalized malaise, enlarged tonsils, and cervical
lymphadenopathy or sepsis like syndrome with rapidly progressive lymphoma (Weinstock et al.,
2006). PTLD may involve virtually any organ system, including the central nervous system, bone
marrow, intestine, kidneys, liver, spleen and lungs. Often, diffuse disease is diagnosed only at
autopsy in patients thought to have fulminant sepsis or severe GVHD.
Most lymphoproliferations that arise after solid organ grafts are of host cell origin, whereas those
that occur after bone marrow transplantation are often derived from donor cells (Baumforth et al.,
1999). Following organ transplantation the incidence rates of this potentially fatal syndrome vary
according to the type of graft and the immunosuppressive regimen (Paya et al., 1999; Ellis et al.,
1999; Pen, 2000; Kew et al., 2000; Hopwood et Crawford, 2000). The duration of
immunosuppression, the dosage, and the number of agents used influence both the risk of post-
transplant lymphoproliferative disease and its clinical pattern (Baumforth et al., 1999).
In association with allogeneic stem-cell transplantation (SCT), PTLD has been considered rare
(incidence  1 percent), albeit with risk factors associated with severe immunosuppression, higher
rates may be encountered (Zutter et al., 1988; Witherspoon et al., 1989; Baumforth et al., 1999;
Ifthikharuddin et al., 2000). Risk factors such as HLA disparity, graft T-cell depletion, severe graft-
versus-host disease (GVHD), anti-thymocyte globulin (ATG) treatment or anti-CD3 monoclonal
antibodies may increase the risk to as high as 15-25% (Lucas et al., 1998; Zutter et al., 1988; Curtis
et al, 1999). Consistent with the essential role of T cells in controlling the proliferation of latent
EBV-infected B-cells, each of these risk factors is associated with prolonged and severe T-cell
immunodeficiency (Weinstock et al., 2006). In fact, methods of T-cell depletion that selectively
target T cell or T- and NK-cell populations confer a significantly higher risk of PTLD than methods
that deplete both T- and B cells (Curtis et al., 1999; Cohen et al., 2005; Weinstock et al., 2006). The
importance of T-cell dysfunction is highlighted by the fact that the majority of PTLD cases occur
within the first year post-transplant, when the recipient is severely immunocompromised to prevent
GVHD or graft rejection (Gottschalk et al., 2005).
Early diagnosis of PTLD is demanding. Significant attention has been focused on assays for the
early diagnosis of PTLD for two reasons. First, clinical presentation can be non-specific and easily
confused with other infections or GVHD (O´Reilly et al., 1997; Gottschalk et al., 2005; Weinstock
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et al., 2006). Second, the disease tends to be aggressive, and the prognosis without specific
treatment, poor (Zutter et al., 1988; Benkerrou et al., 1998; Lucas et al., 1998). However, general
reduction of immunosuppression, donor lymphocytes or EBV-specific cytotoxic T cells, and
infusions of anti-CD 20 antibody have yielded promising results (Papadopoulos et al., 1994;
Ifthikharuddin et al., 2000; Kuehnle et al., 2000; Verschuuren et al., 2002). It is reasonable to
assume that early treatment improves survival. Quantitative PCR (qPCR) for EBV DNA is a new,
highly encouraging approach (Kimura et al., 1999; Niesters et al., 2000; Ohga et al., 2001; Wagner
et al., 2001). Also, the efficacy of PTLD treatment can be monitored with EBV qPCR (Rooney et
al., 1998; Yang et al., 2000; Meerbach et al., 2001).
6.26 GASTRIC CARCINOMA
In immunocompetent individuals, EBV infection also might be associated with gastric cancers.
EBV presence varies from >90% in lymphoepithelioma-like gastric carcinomas to between 5 and
25% in gastric adenocarcinomas (Niedobitek et al., 1992; Pittaluga et al., 1992; Oda et al., 1993;
Wu et al., 2000; Thompson et al., 2004). Whether EBV plays a pathogenic role in either of these
two tumors is unclear (Pittaluga et al., 1992; Oda et al., 1993; Thompson et al., 2004). It has been
proposed that in lymphoepithelioma-like gastric carcinoma, EBV spreads from the nasopharynx to
the stomach (Iezzoni et al., 1995; Wu et al., 2000; Thompson et al., 2004). With regard to gastric
adenocarcinomas, EBV may enter the gastric epithelium without the use of a receptor; by binding of
IgA antibody with EBV particles derived from B lymphocytes and the uptake of these particles by
gastric epithelial cells (Fukuyama et al., 1994; Thompson et al., 2004) or via a receptor other than
CD 21 (Yoshiyama et al., 1997).
EBV exhibits a novel latency pattern in gastric adenocarcinomas that includes the production of
BARF-1, and the absence of LMP-1 (Strockbine et al., 1998; Kume et al., 1999; zur Hausen et al.,
2000). Although any mechanism in gastric malignancies relating EBV to tumorigenesis remains
highly speculative, there is a delay in apoptosis in EBV-positive gastric carcinomas and a decrease
in cellular differentiation (Biose et al., 1993; Kume et al., 1999; Wu et al., 2000; Thompson et al.,
2004).
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6.27 EBV AND BREAST CANCER
The association between EBV and breast cancer is still quite controversial: EBV has been detected
in subsets of breast cancer tumors (Labrecque et al., 1995; Luqmani et Shousha, 1995; Bonnet et al.,
1999; Fina et al., 2001; Arbach et al., 2006), but negative results have also been obtained (Chu et
al., 2001; Deshpande et al., 2002; Hermann et Niedobitek, 2003; Murray et al., 2003). Low viral
loads have been detected in breast cancer biopsy specimens, but the infected cells have not been
clearly identified. Arbach and his colleaques (2006) detected EBV DNA by quantitative PCR in
whole tumors and microdissected tumor cells. Half of tumor specimens contained EBV DNA with
low copy numbers. In this study the viral load was highly variable from tumor to tumor and EBV
genomes were heteroneously distributed in morphologically identical tumors cells (there were some
clusters of isolated tumor cells with relatively high genome numbers while other tumor cells from
the same sample may be negative for EBV DNA). Arbach and colleagues (2006) detected EBNA-1
and BARF-1 transcripts in almost all of the EBV-positive tumors and LMP-1 RNA in three of the
15 cases studied.
Hennard and colleagues (2006) have reported that the 2B4 monoclonal antibody, which have been
commonly used to demonstrate EBNA1 protein in tumor samples, cross-reacts with the MAGE4
protein. The MAGE4 protein is a cancer testis antigen which is expressed in a number of tumor
types (Hennard et al., 2006). The authors recommend that this 2B4 monoclonal antibody should not
be used to screen tissue samples for EBV (Murray et al., 2003; Huang et al., 2003). The PCR
studies of microdissected tissues show that a small percentage of tumors carry EBV (Arbach et al.,
2006; Murray, 2006). Interestingly, EBER expression has not been detected; it remains to be seen
whether EBER-negative form of latency really exists (Murray, 2006). In conclusion, in those EBV
positive cases, virus is present at low copy numbers and detectable only in a fraction of tumor cells
(Arbach et al., 2006; Murray, 2006). It is possible that although EBV does not have an etiologic role
in the genesis of breast cancer, the virus might contribute to tumor progression (Arbach et al., 2006,
Murray, 2006).
58
6.28 EBV AND HIV
T cells from patients with AIDS suppress EBV-infected B cells less effectively than do cells from
immunocompetent individuals (Birx et al., 1986). Patients with HIV have increased amounts of
EBV in their oropharyngeal secretions (Jenson et al., 1999). A decline in EBV-specific cytotoxic T
cells and an elevated and increasing EBV viral load preceded the development of EBV-associated
non-Hodgkin’s lymphomas in patients with HIV infection (Kersten et al., 1997; Cohen, 2000).
Oral hairy leukoplakia occurs in HIV infected patients as well as in some immunosuppressed
transplant recipients. It presents with raised, white, corrugated lesions of the oral mucosa. It is a
non-malignant hyperplastic lesion of epithelial cells. EBV DNA and herpesvirus particles are
present in the upper, keratinized epithelial cells of the lesions (Cohen, 2000). Multiple EBV strains
are often present in the same lesion. Oral hairy leukoplakia lesions show active viral replication and
expression of lytic viral proteins (Greenspan et al., 1985; Triantos et al., 1997).
Lymphoid interstitial pneumonitis occurs primarily in children, but also in adults infected with HIV.
It is characterized by diffuse interstitial pulmonary infiltrates and alveolar septa are infiltrated with
lymphocytes, plasma cells, and immunoblasts (Cohen, 2000). EBV DNA and proteins have been
detected in the pulmonary lesions (Andiman et al., 1985).
About 50 to 60 percent of non-Hodgkin’s lymphoma tumors in HIV-infected patients contain EBV
DNA or proteins (Hamilton-Dutoit et al., 1991; Shibata et al., 1993). Most of the tumors are
classified as either immunoblastic lymphomas of Burkitt-type, while a smaller number are large-cell
lymphomas (Cohen, 2000). Virtually all AIDS-related central nervous system lymphomas are
derived from germinal center B cells and almost always contain EBV DNA (MacMahon et al.,
1991; Cesarman et al., 1999). The prognosis of HIV related primary central nervous system
lymphoma is very poor, with median survival time not exceeding 2 months. Brain biopsy was the
method of choice for the definitive diagnosis, but it was and remains an invasive procedure with
morbidity and mortality as well as considerable costs in terms of patients' management and quality
of life. The strict association between AIDS-related central nervous system lymphoma and EBV led
to the suggestion that EBV DNA in cerebrospinal spinal fluid (CSF) might serve as a diagnostic
marker, reducing the time required for diagnosis and allowing a minimally invasive approach
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(Antinori et al., 1997; Cingolani et al., 2005). The clinical usefulness of this methodology has been
largely demonstrated through clinical practice.
6.29 DIAGNOSIS OF EBV INFECTIONS
Serological diagnosis of EBV primary infection is classically based on detection of heterophile
antibodies and on measurement of antibody reactivity for various EBV antigens, including viral
capsid antigen (VCA), the early antigens (EA), and members of the Epstein-Barr virus nuclear
antigen (EBNA) family (Table II). Characteristic for EBV primary infection are positive VCA IgM
and IgG results and lack of EBNA-1 antibodies (Henle et al., 1974; Linde, 1996). EA IgG becomes
detectable after VCA IgG and disappears within a few months (Henle et al., 1971). During
convalescence, VCA IgM antibodies usually disappear and the EBNA-1 test becomes positive,
while VCA IgG persists for life. However, even in immunocompetent seropositive individuals
EBNA-1 antibodies can sometimes remain negative (Lamy et al., 1982; Horwitz et al. 1985;
Kampmann et al. 1993; Linde, 1996), and more often in immunocompromised patients or in chronic
mononucleosis (Henle et al., 1981; Miller et al., 1987; Kampmann et al., 1993).
A sign of viral reactivation can be the reappearance of VCA IgM antibodies, but VCA IgM in some
patients remains detectable long after EBV infection even with no known reason (Schmitz et al.,
1972; Sumaya, 1977). To date, no single commonly accepted serological criterion exists for EBV
reactivation. Many different parameters have been used: rise of EA IgG or EA IgA titer (Hornef et
al., 1995), seroconversion of EA IgM (Hornef et al., 1995), decrease of EBNA IgG (Quesnel et al.,
1992; Taneichi et al., 1993; Hornef et al., 1995), increase of VCA IgG (Rahman et al., 1991;
Quesnel et al., 1992; Glaser et al., 1994) or simultaneous positivity to EA IgM and EBNA IgG
(Obel et al., 1996). The ZEBRA protein (BamHI Z EBV replication activator) controls the switch of
EBV from a latent to a productive cycle (Countryman et al., 1985 and 1987; Chevallier-Greco et al.,
1986; Lieberman et al., 1986), and ZEBRA IgG has been proposed as a serological marker for EBV
reactivation (Maréchal et al., 1993). On the other hand, while ZEBRA antibodies are rarely
detectable in healthy EBV seropositives (2-4%), they do not uncommonly (75-87%) occur in
patients with nasopharyngeal carcinoma, but also during infectious mononucleosis (85%) (Joab et
al., 1991; Mathew et al., 1994). Furthermore, it seems that in the ZEBRA protein different B-cell
epitopes are associated with different EBV-associated diseases (Tedeshi et al., 1995). In Finland
Lehtinen and colleagues (1993) have reported that elevated EBV EA and EBNA antibody levels
were associated with a statistically significant excess risk of malignant lymphoma/leukaemia. These
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elevated antibody responses may be due either to destruction of neoplastic EBV positive B-cells
and/or to activation of latent EBV infection early in the lymphomagenesis.
Measurement of IgG avidity has been shown to be a powerful tool for differentiation of primary and
secondary infections of various pathogens (Hedman et al., 1988, 1991 and 1993; Blackburn et al.,
1991). Also in EBV serodiagnosis, avidity of VCA IgG or EA IgG separates primary and secondary
infections both in immunocompetent and immunocompromised individuals (De Ory et al., 1993;
Andersson et al., 1994; Vetter et al., 1994; Gray 1995; Weissbrich, 1998; Korhonen et al., 1999).
Some difficulties have been encountered in detecting EBV at the tissue level, which is necessary for
tumor diagnosis. The low copy number of viral genomes and the restricted pattern of viral antigen
expression limit the reliability of many standard techniques including Southern blot hydridisation,
antigen detection and in situ hybridisation (ISH) of mRNA or DNA targets (MacMahon et al.,
1994). On the other hand, sensitive techniques such as PCR can detect EBV in normal tissues.
Monoclonal antibodies to the EBV latent proteins EBNA-2 and LMP-1 have been used to
demonstrate viral expression in lymphoproliferative disease, Hodgkin’s disease and nasopharyngeal
carcinoma (Young et al., 1989; Pallesan et al., 1991; Brousset et al., 1992). Due to variable
expression of EBV latent proteins and technical difficulties with fixed tissues, the failure to detect
these proteins does not necessarily indicate the absence of EBV (MacMahon et al., 1994).
However, targeting of the EBER transcripts with the in situ hybridisation method has proved to be a
sensitive and specific technique (MacMahon et al., 1994). EBERs are excellent targets for in situ
hybridisation, because they are abundantly expressed during EBV latency with an estimated copy
number of ten million per cell (Arrand et al., 1982; Howe et al., 1986; MacMahon et al., 1994).
With EBER in situ hybridisation EBV has been localised in Reed-Sternberg and Hodgkin’s cells
but occasionally also in small benign-appearing cells in tumor tissue in Hodgkin’s lymphoma
(Weiss et al., 1991; Herbst et al., 1992; Khan et al., 1992). With this technique EBV can be detected
in EBV-associated lymphoid and epithelial tumors, in benign lymphoid tissue and in cultured cell
lines (MacMahon et al., 1994). Oral hairy leukoplakia and some hepatocellular carcinomas are the
exceptions; EBERs are not expressed (Gilligan et al., 1990; Niedobitek et al., 1991; Sugawara et al.,
1999).
For definitive PTLD diagnosis, a biopsy is required for morphological analysis, detection of EBV
antigens by immunohistochemistry and EBER in situ hybridisation; furthermore, the clonality of B-
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cell growth may be determined by immunoglobulin light chain type or rearrangement of the
corresponding genes (Hanto et al., 1983; Nalesnik et al., 1988; Randhawa et al., 1992; Knowles et
al., 1995). However, due to the rapidity of PTLD progression especially after SCT, the diagnosis
must be obtained quickly. New PCR-based methods show promise in permitting fast quantitation of
viral DNA in fluidic or cellular samples (Kimura et al., 1999; Limaya et al., 1999; Niesters et al.,
2000; Hukkanen 2000 and 2002). Also the efficacy of PTLD treatment may be monitored by
quantitation of EBV load, aiming at a favourable balance between the degree of
immunosuppression and the preponderance of (graft or host) rejection (Rooney et al., 1998;
McGuirk et al., 1999; Yang et al., 2000; Meerbach et al., 2001; Weinstock et al., 2006).
Diagnosis of EBV infection
PRIMARY INFECTION CONVALESCENCE REACTIVATION PTLD
VCA IgM +++ neg (+) + +/-
VCA IgG +++ +++ +++ +/-
Heterophile ab +++ neg +/- +/-
EBNA-1 IgG neg +++ ( -) +++ +/-
EBNA-2 IgG +/- ++
EA-D IgG ++ neg + +/-
VCA IgG avidity low high high
EBER ISH +++
EBV qPCR +++ +++ +++
Table II. Summary of diagnostic EBV antibody, ISH and PCR findings.
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7. AIMS OF THE PRESENT STUDY
(i) Our first goal was to assess the relation between the occurrence of VCA IgM together
with high-avidity VCA IgG antibodies, and the presence of cytomegalovirus infection.
(ii) To set up an in situ hybridisation assay for detection of EBV RNA in tissue sections and
for diagnosis of EBV infection at the cellular level.
(iii) To set up up a real-time PCR assay for quantification of EBV-DNA in serum or plasma
samples for the diagnosis of PTLD.
(iv) To estimate the contributory role of EBV, cytomegalovirus and human papilloma
viruses in the development of malignancies after heart transplantation.
(v) To determine the incidence of fatal Epstein-Barr virus –related PTLD in a large number
of stem-cell transplantations, and to assess the diagnostic value of the real-time
quantitative PCR for EBV-DNA.
(vi) To identify the risk factors for PTLD.
(vii) To evaluate the frequency of EBV reactivations and the kinetics of development of
PTLD in a large cohort of unselected stem-cell transplant recipients.
(viii) To evaluate the development of PTLD according to the copy number levels of EBV
DNA.
(ix) To find out the frequency and clinical significance of EBV infections of various types
occurring after liver transplantation in adult recipients.
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8. MATERIALS AND METHODS
8.1 PATIENTS (I, II, III, IV, V, VI)
Study I: Altogether, 192 samples of serum from 60 patients with serologically confirmed CMV
primary infection, defined by seroconversion or  fourfold rise of CMV IgG or low avidity of CMV
IgG, together with detectable CMV-IgM antibodies, were assayed for EBV VCA IgM and IgG.
Samples with diagnostic findings, seroconversion of VCA-IgM or  fourfold rise in VCA-IgG,
were further examined for VCA IgG avidity, EA IgG, EBNA IgG, HHV-6 IgG and as an
immunofluorescence (IF) specificity control for nephropathia epidemica IgG (see below). For
additional control, samples were studied for IgG antibodies against another latently infecting
herpesvirus; varicella zoster virus.
According to clinical data, 50 patients (age range 3-64 years, mean 31) with 154 sera were
immunocompetent. The cardinal symptoms were: fever, lymphocytosis, fatigue, and headache. The
mean period between the diagnostic samples was 37 days. Of the 60 patients, ten (38 sera) were
organ transplant recipients (2 heart, 3 liver, and 5 kidney) with posttransplant CMV primary
infection (age range 17-61 years, mean 43). The serodiagnosis of CMV primary infection in the
latter group was made 30 to 237 days (mean 105) after transplantation as indicated by the collection
date of the first seropositive sample of each patient containing low-avidity CMV IgG. The mean
period between the diagnostic samples in this group was 90 days.
Conversely, serum pairs from 22 patients (age range 1-42 years, mean 16) with EBV primary
infection, diagnosed by positive EBV VCA IgM together with low-avidity VCA IgG, were studied
for CMV IgM, IgG, and IgG avidity. The mean sample interval was 17 days. All the serum samples
described had been referred for diagnostic purposes to the clinical virus laboratory of the Helsinki
University Central Hospital.
As a separate control group, sera from 170 children (age range <1-15 years, mean 3.8) with acute
septic or severe respiratory infection treated at The Hospital for Children and Adolescents,
University of Helsinki, were studied for VCA IgM, and follow-up samples of the IgM positive sera
were further studied for VCA IgG and IgG avidity. Serum pairs from these controls were also
studied for HHV-6 IgG.
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Study II: In total, 249 heart transplantations were performed in the Helsinki University Central
Hospital between February 1985 and October 1999 (Mattila et al., 1997). The presence of EBV and
human papilloma virus (HPV) and cytomegalovirus (CMV) was studied in 20 patients who
developed malignancies after heart transplantation. The tumors were analyzed for the presence of
HPV by PCR and for EBV by in situ hybridisation. CMV infection was verified by
immunochemical quantitation of CMV antigen in peripheral blood (see below).
In October 1999, 170 (68%) of the patients were alive. The indications for heart transplantation
were dilating cardiomyopathy (CMP) in 130 patients, ischemic heart disease (IHD) in 94, valve
disease in 15, congenital heart disease in six, and myocarditis in four cases. The
immunosuppression consisted of anti-thymocyte globulin (ATG), cyclosporine A (CyA),
azathioprine (Aza) and methylprednisolone (MP). ATG (Fresenius or Merieux) at 2.5mg/kg was
given during the first 3 post-operative days. CyA was started on the first post-operative day aiming
at level 250-350 μg/L during the first 3 post-operative months and then tempering down to 150-200
μg/L during the first post-operative year. Aza at 2 mg/kg was started on the first post-operative day.
The dosage was reduced if the white blood cell count per mL dropped to less than 3000. One gram
of methylprednisolone was given during the operation and subsequently for 3 days. The dose was
then tapered down to 0.1 mg/kg for the first month post-operatively. Acute rejection was diagnosed
by endomyocardial biopsy and treated with 0.5-1.0 g of methylprednisolone for 3 days, after which
an endomyocardial biopsy was taken. If the rejection had not subsided, ATG was administered.
Acyclovir 800mg daily was given for 6 wk to all patients for prophylaxis against infections of the
herpes virus group, and trimethoprim-sulfa-methoxazole was given three times a week for 6 months
for prophylaxis of Pneumocystis jirovecii infections.
Study III and IV: During 1994-1999 257 adult patients underwent allogeneic SCT at Helsinki
University Central Hospital, 132 (51%) recipients were alive and 125 (49%) had succumbed by
June 2001. The cause of death was transplant-related in 76 patients (61%), relapse in 42 patients
(34%), and other in seven cases (5%). Seventy-seven (62%) of the 124 deceased patients underwent
autopsy. Their post-morten reports were reviewed in purpose of finding possible PTLD cases. In
suspect cases archived post-mortem paraffin blocks were re-examined immunohistologically for
EBV antigens (LMP, EBNA) and by in situ hybridisation for EBV RNA (EBER 1 and 2) (see
below). From a subset of the PTLD cases (N=12) and a series of corresponding stem-cell recipient
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controls (N=36), consecutive samples of serum (N=103 and 364, respectively) were studied by
qPCR for EBV DNA, and the clinical data were reviewed.
Of the donors 173 were siblings and 84 were unrelated. Most (250) transplants were carried out
with a conventional myeloablative regimen consisting of cyclophosphamide and total body
irradiation (TBI), and in transplants from an unrelated donor also antithymocyte globulin (ATG)
was also used. In seven transplantations, the conditioning was non-myeloablative; fludarbine
combined with cyclophosphamide or a single 2 Gy dose of TBI. The indication for transplantation
was a hematological malignancy in 253 patients and aplastic anemia in four patients. All donors,
except one sibling with a single HLA A locus difference, were matched for HLA A, B, and DR. The
grafts were non-manipulated apart form red cell and plasma removal from bone marrow grafts in
cases of ABO-incompatibility. For graft versus host disease (GVHD) prophylaxis in myeloablative
transplantation, the patients received cyclosporine A (CyA), short-course methotrexate, and
methylprednisolone (MP) (Ruutu et al., 2000); and in non-myeloablative regimens, CyA with
mycophenolate. Acute GVHD was assessed and graded according to previously published criteria
(Thomas et al., 1975) and treated with intravenous MP. In corticosteroid-resistant cases ATG was
given as second-line treatment.
As a positive-control group for the EBV qPCR assay (see below), sera were collected from 16
patients with serologically verified EBV mononucleosis (detectable EBV-IgM together with low
avidity of EBV-IgG) 4-22 days (mean 11) after clinical onset. Of these mononucleosis patients 94%
(15/16) presented with EBV DNA in serum, with copy numbers ranging from 4400 to 249 300
(mean 45 700) per ml. As negative-control groups, we had 13 members of healthy laboratory staff
and eight patients with non-EBV tonsillitis. No sera from these controls contained detectable levels
of EBV DNA.
Study V: In total, 105 adult liver allograft recipients transplanted between 1999-2002 were
sequentially monitored for CMV, HHV-6 and HHV-7 during the first year after transplantation, and
the specimens were retrospectively used to investigate the presence of EBV by qPCR (see below).
As basic immunosuppressive therapy, the patients received combinations of steroids, azathioprine,
and cyclosporine or tacrolimus. Rejections were treated with high doses of steroids. No routine
antiviral prophylaxis was given, besides ganciclovir (5mg/kg twice daily) during rejection therapy.
CMV infections were diagnosed using the standard pp65-antigenemia assay and by quantitative
plasma DNA-PCR (Cobas Amplicor CMV Monitor, Roche, or real-time TaqMan PCR).
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Symptomatic CMV infections were treated with intravenous ganciclovir (5mg/kg twice daily) for at
least two weeks. As all our transplant recipients were adults, pre-transplant EBV serology (available
for 61/105) showed a seroprevalence of 97%; post-transplant EBV serology was performed only by
demand.
The clinical material comprised 1284 consecutive samples of EDTA-blood obtained weekly during
the patients´ hospitalization and thereafter according to our clinical protocol at 1, 2, 3, 6, 9 and 12
months after transplantation and in case of clinical symptoms. The blood sampling for the EBV
DNA-PCR occurred in parallel with the sampling for the CMV-pp65 antigen test, CMV DNA-PCR
and HHV-6 and HHV-7 antigen detection, which were performed immediately. Plasma was isolated
within 24 hours of EDTA-blood and used for PCR. Plasma samples were stored at -70°C for later
retrospective analysis.
Study VI: Altogether 409 adult patients were treated with haematopoietic stem cell transplantation
for hematological malignancy or severe aplastic anemia during the years 1988 – 1999 at Helsinki
University Central Hospital (HUCH). Four hundred and six patients were included in the study.
Altogether 5479 serum samples from 406 adult allogeneic SCT recipients treated during 1988-1999
at Helsinki University Central Hospital were studied by qPCR for EBV DNA. The patients in the
studies III and IV are also included in this patient material. Three patients were excluded due to
missing serum samples. The sera had been collected sequentially, 2 to 28 samples from each
patient. The clinical and transplant data of the patients are described in detail in Juvonen et al.
(2007).
8.2 SEROLOGICAL DIAGNOSIS OF EBV INFECTION (I, III)
EBV VCA IgM was determined by an immunofluorescence assay (IFA) (Gull Laboratories, Salt
Lake City, UT), in which rheumatoid factor interference was prevented by GullSORB IgG
Inactivation Reagent (Gull Laboratories). VCA IgG was measured by an EBV IgG enzyme
immunoassay (EIA) (Gull Laboratories) performed according to the manufacturer’s instructions.
EA IgG was measured by IFA (Gull Laboratories). This test detects both diffuse (D) and restricted
(R) components of the EBV EA complex. EBNA IgG was measured with anticomplement IFA
(Gull Laboratories) using as antigen Raji cells, which preferentially express EBNA-1. Heterophile
antibodies were determined by the agglutination slide test Monosticon DRI-DOT (Organon
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Teknika, Boxtel, Netherlands). VCA IgG avidity was measured on EBV VCA EIA plates (Gull
Laboratories) by a protein-denaturing EIA employing endpoint titration of IgG (Hedman et al.,
1989 and 1993). Briefly, the sera were diluted in PBS containing 0.05% Tween 20 (PBST) serially
in fourfold steps from 1:40 to 1:10,240, or from 1:10 to 1:2560, depending on the VCA IgG titer.
After 1 hr incubation at 37°C, the wells containing the first four (lower) dilutions were washed with
6 M urea in PBST and those with the last four (higher) dilutions with PBST alone. All wells were
then treated for 30 min at 37°C with alkaline phosphatase-conjugated antihuman IgG followed by
substrate. Two antibody titration curves were constructed for each sample: one of the urea-washed
wells and the other of the PBST-washed wells. IgG avidity was calculated by the percent ratio of
antibody titers (urea+/urea-) x 100. Avidity 25% indicates primary infection; 25-40% is
borderline; and 40% indicates past immunity (Hedman et al., 1993; data not shown). In three cases
with controversial results, EBV-IgG avidity was measured by the Enzygnost EBV IgG kit (Behring
Diagnostics, Marzburg, Germany) containing an EBV antigen mix employing single dilutions of
serum (Hedman et al., 1988) as described by Weissbrich (1998).
8.3 SEROLOGICAL DIAGNOSIS OF CMV, HHV-6, NEPHROPATHIA EPIDEMICA AND
VARICELLA ZOSTER (I)
CMV IgM and CMV IgG were measured by indirect EIA (Labsystems, Helsinki, Finland)
according to the manufacturer’s instructions. CMV IgG avidity was measured with EBV IgG-EIA
kits (Labsystems) essentially as described above for VCA IgG avidity. CMV-IgG avidity 20%
indicates primary infection; 20-35% is borderline; and 35% denotes past immunity (Hedman et
Andersen, 1993). HHV-6 IgG was measured by an in-house IFA using infected HSB-2 cells as
antigen as described previously (Linnavuori et al., 1992). Nephropathia epidemica IgG was
determined by IFA with Puumala virus-infected Vero E6 cells (Hedman et al., 1991). The pattern of
IgG fluorescence indicating acute infection or past immunity was evaluated and categorized as
shown before (Vapalahti et al., 1995). Varicella zoster IgG was measured by indirect EIA on
polystyrene strips (Labsystems) coated with varicella zoster EIA antigen (Virion, Rüschlikon,
Switzerland).
8.4 DIAGNOSIS OF CMV (II, V)
CMV infections were diagnosed by the presence of pp65 antigen-positive leukocytes (100 positive
cells per 50 000) in peripheral blood as determined by immunochemical staining with monoclonal
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antibody (Biotest Pharma, Frankfurt, Germany) (Koskinen et al., 1993) in patients with a clinical
picture compatible with CMV disease (fever, leucopenia, thrombocytopenia, hepatopathy,
arthralgia, gastroenteritis, or pneumonia). Before 1988, when the CMV antigen test was not
available, CMV infections were diagnosed by the appearance of inclusion bodies in cytology
samples obtained by bronchoalveolar lavage, by the appearance of CMV-specific IgM antibodies,
or by a fourfold rise in CMV-specific IgG antibodies as detected by the respective indirect enzyme-
linked immunoassays (Labsystems, Helsinki, Finland).
In study V for detection of CMV the standard CMVpp65 antigenemia test (see above) and
quantitative CMV-DNA PCR were used. Quantitative plasma CMV DNA-PCR (Cobas Amplicor
CMV Monitor, Roche, or real-time TaqMan PCR) was used for quantitation of CMV DNA in
plasma (Piiparinen et al., 2002 and 2004).
8.5 DIAGNOSIS OF HPV (II)
In the 15 patients with epithelial malignancies eight tumors occurring in seven patients were studied
for HPV DNA. Five skin cancers (two samples from the same patient), one carcinoma of the tonsil,
one of the tongue, and one of the lip were studied. HPV DNA was detected by PCR. Two sets of
primers CPIV/CPV and GP5+/GP6+, were used for each tumor. The CPIV/CPV primers detect a
variety of mucosal and cutaneous HPV types (Tieben et al., 1994) and the GP5+/GP6+ primers a
large number of mucosal HPV types (De Roda Husman et al., 1995). The PCR conditions for the
CPIV/CPV were 2 mmol/l MgCl2, 0.2 mmol/L of each dNTP, 0.4 μmol/L of each primer, 1 U
AmpliTaq Gold (Perkin-Elmer, Foster City, CA, USA) in 50 μL, and the PCR run consisted of 10
min of hot start at 95°C and 35 three-step cycles of 30 s at 95°C, 60 s at 50°C, 60 s at 72°C. The
PCR conditions for the GP5+/GP6+ were 1.5 mmol/L MgCl2, 0.2 mmol/L of each dNTP, 0.4
μmol/L of each primer, 1 U AmpliTaq Gold in 50 μL. The PCR consisted of 10 min of hot start at
95°C and 40 three-step cycles of 60 s at 95°C, 120 s at 40°C, and 90 s at 72°C. The PCR run ended
with 4 min at 72°C. One-fifth of the PCR product was run in an agarose gel, stained with ethidium
bromide, and visualized under UV light. The amplified fragment from one of the HPV DNA-
positive patient was cloned and sequenced to determine the HPV type.
8.6 DIAGNOSIS OF HHV-6 AND HHV-7 (V)
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HHV-6 infections were identified by the qualitative HHV-6 antigenemia test (Lautenschlager et al.,
2000), which detects the virus-specific antigens in peripheral blood mononuclear cells (PBMCs).
The presence of viral antigens in the cytopreparations was demonstrated by indirect
immunoperoxidase staining with monoclonal antibodies (MAB8533 and MAB 8535; Chemicon
Inc.,Temecula, CA, USA) against an early HHV-6 specific antigen (variant A and B), and a HHV-6
variant B virion protein, as described previously (Lautenschlager et al., 2000). HHV-7 specific
antigens were detected in the cytocentrifuge PBMC preparations by using immunoperoxidase
staining with two monoclonal antibodies (Biodesign International, Saco, ME, USA) to detect the
early and late (gp110 and gp160) antigens of HHV-7, respectively, as described previously
(Lautenschlager et al., 2002).
8.7 DIAGNOSIS OF MALIGNANCY (II)
Diagnosis of malignancy was based on microscopy of biopsy specimens. Lymphoma diagnosis was
based on immunohistochemical staining of the tissue specimens with antibodies against CD45,
CD19, and CD3 antigens. Lymphomas were classified according to the Revised European-
American Lymphoma classification (Harris et al., 1994), because this lymphoma classification was
the mostly used in those days. Two of the lymphomas were Burkitt’s (patient 17 and 19), one
located in the submandibular lymph nodes (patient 19) and the other in the ileum (patient 17). Three
patients had CD20 + diffuse large cell lymphomas (patients 15, 16, and 18), two were located in
lymph nodes of the neck (patients 15 and 18), and one in retroperitoneal lymph nodes (patient 16).
In one case, involvement of the ileum was also seen in addition to lymph nodes of the neck (patient
15). Patient 20 had peripheral T-cell lymphoma.
8.8 B-CELL CLONALITY (III, IV)
Clonality of B-cells was determined by genomic DNA extracted from paraffin sections (Jee et al.,
2001) by PCR for immunoglobulin gene rearrangement (Welterlin et al., 2000). The primers were:
VH1, 5´-CTG TCG ACA CGG CCG TGT ATT ACT G-3´; 5´-GGG TCC CTG AGA CTC TCC
TGT GCA-3´; VH1/VH3, 5´-AAC TGC AGA GGA GAC GGT GAC C-3´; CT (3A), 5´-TCA
GAG TGG GCA CAT GTT GG-3´; CT (3B), 5´-TTC CTA CCC TGC CAT CCA TC-3´. The
detection threshold of this method is 1-5% clonality. With paraffin-embedded tissues the method is
highly specific but only moderately (~80%) sensitive (Welterlin et al., 2000).
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8.9 EBV IN SITU HYBRIDISATION (II, III, IV, V, VI)
To detect EBV in the malignant cells, the tumor tissues were studied by in situ hybridisation for
Epstein-Barr-encoded RNA (EBER 1 and EBER 2) (MacMahon et al., 1991; McClain et al., 1995).
Fixed paraffin sections of the malignant tissues were permeabilized proteolytically by proteinase K.
In situ hybridization was performed using a fluorescence-labeled peptide nucleic acid probe
complementary to EBER 1 and EBER 2 (Dako, Glostrup, Denmark) and assayed by Ventana ES
automated slide stainer (Ventana Medical Systems, Tucson, AZ, USA). The probe was visualized
by anti-fluorescein antibody (Boehringer Mannheim, Mannheim, Germany) and Ventana DAB
detection kit (Ventana Medical Systems). Hematoxylin was used as counterstain. To confirm
preservation of RNA, separate slides of each sample were assayed with a positive control PNA
probe (Dako) directed against glyceraldehyde 3-phosphate dehydrogenase (GAPDH) RNA. A
random PNA probe (Dako) was used as a specificity control.
8.10 EBV qPCR (III, IV, V, VI)
For the qPCR assay, DNA was purified from 200 μl serum by proteinase K digestion (0.5mg/ml in
10 mM Tris-buffer, pH 8.0, containing 10 mM NaCl 1mM EDTA and 0.5% SDS) overnight at
37 °C, followed by phenol and chloroform extraction and ethanol precipitation. The purified DNA
was diluted in 50 μL, of which 5 μL was used as a template for the qPCR reaction (Heid et al.,
1996). The primers amplifying a conserved sequence of viral DNA polymerase (BALF5) gene and
a fluorogenic probe for this area have been described by Kimura and colleagues (1999). The probe
was synthesized by PE Applied Biosystems (Foster City, CA, USA). Five microliters of purified
DNA was added to a PCR mixture containing 1 x TaqMan Universal PCR Master Mix (PE Applied
Biosystems), 0.3 μmol of each primer and 0.2 μmol of the fluorogenic probe. Following 2 min at
50 °C for AmpErase UNG enzyme activity and 10 min at 95 °C for activating AmpliTaq Gold DNA
polymerase, 40 cycles of 15 s at 95 °C and 1 min at 60 °C were carried out by a model 7700
Sequence Detector (PE Applied Biosystems).
Real-time fluorescence was measured, and the threshold cycle value (Ct) for each sample was
calculated (Heid et al., 1996). For each PCR run, a standard curve was prepared by sequential
logarithmic dilutions of EBV DNA extracted from 6.00 x 109 EBV particles, strain B95-8
(Advanced Biotechnologies Incorporated, Columbia, MD, USA). The dilutions corresponded to
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106-101 EBV particles per reaction. The curve was created with ABI 7700 Sequence Detection
System software by plotting the Ct values against the known EBV DNA concentration. The
detection limit for DNA positivity was 500 copies per ml serum. All the samples were tested in
duplicate of which the mean value was taken as the DNA copy number. If the difference of the
duplicate Ct values was more than 0.5 cycles, the PCR reaction was performed again. Besides a
standard curve obtained with EBV control DNA, each run included several negative and non-
template controls, and a positive control containing EBV-DNA of a known copy number.
Diagnostic sensitivity was calculated among the 12 cases by the number of qPCR-positive samples
relative to the number of samples drawn after clinical onset of PTLD. Diagnostic specificity was
calculated among the 36 SCT recipient controls by the number of qPCR-negative samples relative
to the total number of samples.
Some modifications were made in study V: Plasma of the specimens, which were obtained for
routine monitoring of the betaherpesviruses and stored for later analysis, were retrospectively
investigated for EBV-DNA. EBV DNA was isolated by using the MagNa Pure LC Instrument
(Roche). MagNa Pure LC Total nucleic acid isolation kit (Roche) was used for extraction of total
nucleic acid from 200l of plasma samples. The purification followed the manufacturer´s
instructions. The nucleic acid was eluted in 50l of low salt elution buffer, where of 12.5 l was
used for each PCR run.
In study VI the sera were assayed retrospectively in pools of five, each comprising sequential sera
from the same patient when possible. If the pool was EBV qPCR positive with a detection limit for
DNA positivity of 500 EBV copies/ml, its constituent sera were re-examined individually. Samples
with positive results were re-examined. Before onset of this study, we carefully set up the pooled-
sample PCR approach, by investigating a large number of serum samples with a known, variably
high EBV DNA level (103 sera from 12 PTLD cases presented in III; data not shown).
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8.11 STATISTICAL ANALYSIS (IV)
Study IV: The 2 –test with continuity correction or Fisher’s exact test, when appropriate, was used
to compare (graft-versus-host disease) GVHD and the use of (anti-thymocyte globulin) ATG in
relation to the risk of PTLD. The role of GVHD was examined by cross-tabulating PTLD and ATG,
also separately, in the groups with or without GVHD.
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9. RESULTS
9.1 CMV-INDUCED EBV IMMUNOREACTIVATION (I)
In serological diagnosis of mononucleosis we had not uncommonly discovered high-avidity VCA
IgG antibodies, indicating past immunity, in EBV VCA IgM positive patients. Further studies often
revealed CMV primary infection. Here, we wanted to determine systematically if and how
frequently CMV induces such findings.
We assayed 192 samples of serum obtained from 60 patients with serologically confirmed CMV
primary infection. Among the 50 immunocompetent patients with CMV primary infection, 46 had
past immunity for EBV. Altogether 18 (38%) patients had VCA-IgM antibodies in one or more
sera. In analysis of sequential samples, eight patients showed antibody profiles of EBV reactivation:
seroconversion of VCA IgM and/or  fourfold rise of VCA IgG, together with high or intermediate
avidity of VCA IgG. All eight patients were EBNA IgG-seropositive; one of these showed a
fourfold titer rise in EBNA IgG. EA IgG was detectable in most of the patients. Of these patients
with EBV reactivation, half had in their first samples high (>40%) VCA IgG avidity and the other
half had borderline (25-40%) avidity. In one patient, the VCA IgG avidity decreased during follow-
up, finally reaching a low level. However, with the EBV antigen mix, IgG avidity of this patient
remained constantly high, confirming that this patient had past immunity for EBV. Among these
eight patients only one was barely and transiently positive for heterophile antibodies and another
had a borderline result; the remaining six patients had no detectable heterophile antibodies.
Interestingly, all eight patients with both a CMV and an EBV diagnosis had also high HHV-6 IgG
titers; four had  fourfold titer rises in HHV-6 IgG. Of these eight patients with EBV antibody rises,
two had Puumala-virus IgG antibodies of past immunity; non-specific antibodies against uninfected
Vero E6 cells were not observed.
The clinical data of the patients with CMV primary infection-induced EBV antibody rises were
compared with those having CMV primary infection without signs of EBV infection. In all, the
clinical pictures in these two groups were similar. However, the patients with CMV-induced EBV
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“immunoreactivation” reported a sore throat somewhat more frequently (P=0.04) than did those
with CMV primary infection alone.
Of the 60 patients with CMV primary infection, 10 were organ transplant recipients. All of them
were EBV-seropositive; five showed serological pictures of EBV recurrence. Of these five patients,
three had  fourfold increases of VCA IgG and three had seroconversions of VCA IgM. Five
patients had EBNA IgG; none showed decreasing titers, whereas one had a fourfold titer rise in
EBNA IgG. EA IgG was detectable in 2/5 patients, of which four had in their first samples high
(<40%) VCA IgG avidity and one had borderline (25-40%) avidity. Two patients showed decreases
of VCA IgG avidity, whereas with the EBV antigen mix such avidity decreases were not seen. None
of these five patients had heterophile antibodies. Concomitant with their serological pictures of
EBV reactivation, all five patients demonstrated  fourfold titer rises in HHV-6 IgG. One patient
had past immunity for Puumala virus, while non-specific Vero-cell antibodies were not seen. Of the
total of 60 patients with CMV primary infection, 58 were varicella zoster virus seropositive. The
varicella zoster IgG antibodies rose significantly in only one patient.
Conversely, 22 patients with EBV primary infection were studied for CMV IgM, IgG and IgG
avidity. Among these patients, 10 were CMV-seropositive, and none presented with a CMV
serodiagnosis. As a separate control group, sera from 170 children with acute septic or severe
respiratory infection were studied for EBV and HHV-6 serology. Among the 170 controls, only two
were EBV IgM-seropositive; both had low avidity of VCA IgG, indicating EBV primary infection,
whereas none showed a picture of EBV immunoreactivation. Similarly, only 3/170 (2%) controls
showed diagnostic rises in HHV-6 IgG.
We concluded that CMV is a particularly active immunoactivator of some, but not all, members of
the herpes virus family and suggest that the in vivo interplay between CMV and EBV occurs
unidirectionally. The high frequency of heterologous herpes virus immunoreactivations poses
demands on – but also provides useful opportunities for laboratory diagnosis of herpesvirus
infections.
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9.2 MALIGNANCIES AFTER HEART TRANSPLANTATION (II)
Altogether, 249 heart transplantations were performed in the Helsinki University Central Hospital
during 1985-1999. Of these transplant recipients, 20 (8.0%) developed malignancies during the
follow-up period (mean 6.5 yr). Fourteen had epithelial malignancies, five had lymphoma, and one
had both lymphoma and spinocellular carcinoma of skin. Among epithelial malignancies were four
pulmonary tumors, two urinary bladder carcinomas, one renal adenocarcinoma, one epidermoid
carcinoma of the tongue, one spinocellular carcinoma of the lip, one melanoma of the skin, two
basal cell carcinomas of the skin, five case of Morbus Bowen of the skin, and four spinocellular
carcinomas of the skin. We determined the presence of EBV, human papilloma viruses (HPV) in
these tumors and quantified manifest CMV infections to evaluate the role of these viruses in the
development of post-transplantation malignancies.
The indications for transplantation were ischemic heart disease (IHD), dilating cardiomyopathy
(CMP), valvular insufficiency, and pulmonary hypertension. Among the patients with malignancies,
IHD was over-represented. Thirteen (65%) of the 20 tumor patients had undergone heart
transplantation for complication of IHD, whereas in the whole transplant series, the proportion of
IHD was significantly lower (38%). The proportion of IHD was especially high in patients who
developed epithelial malignancies (80%). Overall, among the patients transplanted for IHD, 14%
developed post-transplantation malignancies.
The mean age during transplantation of those who developed epithelial malignancies (mean 52.5 yr)
was significantly higher than the mean age in the whole transplant series (mean 42.2 yr). The mean
age of those who had undergone transplantation for IHD (52.8 yr) was also higher than the mean
age in the whole transplant series. The mean age during transplantation of the patients subsequently
developing lymphomas was 46.5 yr.
The interval from transplantation to detection of malignancy varied from 2 to 84 months. The mean
interval both in the patients with epithelial malignancies and in those with lymphoproliferative
disease was 4 yr. Rejection episodes were not more common in the patients with malignancies: 20%
compared to 28% in the entire series.
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To evaluate the role of EBV in the development of post-transplantation malignancies, the tumor
tissues were studied by using in situ hybridisation for Epstein-Barr-encoded RNA (EBER).
Intracellular EBV RNA was demonstrated in the two Burkitt’s lymphomas and in one diffuse large
cell lymphoma (Fig V). The EBER ISH assay worked beautifully with these rather old, paraffin
embedded tissue samples; negative and positive control probes were used with on each sample to
confirm the preservation of cellular RNA.
Figure V. Post-transplantation Burkitt’s lymphoma (patient 19) studied by in situ hybridisation for
EBER (A). The same tissue section hybridised with a negative control probe (B). From II, by
permission.
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Of the three patients with EBV positive lymphomas, two had a history of post-transplantation CMV
infection as opposed to only two of the 14 patients with epithelial malignancies. The frequency of
post-transplantation CMV infection in the whole transplant series was 15%, lower than among the
patients who developed lymphomas (3/6) and lower than in those who developed EBV-positive
lymphomas (2/3). Eight epithelial tumors were screened for HPV DNA, and one was positive. It
was an epidermoid carcinoma of the tonsil harbouring HPV type 16.
These results confirm the presence of EBV in lymphomas of heart transplant recipients and suggest
that CMV migh have a contributory role in the development of EBV-associated lymphomas.
9.3 LYMPHOPROLIFERATIVE DISEASE AFTER ALLOGENEIC STEM CELL
TRANSPLANTATION (III)
We determined the incidence of fatal PTLD among 257 allogeneic stem cell transplantations
performed in Helsinki, Finland during 1994-1999. We also assessed the suitability of a quantitative
EBV-DNA-PCR for pre-emptive diagnosis of post-SCT PTLD by using ordinary serum samples.
Of the 257 SCT, 132 (51%) recipients were alive and 123 (49%) succumbed by June 2001. The
necropsies were analyzed for EBV-related PTLD and the post-mortem analysis revealed 18 cases of
PTLD presenting with disseminated infiltrations of EBV-positive lymphocytes. PCR for
immunoglobulin gene rearrangement verified clonal proliferation of B-cells in most (59%) cases.
The overall incidence of PTLD was 7%; for sibling transplantations 3%, for transplantations with
an unrelated donor 14%, and for the deceased, 14%. None of the sibling-graft recipients without
aggressive treatment for acute GVHD developed PTLD. Conversely, all the PTLD patients with a
sibling donor had undergone intense immunosuppressive treatment for severe acute GVHD,
including ATG. All the PTLD patients with an unrelated donor had received ATG. All the 12 PTLD
patients with an unrelated donor had received ATG as part of conditioning before transplantation,
and five for treatment of severe acute GVHD. In all, the incidence of PTLD was as high as 40%
(6/15) among SCT recipients having required intensive GVHD treatment.
Among the 18 PTLD patients, a subset of 12 from whom 103 serum samples obtained sequentially
between transplantation and death were available, and were studied further for EBV antibodies and
DNA. Before transplantation none of the patients had EBV-IgM, and 11/12 had EBV IgG of high
avidity indicating past immunity. The other patient remained EBV-IgG seronegative throughout
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follow-up. Post-transplantation, EBV-IgM or heterophile antibodies were not seen, and only one
patient presented with a diagnostic rise of EBV-IgG, with constantly high avidity. All in all, EBV
serology was of little value in PTLD diagnosis. One the other hand, EBV-DNA in serum became
detectable during follow-up of each PTLD patient. The viral DNA was first seen 70 days (median;
range 24-154) after transplantation, and 23 (4-86) days before death. The EBV-DNA copy numbers
rose progressively to levels as high as 106-109 per ml serum in PTLD patients sampled shortly
before death (Fig. VI). By comparison, fever, the first PTLD clinical symptom appeared 15 days (2-
85) before death. All the 15 samples drawn after clinical onset (Fig. VI) were positive for EBV-
DNA, corresponding to a qPCR diagnostic sensitivity of 100%. Considering the notable variation in
the sample intervals, EBV-DNA appeared to be detectable even before onset in all the patients with
appropriate sampling (Fig. VII). Thirty-six SCT recipients were chosen as controls on account of
GVHD of similar grade as in the cases; 13 of the donors were siblings and 23 were unrelated.
Among the controls, EBV-DNA was detectable in 14/364 (3.9%) sera, corresponding to a
diagnostic specificity of 96%. At follow-up, the EBV-DNA positivity of the controls, unlike that of
the cases, was confined within isolated samples, and the EBV DNA copy number levels remained
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Figure VI. Time course of EBV genome loads measured by real-time PCR in consecutive sera from
12 patients who succumbed from PTLD. Each line indicates the viral load (DNA copies per 1 ml
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Figure VII. The same EBV genome loads as in Fig.VI, plotted relative to the onset of PTLD-fever
in each patient (marked as day 0). From III, by permission.
9.3.1 ANALYSIS OF RISK FACTORS FOR POST-SCT PTLD (IV)
The relation between the occurrence of post-SCT PTLD and the intensity of the immunosuppressive
treatment was further studied, to identify high-risk patient groups.
Of the 257 SCT patients, 133 (52%) were alive by June 2001 with a median follow-up time of 1490
days (556–2711), and 124 (48%) had died with a median follow-up time of 274 days (4–1661). The
cause of death was transplant-related in 76 patients (61%), relapse in 42 patients (34%), and other in
seven cases (5%). In all, 77 (62%) of the 124 deceased patients underwent autopsy. The analysis of
the post-mortem reports and the re-evaluation of the autopsy materials revealed or confirmed 19
cases of histopathologically verified PTLD, each presenting with disseminated, multiorgan
infiltration of lymphocytes (Table 1). According to the WHO classification, PTLD was
monomorphic in 12 patients, polymorphic in six patients, and Hodgkin’s-like in one case. Of all
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patients, ten showed monoclonality by immunoglobulin heavy-chain rearrangement as detected by
PCR.
In 14 cases, PTLD had been diagnosed before the present analysis. In seven of them, PTLD had
been diagnosed while the patients were alive based on the histology and positive EBV staining of
lymph node and kidney biopsies (LMP) (Patient No. 9) or liver biopsy (LMP) (No. 15), the
appearance of EBV positive (EBER and EBNA) and CD20 positive atypical lymphocytes in
circulation (Nos. 5 and 6), or the presence of high copy numbers of EBV-DNA in plasma by PCR
(Nos. 3, 16, and 19). After death, autopsy confirmed the diagnosis of PTLD in all of these patients
(Table 1, study IV). In addition, PTLD was diagnosed in seven more patients at autopsy (Table 1,
study IV). In five cases, PTLD was diagnosed as a result of the present study. PTLD was not
diagnosed in any of the survivors.
Six of the 19 patients with PTLD had been transplanted from a sibling donor and the remaining 13
patients from an unrelated donor. One PTLD patient with an unrelated donor had received
nonmyeloablative conditioning (fludarabine+TBI), and she was also the only PTLD patient having
received a blood stem cell graft. All other PTLD patients had been transplanted with a bone marrow
graft after myeloablative conditioning. In three patients with an unrelated donor, PTLD occurred
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after graft-versus-host disease (GVHD) induced by donor lymphocyte infusion (DLI) given for
post-transplant relapse.
In this re-analysis, confirmed PTLD occurred in 19 of the total of 257 patients (7.4%), in 19 of the
124 deceased patients (15.3%), in 13 of the 84 patients with an unrelated donor (15.5%), and in six
of the 173 patients with a sibling donor (3.5%). In 16 patients the onset of PTLD was early, and the
patients died at a median of 96 days (range 67–221 days) from transplantation. In the remaining
three patients, DLI with subsequent GVHD and its treatment was apparently the precipitating event
for PTLD.
9.3.2 CLINICAL PICTURE OF POST-SCT PTLD (IV)
The clinical and autopsy findings of the patients with PTLD are shown in Table 1 (study IV). The
clinical picture of PTLD lacked distinctive features. With one exception, all patients had fever
which appeared at a median of 72 days (29–162) after transplantation (or DLI), and at a median of
16 days (3–155) before death. During life only four patients had palpable lymphadenopathy, and in
addition two patients had lymphadenopathy diagnosed by computerized tomographic scan. At
autopsy, only six patients had enlarged lymph nodes, although all patients had multiorgan
lymphocyte infiltrations. In all, 11 patients showed reactive lymphocytes in circulation. The lactate
dehydrogenase concentration was elevated with a rapid increase before death in all patients studied
(18/19). Sera were available for EBV-PCR analysis from 13 patients and high copy numbers of
EBV- DNA were detectable in all of them at the onset of the symptoms and signs of PTLD. Before
transplantation, none of the 13 patients had EBV-IgM and all patients except one (No. 7) had EBV-
IgG in their sera, indicating past immunity.
For PTLD treatment three patients (Nos. 5, 6, and 16) received DLI, two patients (Nos. 3 and 19)
were treated with one infusion of Rituximab, and one patient (No. 15) with local irradiation and one
course of cytotoxic treatment (CHOP). The response was poor in all patients.
9.3.3 THE ROLE OF IMMUNOSUPPRESSION IN RELATION WITH PTLD (IV)
We noticed that all patients with PTLD had been treated with antithymocyte globulin (ATG) either
before transplantation, as part of conditioning (unrelated donor), or after transplantation for GVHD,
or both. Of the 257 patients, 64 had grade II–IV acute GVHD and were treated with high-dose
methylprednisolone (MP). In 30 patients the response to MP was poor, and the patients were given
ATG as the second-line treatment. Of the 36 patients given donor lymphocyte infusions (DLI), 11
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had grade II-IV acute GVHD after treatment. They were given varying doses of methylprednisolone
(MP) and only two patients with an unrelated donor received ATG as second-line treatment.
Among the 173 transplantations from a sibling donor, PTLD was diagnosed in six patients. They all
had experienced grade II–IV steroid-resistant acute GVHD and had been treated with ATG. By
contrast, among the 158 sibling donor recipients who had not been given ATG, none had PTLD
diagnosis. Of the 84 patients transplanted from an unrelated donor with ATG as part of the
conditioning, 13 developed PTLD. In nine PTLD patients, ATG had been given only before
transplantation. Three of the four patients given Thymoglobuline® 10 mg/kg/day and five of the 26
patients given Thymoglobuline 4 mg/kg/day on three days pretransplantation developed PTLD.
Eight of the 13 PTLD patients had not been treated for acute GVHD, one patient had had acute
GVHD grade II treated only with MP, and one PTLD patient had had steroid-resistant acute GVHD
treated with ATG. In addition, PTLD occurred in three of the 11 patients transplanted from an
unrelated donor who had post-transplant relapse and were treated with DLI. All the three patients
experienced grade II–IV acute GVHD induced by DLI and two of them were treated with ATG.
The use of ATG was a statistically significant risk factor for PTLD (P<0.0001), and the PTLD/ATG
correlation also remained significant when analysed separately in the groups with or without
GVHD.
In conclusion, following stem cell transplantations from an HLA-identical donor with a non-T-cell
depleted graft, the risk of PTLD correlated strongly with the intensity of the immunosuppressive
treatment. Intensive immunosuppression is a central factor in the development of PTLD, and in this
material, the relation between the PTLD and ATG treatment was found to be very close. None of
the patients who did not receive ATG developed PTLD.
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9.4 EBV INFECTIONS AND LIVER TRANSPLANTATION (V)
The goal of the next study was to clarify the incidence and clinical significance of EBV infections
after liver transplantation in Finland. Altogether, 105 liver transplant recipients during years 1999-
2002 were sequentially monitored for CMV, HHV-6 and HHV-7 during the first year after
transplantation, and the plasma samples were retrospectively studied for EBV-DNA by qPCR.
Only 4% (49/1284) of the plasma specimens were positive for EBV-DNA. EBV-DNA was detected
in fourteen patients (13%) during the first 12 months. Most patients had EBV-DNA concurrently
with CMV (71%) or together with HHV-6 (79%); however only one third of them (29%) had a
diagnosis of all three betaherpesviruses. Most patients had EBV-DNA within the first three months
after liver transplantation. All examples of low-level EBV-DNA positivity subsided quickly. The
peak viral loads of 13 patients were relatively low (median 2100 EBV-DNA copies/ml plasma,
range 568-6600) and EBV-DNA usually disappeared within a few weeks (Figure VIII). No clinical
signs or symptoms could be attributed to the EBV-DNAemias. Thus, all these EBV episodes of low










































Figure VIII. Viral loads in plasma of the 13 liver transplant recipients with low copy numbers of
EBV-DNA. From V, by permission.
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9.4.1 PTLD AFTER LIVER TRANSPLANTATION (V)
Although most EBV reactivations were harmless, PTLD was diagnosed in one patient. This patient
showed low-level EBV-DNA positivity on day 22 after transplantation, was negative thereafter
until day 49, and again was weakly positive up to day 70. On day 175 he suddenly developed a new
episode with high copy numbers continuing for six months (median 28 000 copies/ml, range 9851-
86 975 copies/ml). None of the other herpesviruses were activated during that time.
Clinical course of PTLD: In 2002 a liver transplantation was performed in a 49-year-old man with
liver cirrhosis. CMV infection and a partial thrombosis of the portal vein delayed the post-transplant
recovery. Six months after transplantation the patient became jaundice and a CT scan revealed an
infiltrative, neoplastic lesion in the head of the pancreas with dilatation of the bile ducts.
Histological biopsy showed PTLD, comprised predominantly of B-cells with severe proliferation.
The tumor was positive for EBNA by immunohistochemistry and for EBER by in situ
hybridisation. The immunosuppressive therapy except corticosteroids was interrupted. The patient
received five doses of Mabthera® (a monoclonal antibody against the CD20 antigen) without a
clinical response. Thereafter, radiation therapy and cytotoxins were given. The therapies were
interrupted for serious gastrointestinal bleedings from the tumor and septicemia. The patient died
six months after the diagnosis of PTLD.
In conclusion, concerning liver transplantations, EBV PTLD is a rare but hazardous disease. Low-
level EBV DNAemia is often harmless, temporary and concurrent with other beetaherpesviruses.
Also in liver recipients EBV qPCR seems to be crucial for PTLD diagnosis. During PTLD
treatment sequential monitoring of EBV DNA levels appears important and can be used to guide
therapy decisions.
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9.5 ANALYSIS OF 406 SCT RECIPIENTS WITH EBV qPCR (VI)
Altogether, 57 of 406 patients (14.0%) showed EBV DNA in at least one serum sample. The total
number of positive samples was 105 (1.9%) out of the 5479 samples studied.
Group I: Twenty two patients (5.4%) showed high (median 40 million) copy numbers of EBV
DNA. In all 22 patients the EBV copy numbers rose progressively, with peak levels occurring
shortly before death (14 patients), or the count was already high in the first positive sample (eight
patients). In the first positive sample of all 22 recipients, the median EBV-DNA copy number was
32 million, range 600-660 million. The difference between the last negative and the first positive
sample was 5-52 days (median 21 days). The median count in the last sample was 54 million
(median; range 50 100-1090 million); these last samples were taken at a median of 8 days (range 1
to 61 days) preceding death. The viral DNA was first detected at a median of 63 days (range 24 to
330 days) after transplantation, or at a median of 18 days (range 4 to 84 days) before death (Figures
IX and X). In one relapsed patient the EBV DNA appeared at ten months post-transplantation
following donor lymphocyte infusion-induced GVHD. All 22 patients died, and the diagnosis of
EBV-PTLD could be confirmed in autopsy in 15 cases showing disseminated infiltrates of EBV-
RNA containing lymphocytes.
Group II: In addition, 16 patients (3.9%) showed a positive EBV-PCR finding with a low copy
number, median 5370 (range 800 - 17 650) observable in only one or two samples before death (15
patients) or in the last sample available (one patient alive) (Table 4 & Figure IX). These terminal
samples had been collected at a median of 94 days (range 18 – 534 days) after transplantation, or at
a median of 69 days (range 3 – 444 days) before death. Five of these patients showed histologically
confirmed PTLD in the post-mortem study. The last serum samples of those five patients were
taken at a median of 80 days (range 4-230 days) before death. The other causes of death were
GVHD (six patients), other infections (one), relapses (two) and veno-occlusive disease (one).
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Table 4. EBV qPCR findings of the last samples in 16 patients with low terminal EBV-qPCR
finding in relation to time (mo) after transplantation and time (mo) before death. From VI, by
permission.
n Time (mo) after Time (mo)
EBV
DNA Death
transplantation to death count cause
1 0,6 0,1 7700 VOD
2 8,5 14,6 3220 Relapse
3 5,0 1,3 8910 Relapse
4 2,0 3,9 4190 PTLD
5 2,9 1,6 3080 Infection
6 2,0 0,2 1270 GVHD
7 2,0 7,7 3410 PTLD
8 2,5 0,7 8340 GVHD
9 5,1 1,1 800 PTLD
10 17,9 alive 2060
11 2,0 0,4 1355 GVHD
12 2,2 0,2 4990 GVHD
13 2,0 0,9 800 GVHD
14 2,4 0,1 15000 PTLD
15 3,0 0,8 3200 GVHD
16 3,0 0,7 17650 PTLD
Group III: Nineteen patients (4.7%) showed in serum transient EBV DNA positivity. At follow-
up, ten of these 19 patients had only one sample containing EBV-DNA (the initial positive sample);
seven patients had two positive samples, and two had three positive samples. The viral DNA was
first seen at a median of 98 days (range 24 – 537 days) after transplantation. The EBV DNA copy
numbers (median 6300; range 700 - 36 200) remained <50 000 in all patients. During follow-up
none of these patients was known to develop PTLD. Of these 19 patients seven are still alive.
Group IV, all the remaining patients: All in all, 349 patients (86%) had no detectable EBV DNA
in serum. During follow-up only two of these patients were known to develop PTLD, beyond
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Figure IX. Follow-up of the patients with fatal EBV infection; each line represents one patient. The
levels of EBV DNA in patients with transient EBV infection or low terminal copy numbers are































Figure X. The same EBV DNA loads as in Figure IX, plotted relative to death (marked with 0).
From VI, by permission.
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9.5.1 AN ALGORITHM TO DISTINGUISH BETWEEN SEVERE AND TRANSIENT EBV
INFECTION (VI)
We compared the EBV qPCR data of patients with fatal or transient EBV infection, and we created
an algorithm for prediction of the severity of EBV infection. As mentioned above, 22/406 (5.4%)
patients with fatal EBV-infection showed high (median 40 million) copy numbers of EBV DNA. In
all 22 patients the EBV copy numbers rose progressively or the count was already high in the first
positive sample. Transient EBV DNA positivity was seen in 19/406 (4.7%) patients. By comparing
the amount of EBV DNA and the rapidity of the increase in the EBV DNA levels, these two groups
of patients could be distinguished: The first criterion is the EBV DNA level in the first positive
sample: low (<50 000 copies/ml) or high (50 000 copies/ml). If this EBV DNA level is 50 000,
the patient can be classified as having life-threatening EBV infection. On the other hand, if this
initial EBV DNA level is <50 000, two possibilities exist: (i) The subsequent sample is EBV-qPCR
negative. Conclusion: the patient does not have life-threatening EBV infection. (ii) The subsequent
sample(s) is EBV-qPCR positive. Then, the rapidity of the increase in the DNA levels is
considered, according to the mean value of the derivatives of the log-transformed EBV DNA
values. If this value exceeds 3.6, the patient is at a high risk of having life-threatening EBV
infection (Figure XI).
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Figure XI. An algorithm was created by using the EBV PCR data of groups I and III for distinction
of the patients who had fatal EBV infection from those who had only transient EBV infection. The
patients with EBV infection of fatal outcome (red asterisks) fall above the cut-off, and those with
spontaneously resolving EBV infection (blue circles), below it. From VI, by permission.
In conclusion, low-level EBV-DNA positivity in serum occurs relatively frequently after stem-cell
transplantation and may subside without specific treatment. However, high molecular copy numbers
(>50 000) predict the development of PTLD very strongly, are not spontaneously reversible, and
warrant immediate treatment. Moreover, for identification of the patients with severe EBV
infection, we created an algorithm which distinguished all the patients with a fatal EBV infection
from those with a transient EBV reactivation. In the former patients unlike in the latter, with the
EBV DNA levels rising rapidly, the mean value of the derivatives of the log-transformed DNA
values exceeded the cut-off value of 3.6, cautioning against life-threatening EBV infection.
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10. DISCUSSION
10.1 CMV INDUCED EBV IMMUNOREACTIVATION (I)
We demonstrated with widely used EBV antibody assays that a large proportion of patients with
CMV primary infection showed antibody profiles of EBV recurrence: seroconversion of VCA IgM
and/or  fourfold rise of VCA IgG, together with high (or intermediate) avidity of EBV IgG.
Immunocompetent individuals and transplant recipients differed in the frequency of CMV-
associated EBV serodiagnosis (17% and 50%, respectively). In contrast, EBV primary infection
reciprocally did not appear to induce immunoreactivation of CMV.
In the literature, to date no single commonly accepted serological criteria exist for EBV
reactivation. Many different parameters have been used: rise of EA IgG or EA IgA titer (Hornef et
al., 1995), seroconversion of EA IgM (Hornef et al., 1995), decrease of EBNA IgG (Quesnal et al.,
1992; Taneichi et al., 1993; Hornef et al., 1995), presence of VCA IgM (Hornef et al., 1995),
increase of VCA IgG (Rahman et al., 1991; Quesnal et al., 1992; Glaser et al., 1994), or
simultaneous positivity to EA IgM and EBNA IgG (Obel et al., 1996). The ZEBRA protein (BamHI
Z EBV replication activator) controls the switch of EBV from a latent to a productive cycle
(Countryman et al., 1985 and 1987; Chevallier-Greco et al., 1986; Lieberman et al., 1986), and
ZEBRA IgG has been proposed as a serological marker for EBV reactivation (Maréchal et al.,
1993). On the other hand ZEBRA antibodies in healthy EBV-seropositives are rarely detectable,
they not uncommonly (75-87%) occur in patients with nasopharyngeal carcinoma, but also during
infectious mononucleosis (85%) (Joab et al., 1991; Mathew et al., 1994). In this study we chose
strict serological criteria for EBV reactivation: seroconversion of VCA IgM and/or  fourfold rise
of VCA IgG, together with high or intermediate avidity of VCA IgG.
In theory, rising levels of EBV antibodies in CMV primary infection could be due to polyclonal B-
cell stimulation, to antibody cross-reactivity, or to selective stimulation of memory B-cells, either
with or without virus replication due to endogeneous reactivation or exogenous reinfection.
Polyclonal antibody rises have been found long ago in CMV primary infection (Klemola et al.,
1969), but these are usually of the IgM class, in contrast with the extensive titer rises of high-
avidity VCA IgG found in many of our patients. Moreover, rising IgG for varicella zoster virus,
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another latently infecting herpes virus, was observed in only one of our CMV patients, which
further argues against general immunoactivation as a cause of our findings. It is unlikely that,
antigenic cross-reactivity between the betaherpesvirus CMV and the distantly related
gammaherpesvirus EBV would explain the high antibody titer rises; absorption studies have shown
no such cross-reactivity (Linde et al., 1990).
The vast majority of the patients with CMV-induced EBV immunoactivation also showed
immunoactivation for HHV-6. However, the specificity of the HHV-6 antibody rises is less clear-
cut than that of the EBV serodiagnoses. CMV and HHV-6 show high sequence similarity
(Efstathiou et al., 1988; Chou et al., 1992), and immunological cross-reactivities between these two
viruses have been detected in some but not all antibody adsorption studies (Irving et al., 1990;
Sutherland et al., 1991; Ward et al., 1991 and 1993). Kinetic differences have suggested that HHV-
6 antibody rises would be at least partially virus species-specific (Irving et al., 1990). In vitro virus
replication studies (Flamand et al., 1993) have also supported the possibility that EBV could serve
as a stimulatory cofactor for the induction of HHV-6 or vice versa.
Evidence is accumulating on virus-virus interactions in vivo. EBV reactivation by human
immunodeficiency virus (HIV) has been documented by appearance of EBV particles in blood and
secretions (Birx et al., 1986; Alsip et al., 1988; Diaz-Mitoma et al., 1990) and by the progressive
increase of VCA IgG in relation to a decrease in CD4 cell count (Quesnal et al., 1992). Findings
suggestive of EBV activation (coexpression of EA IgM and EBNA IgG) have been observed in
apparently immunocompetent (Färber et al., 1993) or immunosuppressed (Hornef et al., 1995)
patients with CMV infection. Our data provide the first unequivocal evidence for EBV
immunoreactivation in a large proportion of patients with CMV primary infection.
Since our work a case report has been published on EBV hepatitis with ascites, and subsequent
EBV recurrence during CMV primary infection (Rajwal et al., 2003). Drouet and colleagues (1999)
reported signs of CMV and EBV coinfections in graft recipients and speculated that CMV could
stimulate EBV replication and dissemination. Earlier, Meyer and colleagues (1996) noted the
importance of simultaneous active CMV and EBV infection in renal transplant recipients; severe
clinical symptoms were observed only in the group of combined CMV and EBV infections. These
authors proposed that simultaneous EBV replication might be an important co-factor for the
development of CMV disease.
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Our findings make it clear that, with widely used serological procedures a large number of CMV
primary infections are being diagnosed as EBV infections. Such errors can have serious
consequences during immune suppression or pregnancy, when CMV infections are severe.
Furthermore, it can be inferred from these results that the criteria of EBV serodiagnosis need
strengthening. Correct identification of the primarily infecting herpes virus requires serological
markers stronger than IgM detection or an IgG rise. Consistent with earlier data, our findings
showed the usefulness of IgG avidity determination in pointing out the primary infectious agent.
10.2 ROLE OF VIRUSES IN THE DEVELOPMENT OF MALIGNANCIES AFTER
HEART TRANSPLANTATION (II)
Six of the 249 patients after heart transplantation developed lymphomas, of which three were
positive for EBV RNA. This is in line with previous observations of the overrepresentation of EBV
positivity in post-transplantation lymphoproliferative disorders of the B-cell phenotype (Swerdlow,
1992; Boubenider et al., 1997; Liebowitz, 1998; Penn, 1999). Clinical CMV infection appeared to
occur more frequently in the patients who later developed EBV-positive lymphoma (2 of 3) than in
the patients who developed epithelial malignancies (2 of 14) and in the patients of the whole
transplant series (15%) (Mattila et al., 1997). This is interesting in the context of the oncogenic
potential of CMV in vitro (Raza, 1998; Cinatl et al., 1996; Boldogh et al., 1994). On the other hand,
as we concluded above, CMV infections may reactivate EBV in vivo (Hornef et al., 1995; study I),
which in immunosuppressed patients could possibly predispose to B-cell proliferation. However, it
is possible that both CMV disease and the EBV-positive lymphomas in our series merely had a
common, immunosuppression-related cause. Previously, the risk of non-Hodgkin’s lymphomas
after transplantation has been attributed to the aggressiveness of the immunosuppressive regimen
(Opelz et al., 1993).
The average follow-up time of the 20 patients who developed malignancies was 6.5 yr. The annual
risk for cancer was 1.2%, and excluding skin tumors (basal cell carcinoma and Morbus Bowen of
the skin), it was 1.0%. The incidence of new cancers (excluding basal cell carcinoma) in the Finnish
population of 5 million is 8900 (0.18%) a year. It thereby appears that the likelihood of malignancy
development after heart transplantation is severalfold higher than in the general population. The
incidence of cancer after heart transplantation in our material appears to be comparable to that
previously reported for heart and kidney recipients (Birkeland et al., 1995; Curtil et al., 1997).
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EBV in situ hybridisation (ISH) turned out to be an excellent method for detecting EBV in paraffin-
embedded – even old – tissue sections. The EBER transcripts are abundantly expressed in latency
(Arrand et al., 1982; Howe et al., 1986; MacMahon et al., 1994; Nanbo et al., 2002). With EBER
ISH it is easy to localise the EBV containing cells in clinical tissue samples. With this ISH method,
EBV has been localised to the Reed-Sternberg cells in Hodgkin’s disease (Wu et al., 1990). The
sensitivity of EBER detection has allowed for the detection of EBV not only in Reed-Sternberg and
Hodgkin’s cells, but also occasionally in small benign-appearing cells in tumour tissue (Weiss et al.,
1991; Herbst et al., 1992; Khan et al., 1992). EBER ISH works well also in PTLD diagnosis if the
suitable tissue samples are available. Oral hairy leukoplakia and some hepatocellular carcinomas
are the exceptions, in which EBERs are not expressed (Gilligan et al., 1990; Niedobitek et al., 1991;
Ryon et al., 1993, Sugawara et al., 1999). The specificity of the EBER ISH technique has been
confirmed by the lack of any background signal or cross-hybridisation in clinical tissues
(MacMahon et al., 1991; MacMahon et al., 1994). The EBERs are consistently expressed in EBV-
associated tumors regardless of the pattern of latent gene expression (MacMahon et al., 1994;
Nanbo et al. 2000).
Of note, cyclosporin A (CyA) induces immunosuppression by inhibiting the transcription of several
cytokines including interleukins 2 and 4 and gamma interferon by disrupting calcium-mediated
intracellular signals in T lymphocytes upon forming a complex with cyclophilin (Bierer et al., 1990;
Mattila et al., 1990), which inactivates the protein phosphatase calcineurin (Friedman et al., 1991;
Liu et al., 1991). The resulting immunosuppression may lead to an increased risk of
lymphoproliferative disease by impairing immunity to lymphotropic viruses such as EBV. Another
mechanism that might contribute to the development of malignancies during CyA treatment is
enhanced production of transforming growth factor beta (Li et al., 1991; Prashar et al., 1995), which
has been shown to enhance tumor growth in animal models (Hojo et al., 1999). Other
immunosuppressive drugs that are carcinogenic, azathioprine and cyclophosphamide, may also
contribute to the increased incidence of cancer among transplantation patients. Careful adjustement
of the immunosuppressive treatment can be expected to have a beneficial effect on prevention of
post-transplantation malignancies.
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10.3 LYMPHOPROLIFERATIVE DISEASE AFTER ALLOGENEIC STEM CELL
TRANSPLANTATION (III)
During 1994-1999 altogether 257 adult patients underwent allogeneic stem cell transplantation
(SCT) at Helsinki University Central Hospital. We determined by strict histopathological criteria
the incidence of fatal Epstein-Barr virus (EBV) – related PTLD, and set up a quantitative EBV-
DNA-PCR - to our knowledge the first quantitative “real-time” PCR assay in Finland for any
microbial pathogen - and assessed its diagnostic value by using ordinary serum samples. Our study
showed that the risk of developing PTLD is strongly associated with the type and intensity of
immunosuppressive treatment. None of the sibling-graft recipients who had not required aggressive
treatment for acute GVHD developed PTLD. However, the incidence of this disease was 14%
among the recipients from an unrelated donor (who all received ATG prophylactically), and 40%
among such recipients that had required ATG for therapy of GVHD. These findings are in line with
previous reports showing an increased risk of PTLD due to strong immunosuppressive measures
such as T-cell depletion of the graft or administration of ATG or anti-CD3-antibodies (Shapiro et
al., 1988; Zutter et al., 1988; Witherspoon et al., 1989; van Esser et al., 2001).
The lymphoproliferations were disseminated, with EBV-positive lymphocytes infiltrating several
organs; and most cases were clonal. The onset of PTLD in relation to donor cell administration was
early, i.e. within 6 months of SCT or DLI, and disease progression was rapid, in 15 days (range 2-
85) from initial symptoms to death. The clinical picture of PTLD lacked distinctive features,
making clinical diagnosis impossible. Due to the scarcity of lymph nodes for biopsy, histologic
techniques were of little use during the patients’ lifetime. Indeed, in the absence of a rapid and
reliable diagnostic method, PTLD in this retrospective series was diagnosed too late for treatment to
be effective.
All the PTLD patients exhibited EBV-DNA detectable in archived sera by real-time qPCR. The
diagnostic performance of this method, in terms of distinction of the PTLD cases from
corresponding controls, turned out to be excellent. With respect to EBV-DNA positivity in an
individual specimen, the diagnostic sensitivity according to study III was 100%, and also the
diagnostic specificity was very high (96%). Such a high specificity is in line with the absence of
viral DNA in plasma of solid-organ recipients carrying EBV chronically in memory B-cells
(Babcock et al., 2000; Rose et al., 2001). In serial specimens of the cases, but not of the controls,
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the EBV-DNA copy numbers rose rapidly and progressively towards approaching death. The
magnitude of the extracellular EBV-DNA loads in all our patients suggests that the early-onset
infiltrative PTLD involves lytic EBV infection. Similarly (yet not equally) high DNA loads have
been encountered in the present and earlier studies in patients with acute EBV primary infection
(Gan et al., 1994; Yamamoto et al., 1995; Meerbach et al., 2001; Chan et al., 2001; Brengel-Pesce
et al., 2002). Importantly, the appearance of viral DNA in serum preceded the PTLD symptoms, a
prerequisite for pre-emptive treatment.
10.3.1 PRE-EMPTIVE DIAGNOSIS OF LYMPHOPROLIFERATIVE DISEASE (III)
Based on our study it is evident that, for pre-emptive PTLD diagnosis among allogeneic stem-cell
transplant recipients by using quantitative EBV-DNA detection, serum is a highly recommended
sample type. In these patients, cytopenia during the first months is frequent, underlining the
diagnostic utility of serum or plasma relative to leukocytes. Several studies among stem-cell
recipients have quantified EBV-DNA in samples containing leukocytes (Lucas et al., 1998;
Yoshinobu et al., 1999; Gustafsson et al., 2000; Yang et al., 2000; Hoshino et al., 2001; Gärner et
al., 2002). Niesters and colleagues (2000), however, observed plasma to be an excellent sample type
for real-time PCR diagnosis of SCT-associated PTLD; a finding brifly reported earlier (Beck et al.,
1999) and recently confirmed (Berger et al., 2001; Meerbach et al., 2001; Ohga et al., 2001;
Brengel-Pesce et al., 2002). Also in solid-organ-PTLD, serum or plasma is suitable for EBV-DNA
quantification (Limaye et al., 1999; Lei et al., 2000; Wagner et al., 2001). On the other hand,
Stevens and colleagues (2001) stated that in lung transplant recipients with late-onset PTLD,
increased EBV DNA loads in blood are restricted to the cellular compartment; a discrepancy
warranting further study among the various forms of lymphoproliferative disease.
In conclusion, we have shown that EBV-associated early-onset PTLD is an important cause of
mortality also in matched, allogeneic non-T-cell depleted stem-cell transplantations. In light of the
rapidity of disease progression and the emergence of efficient therapeutics, regular monitoring of
EBV DNA levels in serum or plasma can be strongly recommended for routine practise in
profoundly immunosuppressed patients.
10.3.2 ANALYSIS OF RISK FACTORS FOR POST-SCT PTLD (IV)
In the present project, the possible risk factors for the occurance of PTLD were studied in order to
identify high-risk patients in view of prophylactic and pre-emptive treatment. During the years
1994-1999, a total of 257 adult patients underwent non-T-cell-depleted allogeneic stem cell
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transplantation at Helsinki University Central Hospital. Of the donors, 173 were siblings and 84
unrelated. In 250 cases, the conditioning was myeloablative and in seven cases nonmyeloablative.
In most patients the indication for transplantation was a hematological malignancy and in five
patients, aplastic anemia.
PTLD in general is a rare complication of allogeneic stem cell transplantation, yet intensive
immunosuppression increases its incidence (Zutter et al., 1988; Micallef et al., 1998; Lucas et al.,
1998; Curtis et al., 1999; van Esser et al., 2001). Our findings are in agreement with this notion. In
our study, 19 cases of PTLD were found among 257 consecutive allogeneic transplantations of non-
T-cell-depleted grafts from HLA-identical siblings or unrelated donors. In all cases, PTLD was an
early event with the first signs appearing at 29-162 days after the transplantation or donor
lymphocyte infusion, the median being 72 days. The incidence 7.4% (19/257) may be an
underestimate. The present analysis was retrospective and mainly based on the autopsy material,
and only about two-thirds of the succumbed patients were autopsied. No cases of PTLD were
diagnosed among the survivors. The present findings may, however, reflect relatively well the
actual situation, as the early type of PTLD usually is fatal (Zutter et al., 1988; Benkerrou et al.,
1998; van Esser et al., 2001).
The occurrence of PTLD was strongly associated with the degree of immunosuppression. No PTLD
developed among the patients having received a graft from a sibling donor without steroid-resistant
acute GVHD necessitating treatment with ATG. Of the 55 patients transplanted from an unrelated
donor with ATG as part of the conditioning, eight (15%) developed PTLD despite the absence of
GVHD. The larger immunological differences in the unrelated donor situation as compared to the
sibling donors – despite A, B, DR antigen match – may have contributed to the
immunosuppression. Where transplants are performed using graft from an unrelated donor, the
addition of low-dose corticosteroid to the GVHD prophylactic treatment consisting of cyclosporine
and methotrexate may have been a further contributing factor.
The present study also suggests a difference in the immunosuppressive effect between the different
ATG products in the doses used, which is in accordance with the study by Gaber and colleagues
(1998). They showed that the degree of T-cell depletion caused by Thymoglobuline® was
significantly greater and longer-lasting when compared to Atgam®. Thymoglobuline® was also
more effective in the treatment of acute rejection. In our study, the incidence of acute GVHD was
higher and the incidence of PTLD lower, among the patients who had been transplanted from an
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unrelated donor and given pretransplant Atgam® compared to those who had been given
Thymoglobuline®. In the immunosuppressive treatment after stem cell transplantation, the balance
between effective GVHD prophylaxis and the complications of immunosuppression is extremely
delicate. Since this study, the patient management in transplantation from an unrelated donor has
been modified by omitting corticosteroids from the GVHD prophylaxis as well as by reducing the
dose of Thymoglobuline®. The incidence of GVHD has somewhat increased, but those of viral
infections and PTLD significantly decreased (Volin et al., 2002).
EBV-induced PTLD is a serious and often fatal complication of allogeneic stem cell transplantation,
whereby it is of vital importance to identify the high-risk patients for early diagnosis and treatment.
Intensive immunosuppression is a central factor in the development of this complication, and in the
present material, the relation between the PTLD and ATG treatment was found to be close. None of
the present patients who did not receive ATG developed PTLD. Even in those who were given
ATG as part of the conditioning and who did not show any acute GVHD, the risk seems to be
increased, but the effect of the dose and the type of ATG still need further evaluation. The clinical
diagnosis of PTLD is almost impossible, as the symptoms and signs are unspecific. However,
quantitative measurement of EBV DNA in serum was in this as well as in other recent studies
shown to be a very useful for the prediction and the early diagnosis of PTLD (Kimura et al., 1999;
van Esser et al., 2002; Clave et al., 2004; Wagner et al., 2004; study III). The demonstration of
rapidly increasing or high levels of EBV-DNA allow early intervention with reduction of
immunosuppression and use of specific antibodies (e.g. Rituximab®) or donor lymphocyte infusion.
10.4 EBV INFECTIONS IN ADULT LIVER TRANSPLANTATION (V)
PTLD carries a significant mortality also in solid organ transplantations. Although several
publications on EBV viremia in stem cell transplant recipients exist, those after liver transplantation
mainly deal with pediatric patients and only a few have been published on adult liver transplant
recipients.
Pediatric and adult liver transplantations differ markedly concerning the risk for PTLD. For
pediatric patients the PTLD risk is particularly high in EBV primary infection (Newell et al., 1996).
Other risk factors are young age and the combination of EBV-positive donor and EBV-negative
recipients (Ho et al., 1988; Sokol et al., 1993; Cox et al., 1995; Walker et al., 1995). The incidence
of PTLD in pediatric patients varies between 3-13% depending on the immunosuppressive regimen
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(Ho et al., 1988; Malatack et al., 1991; Nalesnik et al., 1992; Newell et al., 1996; Jain et al., 2002),
whereas adult liver recipients have an overall low incidence of PTLD (0.8-3%) (Nalesnik et al.,
1992; Niedobitek et al., 1997; Jain et al., 2002). Monitoring of EBV DNA by quantitative PCR has
been shown to be effective for diagnosis of PTLD also among liver transplant recipients (Riddler et
al., 1994; Lucas et al., 1998; McDiarmid et al., 1998; Gridelli et al., 2000; Spada et al., 2001;
Matsukura et al., 2002).
In our study on adult liver transplant recipients, a low level of EBV-DNA was detected in 13% of
the patients. DNA occurred usually shortly after transplantation and together with reactivation of
other herpesviruses. EBV-DNA subsided within a few weeks. These EBV-DNA episodes seemed to
be clinically nonsymptomatic reactivations. One patient developed PTLD six months after
transplantation with increased amounts of EBV-DNA (median 28 000 copies/ml, range 9851-
86975). Before development of PTLD this patient had shown low-level and transient episode of
EBV-DNA and during PTLD he presented with high levels of EBV DNA. This finding is in
disconcordance with Barkholt and colleagues (2005). They had studied adult liver transplant
recipients with quantitative EBV PCR and they did not find higher EBV DNA loads in serum of the
one patient with PTLD compared with the other patients.
In our study on adult liver transplant recipients, plasma specimens and a real-time TaqMan assay
were used to quantify EBV viral loads. EBV-DNA was detected in 13% recipients with viral loads
of 568-6600 copies/ml plasma, in line with previous studies (Niesters et al., 2000; Wagner et al.
2001), while the peak viral load in the PTLD patient was 86 975 copies/ml. The same TaqMan-
based real-time EBV-DNA PCR turned out to be highly sensitive (100%) and specific (96%) in the
diagnosis of severe EBV infection in bone-marrow stem cell recipients (studies III and IV). The
technique is fast, user friendly and highly reproducible (Kimura et al., 1999; study III).
Furthermore, the MagNA Pure extraction simplifies the DNA extraction for this approach and
shortens its hands-on time (Stöcher et al., 2003; Fafi-Kremer et al., 2004). Of note, automated
extraction of EBV-DNA is easier to perform with whole blood or plasma than with PBMCs, and
facilitates the standardizaton of EBV DNA measurement (Fafi-Kremer et al., 2004). Real-time PCR
technology used here was suitable for consecutive screening of EBV DNA levels and could be used
in diagnosis and monitoring of EBV-induced lymphoproliferative disease in liver transplant
recipients.
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In our retrospective study, only one liver recipient showed high viral loads and developed PTLD
with poor clinical outcome. In conclusion, although most EBV reactivations were not severe, fatal
PTLD was diagnosed in one patient. As far as liver transplantations are concerned, EBV PTLD is a
rare but hazardous disease. Low-level EBV DNAemia is often harmless, temporary and concurrent
with other betaherpesviruses. Also in liver recipients EBV qPCR seems to be crucial for PTLD
diagnosis. During PTLD treatment sequential monitoring of EBV DNA levels is important and can
be used to guide therapy decisions.
10.5 SAMPLE MATERIAL FOR EBV qPCR: SERUM OR PBMC?
Quantitative PCR has been successfully performed with peripheral blood mononuclear cells
(PBMC), with unfractioned blood and with serum or plasma. As yet no consensus exists as to which
is the sample type of choice. All these materials have their pros and cons. When interpreting the
EBV DNA levels of different studies we must keep in mind that the DNA values are not
comparable because they have not been calibrated with a common standard.
Kimura and colleagues (1999), using PBMC for qPCR, studied 18 patients with symptomatic EBV
infections (four chronic active EBV infection, five PTLD, nine patiens with infectious
mononucleosis), ten unsymptomatic transplant recipients and 13 immunocompetent patients
suspected of having EBV primary infection. The mean load of EBV DNA in the PBMC was 103.7
copies/μg of DNA in the patients with PTLD, 104.1 copies/μg in the patients with chronic active
EBV infection, and 102.2 copies/μg in the patients with infectious mononucleosis. These numbers
were significantly larger than those for the recipients without EBV diseases or for the
immunocompetent controls. However, there was some individual overlap. The authors studied both
plasma and PBMC samples from one patient with infectious mononucleosis; the results were quite
uniform (Kimura et al., 1999). Tsai and colleagues (2002) reported the sensitivity of qPCR with
PBMC being only 39% in adult solid-organ recipients with PTLD. Wagner and colleagues (2004)
studied by qPCR the PBMC of SCT recipients and reported 11% with single episodes of high-levels
of EBV DNA (>4000 EBV copies/μg PBMC DNA) and 19% with 2 or more such episodes.
Altogether 9.4% of the recipients developed PTLD symptoms and were treated with EBV-specific
cytotoxic T cells or anti-CD20 antibody. Using PBMC for EBV qPCR Wagner and colleagues
(2004) recommended prompt rather than preemptive PTLD treatment.
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Stevens and colleagues (2001) suggested in a study on pulmonary transplant recipients that the
increased EBV loads in PTLD patients were restricted to the cellular blood compartment. Whole
blood includes all compartments that may harbour EBV, and has been claimed to be the best sample
type for the absolute EBV burden in circulation, as compared with isolated cell fractions (Leung et
al., 2004). Leung and colleagues (2004) studied EBV DNA loads using samples of unfractioned
whole blood in renal, hepatic, and cardiothoracic transplant recipients and found that the post-
transplant EBV loads were significantly higher than the pre-transplant levels. All recipients had
transient rises of EBV –DNA level, whereas that of one patient suspected to have PTLD continued
to rise (Leung et al., 2004). Whole blood EBV DNA quantification has been furthermore claimed to
be more appropriate for the purpose of advocating either prompt or preemptive treatment among
patients who might develop PTLD (Wagner et al., 2004). Scheenstra and colleagues (2004)
analysed whole blood samples of pediatric liver transplant recipients with competitive quantitative
EBV PCR and noticed that the EBV DNA loads are higher in patients with primary infection than
in those who are EBV seropositive before transplantation. In their study two patients who
developed PTLD had a high circulating viral load (20 500 copies/ml and 446 000 copies/ml)
(Scheenstra et al., 2004).
However, as a sample material, PBMC are difficult to obtain from cytopenic patients; such is often
the case when the immune reconstitution is delayed or during the course of Rituximab® therapy
(Yang et al., 2000; van Esser et al., 2002; Clave et al., 2004). Clave and colleagues (2004) studied
by qPCR both cell and plasma samples obtained after allo-SCT: EBV-DNA was seen in 50% of
PBMC and in 16% of samples of plasma, respectively. The patients who showed EBV DNA in
plasma displayed also the highest cellular viral loads (Clave et al., 2004). According to these and
earlier observations EBV DNA seems to appear in plasma or serum during more severe EBV
infections. Our PTLD patients showed increasing amounts of EBV DNA in serum upon progression
of the clinical disease; the levels of EBV DNA increased rapidly towards approaching death.
Niesters and colleagues (2000) reported very high levels of EBV DNA in plasma in PTLD (mean
540 000 copies/ml), moderately high levels in infectious mononucleosis (mean 6400 copies/ml) and
lower levels (mean 440 copies/ml) in transplant recipients without PTLD. Kullberg-Lindh and
colleagues (2006) analysed with qPCR serum specimens of pediatric liver transplant recipients; the
EBV DNA levels were significantly higher in primary symptomatic infection (mean 65 500
copies/ml) compared with primary asymptomatic infection (mean 3700 copies/ml). Also among the
recipients with non-primary EBV infection, the patient with PTLD had higher EBV DNA levels
than those without symptoms (5200 copies/ml v.s. 1360 copies/ml) (Kullberg-Lindh et al., 2006).
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The sensitivity of qPCR with serum samples seems to be exellent (studies III, IV, V and VI; Orii et
al., 2000; Kullberg-Lindh et al., 2006). The specificity is also better with serum; healthy subjects
with latent EBV infection have no EBV DNA in serum, and nonsymptomatic immunosuppressed
recipients have undetectable or low levels of EBV DNA in serum or plasma (studies III, IV, V and
VI; Niesters et al., 2000; Wagner et al., 2000; Brengel-Pesce et al., 2002; Clave et al., 2004;
Kullberg-Lindh et al., 2006). Additionally, also stored samples can be studied upon use of serum or
plasma. The actual volume of serum (or plasma) needed for qPCR assay of our type is very small
(200 μl). Quantification of EBV DNA in plasma or serum is the sample of choice especially in
situations where the cell counts are too low for reliable qPCR results,
10.6 TREATMENT OF PTLD
The cornerstone of PTLD treatment is general reduction of immunosuppression. Because of the
progressive nature of PTLD, the key to management is prompt or even pre-emptive treatment; with
infusions of anti-CD20 antibody, and possibly with donor lymphocytes or EBV-specific cytotoxic T
cells (Papadopoulos et al., 1994; Rooney et al., 1998; Ifthikharuddin et al., 2000; Kuehnle et al.,
2000; Verschuuren et al., 2002). Early recognition of PTLD is particularly important in the SCT
setting, because PTLD in these patients tends to be rapidly progressive (Loren et al., 2003).
10.6.1 REDUCTION OF IMMUNOSUPPRESSION
The effectiveness of immunosupression was described initially by Starzl and colleagues in 1984,
and has been substantiated by Tsai and colleagues (2001). Tsai and colleagues (2001) reported an
89% success rate for this strategy for patients who lacked all of the risk factors (organ dysfunction,
multiple visceral site involvement and a serum lactate dehydrogenase (LDH) value of >2.5 times
the upper limit of normal). So, early action is advisable, before overt PTLD has developed (Cesaro
et al., 2004). Even though withdrawal of immunosuppression in PTLD is clearly beneficial,
significant risks accompany this mode of treatment. In solid organ transplant (SOT) recipients, graft
rejection occurs as a complication in 39% of both responders and nonresponders (Tsai et al., 2001).
In patients with life-sustaining organ transplants such as hearts, livers and lungs, reduction in
immunosuppression should be moderate and closely monitored, as rejection may be fatal (Loren et
al., 2003). In SCT, complications typically manifest as increased risk for GVHD with significant
risk for morbidity and mortality. The EBV status does not predict the response to the reduction of
immunosuppression (Tsai et al., 2001).
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10.6.2 ANTIVIRAL THERAPY
A life-threatening disease, PTLD must be diagnosed and treated early for a favourable clinical
outcome. Reduction of immunosuppression remains the cornerstone of PTLD therapy and can result
in permanent cure (Loren et al., 2003). Initial attempts to prevent PTLD in the solid-organ
transplant population were focused primarily on using antiviral therapies, such as thymidine kinase
inhibitors ganciclovir or acyclovir, to eradicate or control EBV for high-risk patients (Loren et al.,
2003). These drugs inhibit the replication of other herpes viruses, such as herpes simplex and
cytomegalovirus. In vivo, however, they are ineffective against EBV, because EBV survives as an
episome outside of the lymphocyte’s genome. In addition, these drugs do not eradicate latently
infected B cells (Colby et al., 1980; Crumpacker, 1996; Loren et al., 2003). The reports that
prophylactic antiviral drugs minimize PTLD risk have been somewhat unconvincing, involving
very small numbers of patients in observational studies (Loren et al., 2003). Anecdotal reports of
acyclovir or ganciclovir for successful PTLD treatment have not been substantiated (Benkerrou et
al., 1993; Loren et al., 2003). However, most of the other therapies have been combined with high-
dose antiviral therapy, usually acyclovir. Thus, it is difficult to assess the true utility of antivirals.
An interesting approach involves the use of arginine butyrate to induce latent EBV thymidine
kinase expression, followed by treatment with ganciclovir (Faller et al., 2001).
The combination of reduction of immunosuppression and antiviral agents (ganciclovir, famciclovir
or valacyclovir) has also been used successfully with pediatric liver transplant recipients (Green et
al., 1997; Kogan et al., 1999; Holmes et al., 2002). Acyclovir and ganciclovir both demonstrate in
vitro activity against the linear (replicating) form of EBV, but neither agent is active against the
circular EBV episome in immortalized B cells. However, data from nonrandomized studies suggest
that sequential treatment with intravenous ganciclovir followed by oral acyclovir or intravenous
ganciclovir alone may be effective (Davis et al., 1995; McDiarmid et al., 1998; Holmes et al.,
2002). Interestingly, treatment with CMV IgG has yielded promising results: Holmes and
colleagues reported (2002) on five patients with PTLD, who did not respond to the initial
interventions, and were subsequently given intravenous CMV IgG. CMV IgG contains in high titers
antibodies from pooled adult plasma, and also IgG antibodies against EBV in concentrations similar
to those in standard intravenous immunoglobulin products (Holmes et al., 2002). The EBV DNA
PCR level fell in all five of these patients during the course of CMV IgG treatment. A similar
outcome (reduced EBV DNA PCR levels after reduction of immunosuppression, antiviral therapy,
and CMV IgG) has been reported by others (Green et al., 1997 and 1998; Kogan et al., 1999).
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10.6.3 EBV-SPECIFIC CYTOTOXIC T CELLS
Heslop together with his colleagues and Rooney with his colleagues demonstrated that PTLD
resolved after transfer of EBV specific cytotoxic T lymphocytes (CTLs) grown from donor PBMCs.
The method utilized the donor’s autologous EBV-immortalized lymphoblastoid B-cell lines (LCLs)
cocultured with donor PBMCs in the presence of interleukin-2. LCLs can activate polyclonal EBV-
specific CTLs. The adoptive transfer of EBV-specific CTLs grown from donor PBMCs was
successful both in prophylaxis and treatment of PTLD in BMT recipients. These EBV-specific
CTLs not only persist for long periods in BMT patients and contribute to a memory CTL response
but they also proliferate in vivo in the presence of immunosuppressive agents (Heslop et al., 1996;
Rooney et al., 1998; Davis and Moss 2004).
A modification of the protocol for growing ex vivo-derived EBV-specific CTLs using autologous
LCLs was successful in stimulating PBMCs from SOT patient with PTLD (Khanna et al., 1999).
Adoptive transfer of EBV-specific CTLs into the patient resulted in regression of tumor burden
without autoreactivity or graft rejection. Sherrit and colleagues (2003) demonstrated that EBV-
specific CTLs expanded both the magnitude of a memory CTL response and prevented the
recurrence of PTLD. Other studies have also successfully used adoptive transfer of autologous
EBV-specific CTLs both in prophylaxis and treatment of PTLD in SOT recipients, particularly in
early-onset disease (Savaldo et al., 2001; Comoli et al., 2002). One problem with using EBV-
specific CTLs is the time required to generate sufficient numbers of cells for infusion. If a patient
presents with PTLD without PBMCs being collected previously, it takes approximately 3 months to
generate EBV-specific CTLs (Davis et Moss, 2004). Thus alternative treatments such as
chemotherapy, surgical removal of tumor, or anti-CD20 monoclonal antibody therapy are often
commenced. Ideally, a bank of autologous EBV-specific CTLs should be generated and stored for
all SOT patients at high risk of developing PTLD (Davis et Moss, 2004).
As most SOT patients at high risk of developing PTLD are seronegative at the time of
transplantation, it is not known how soon post-transplant EBV-specific CTLs can be grown from
these patients (Davis et Moss, 2004). The ability to generate autologous EBV-specific CTLs from
EBV-seronegative people has been investigated; LCL-stimulated EBV-specific CTLs grown from
seronegative adults were CD3+CD8+ and cytotoxic, but CTLs grown from seronegative children
were CD4+CD25+ and did not recognize autologous LCLs (Savaldo et al., 2002). However,
CD4+CD25+ T cells positively selected from PBMCs stimulated with dendritic cells from these
children expanded into EBV-specific CTLs capable of HLA class II-restricted killing (Savaldo et
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al., 2002). This method could potentially be used to select for EBV-specific CTL precursor cells in
EBV-seronegative patients prior to transplantion, in order to generate an immunotherapy for PTLD.
10.6.4 ALTERNATIVE PTLD THERAPIES FOR SOT PATIENTS
An alternative for the use of autologous EBV-specific CTLs in the treatment of PTLD is the use of
partially HLA-matched allogeneic CTLs from an unrelated donor. It is known that EBV-positive
individuals with particular HLA types will almost always have EBV-specific CTLs that will
respond to particular immunodominant EBV epitopes (Davis et Moss, 2004). For example, HLA B8
individuals will respond to the EBNA 3 epitope FLRGRAYGL, and HLA A2.01 EBV-specific
CTLs will recognize the lytic BMLF1 epitope GLCTLVAML (Burrows et al., 1990; Steven et al.,
1997). A polyclonal EBV-specific CTL culture from an HLA A2 donor with broad reactivity to a
range of lytic and latent EBV proteins should recognize and kill tumor cells in an HLA A2 SOT
patient with recipient-origin PTLD (Davis et Moss, 2004). This hypothesis has been tested in a SOT
patient with PTLD, and a single infusion of HLA-matched allogeneic CTL resolved the disease
without compromising the graft function or inducing autoimmunity (Haque et al., 2001). This study
was extended, and complete remission was induced in three of five patients with early localized
PTLD, while the two patiens had no response (Haque et al., 2002). Thus, allogeneic HLA-matched
EBV-specific CTLs can be used for the treatment of PTLD in patients with common HLA types,
when autologous CTLs are not available.
10.6.5 ANTI-CD20 MONOCLONAL ANTIBODY
An emerging therapy for PTLD is the anti-CD20 monoclonal antibody. Typically, four to six doses
of anti-CD 20 antibody are administered i.v. weekly, which usually depletes CD20+ B cells for over
12 months (Davis et Moss, 2004). Anti-CD20 antibody was initially utilized to treat chemotherapy-
refractory Hodgkin’s lymphoma (Keilholz et al., 1999), and phase II studies indicated that it was
effective and well tolerated with few side effects (Rehwald et al., 2003; Ekstrand et al., 2003). The
overall response was very good; complete remission was observed in 40-60% of Hodgkin’s
lymphoma patients, and a partial response in most other patients (Davis et Moss, 2004). In one
study, the potential for tumor relapse was significant (9/22 patiens), with a median time of only ten
months, thus raising questions of long-term efficacy (Ekstrand et al., 2003).
A study involving twelve BMT children with PTLD indicated that only one of 48 infusions of anti-
CD20 antibody was associated with a grade II adverse event, and eight children went into complete
remission (Faye et al., 2001). Another study tested anti-CD20 antibody on three SOT patients with
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PTLD; the outcome was one complete remission, one relapse two months later, and one death from
hypogammaglobulinemia-associated aspergillus infection (Verschuuren et al., 2002). The reduction
of EBV DNA levels in PBMCs after anti-CD20 treatment is immediate, but this does not always
correlate with remission of PTLD (Yang et al., 2000). A combination of anti-CD20 antibody
treatment followed by adoptive transfer of EBV-specific CTLs may enhance EBV immunity in
PTLD patients, and thus reduce relapse of disease (Davis et Moss, 2004).
10.6.6 LOCAL TREATMENT
When possible, complete surgical excision of localized disease is effective. Localized disease
treated with definitive local therapy (surgery or radiation), combined with reduction of
immunosuppression, has an excellent prognosis: PTLD-related mortality rates have reported
between 0 and 26% (Benkerrou et al., 1993; Davis et al., 1998; Tsai et al., 2001; Loren et al., 2003).
10.6.7 CYTOKINE THERAPY
Attemps to establish a competent immune system to control EBV-related lymphoproliferations with
immune modulators such as cytokines with or without immunoglobulins have been made. Case
series and case reports have described reponses to interferon- and interferon- combined with
intravenous IgG (Shapiro et al., 1988; Faro et al., 1996; Davis et al., 1998; Gross et al., 1999; Loren
et al., 2003). Interleukin-6, a cytokine that promotes the growth and proliferation of B cells,
provides another potential target (Loren et al., 2003). It is difficult to assess the effectiveness of
cytokine therapy as most studies have also incorporated concurrent reduction in
immunosuppression or antiviral agents. Early reports are encouraging (Shapiro et al., 1988;
Benkerrou et al., 1993; Faro et al., 1996; Davis et al., 1998; Haddad et al., 2001).
10.6.8 CYTOTOXIC CHEMOTHERAPY
Chemotherapy has also been used to treat PTLD, generally after the patients have failed to respond
to surgical excision with or without reduction of immunosuppression. Regimens are similar to those
used for non-Hodgkin’s lymphoma, such as CHOP (Loren et al., 2003). While chemotherapy may
occasionally provide long-term relapse-free survival, it is accompanied by a high infection and
mortality rate (Swinnen et al., 1995; Mamzer-Bruneel et al., 2000; Loren et al., 2003).
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10.6.9 CONCLUSION OF PTLD THERAPY
PTLD is an often-fatal complication of both solid-organ and stem cell transplantation. Early
diagnosis of PTLD is important and requires high levels of clinical vigilance. Reduction in
immunosuppression remains the primary therapy for PTLD and can often result in permanent
disease eradication. Further therapies should be tailored to the patient and clinical situation.
Treatment with anti-CD20 antibody of SCT recipients seems to be succesful.
10.7 EBV NEGATIVE PTLD – A DIFFERENT ENTITY?
PTLD is usually, but not invariably, associated with EBV. The reported incidence of EBV-negative
PTLD varies widely, and it is uncertain whether it is analogous to EBV-PTLD. Leblond and
colleagues (1998) reported that PTLD were EBV negative in 34% of patients based on LMP-1
immunostaining, EBER ISH, and in most patients on Southern blot analysis. The EBV-negative
PTLDs occurred later than did the EBV positive cases (Nelson et al., 1996; Leblond et al., 1998;
Nelson et al., 2000). The EBV-negative cases were monomorphic B-cell PTLDs or polymorphic
clonal PTLDs, and the prognosis was very poor (Leblond et al., 1998). Nelson and colleagues
(2000) reported that as many as 21% of PTLD patients (17/80) had an EBV-negative PTLD; and
14% of all samples (18/133) were EBV negative. Of the 17 patients with EBV negative PTLD,
eight had liver transplants, six kidney transplants, two heart transplant, and one bone marrow. The
incidence of EBV negative PTLD seems to be increasing; all but one of the EBV negative PTLDs
occurred after 1990 (Nelson et al., 2000). Four patients with EBV-negative PTLD, all with clonal B
cells, showed complete remission with mere reduction of immunosuppression (Nelson et al., 2000).
Of the nine patients with EBV negative monomorphic PTLD, seven died despite chemotherapy
(Nelson et al., 2000). Leblond and colleagues (1998) reported EBV negativity to be an adverse
prognostic indicator: 9/11 patients with EBV-negative PTLD died, including seven treated with
chemotherapy. The two survivors received combination chemotherapy, and one was disease free at
44 months, while the other was only in partial remission at 12 months. Therefore, EBV-negative
PTLDs have distinct features, yet some do respond to decreased immunosuppression, similar to
EBV-positive cases (Nelson et al., 2000).
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10.8 FURTHER IMPLICATIONS OF EBV qPCR
In conclusion, quantitative PCR for EBV DNA seems to be an exellent approach for diagnosing
EBV infections and most importantly PTLD in transplant recipients. Also, cell-free EBV DNA has
been detected in the plasma and serum of patients with nasopharyngeal carcinoma (NPC)
(Mutirangura et al., 1998; Lo et al., 1999). Lo and colleagues (1999) observed continuously low or
undetectable levels of EBV DNA in serum samples among patients who remained in remission.
This suggests that quantitation of cell-free EBV DNA may be a valuable tool for monitoring of
NPC patients against tumor recurrence. Bortolin and colleagues (2006) followed up a large cohort
of patients with undifferentiated carcinoma of nasopharyngeal type (UNCT) in Italy and noticed
during follow-up a statistically significant difference of EBV DNA loads between patients with and
without clinical relapse. They concluded that EBV DNA reflects the biological activity of UNCT
and may be a prognostic factor also in a low-incidence region. However, quantitative EBV PCR is
not suitable for a screening test for individuals at high risk for nasopharyngeal carcinoma (Yang et
al., 2006).
In EBV-positive lymphomas among immunocompetent patients, release of EBV DNA from tumor
cells to plasma could be useful for disease monitoring. Au and colleagues (2004) quantified serially
plasma EBV DNA by qPCR in 39 cases of EBV positive (natural killer cell 23, T cell 8, B cell 4,
Hodgkin 4) lymphomas. In all cases of EBV-positive lymphomas, EBV DNA was detectable at
diagnosis (105-1010 copies/ml). It paralleled the clinical course, with EBV DNA becoming
undetectable at remission and remaining elevated in refractory disease. On multivariate analysis
high-level presentation of EBV DNA (<7.3 x 107 copies/ml) was significantly associated with an
inferior overall survival. Au and colleagues (2004) concluded that in EBV-positive lymphomas,
plasma EBV DNA is valuable as a tumor biomarker and for prognostication. Recently, Gandhi and
colleagues (2006) reported that EBV-DNA in plasma can be used as a non-invasive biomarker for
EBV-positive Hodgkin’s lymphoma and serial monitoring of EBV DNA levels could predict
response to therapy.
EBV is also associated with pathogenesis of AIDS lymphoma and viral DNA is present within the
malignant cells in about half of the patients. Fan and colleagues (2005) analysed by quantitative
PCR, EBV-DNA in plasma of all EBER-positive AIDS lymphoma patients, and the viral loads fell
rapidly upon initiation of treatment except in two patients with persistent tumor. They concluded
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that EBV qPCR is very promising in diagnosis and management of EBV-related lymphomas.
Detection of EBV DNA in the cerebrospinal fluid (CSF) is associated with AIDS-related brain
lymphoma. Bossolasco et al. (2002) quantified EBV DNA in CSF and plasma from patients with
AIDS-related non-Hodgkin’s lymphoma (NHL). High CSF EBV DNA levels were found in HIV-
associated brain lymphomas. Bossolasco and colleagues (2006) have recently quantified EBV DNA
load in CSF of patients with HIV-related brain lymphomas: they noticed the EBV loads to be
significantly lower during and after ganciclovir treatment indicating that this drug might be useful
in management of HIV-related CNS lymphoma.
10.9 EBV INFECTIONS AFTER ALLOGENEIC STEM CELL TRANSPLANTATION (VI)
Our final goal was to determine the number and clinical significance of EBV infections, and their
relation with EBV-associated PTLD in a large cohort on unselected SCT recipients. Of the 406 SCT
performed in Helsinki during 1988-1999, 5479 consecutive samples of serum were retrospectively
studied by EBV qPCR.
Altogether, EBV infections after stem cell transplantation were relatively common; 14% of our
patients had detectable EBV-DNA in at least one serum sample. This is in concordance with others’
observations; Cesaro and colleagues (2004) reported EBV reactivation (as determined by increasing
viral load by qPCR) in 53% of pediatric allo-SCT recipients. The higher rate of EBV DNA
positivity in that study may have been be due to two (or more) reasons; the patients were children
(median age 9.6y), and the sample material was blood mononuclear cells. The only risk factor
significantly associated with EBV reactivation was ATG. Earlier, van Esser and colleagues (2001)
analysed plasma samples from adult SCT recipients using qPCR and reported an indicidence of
EBV reactivation of 28%. In that study, none of the unmanipulated SCT recipients developed
PTLD. Clave and colleagues (2004) detected EBV DNA in peripheral blood mononuclear cells of
50% (28/56) of allo-SCT recipients. Plasma EBV DNA was detected in 16% (9/56) of recipients,
who also displayed the highest cellular viral loads (Clave et al., 2004).
In the present retrospective study 22 (5.4%) recipients showed high copy numbers (>50 000) of
EBV DNA. The EBV-DNA levels of these patients rose progressively, with the peak levels
occurring shortly before death, or with the counts high already in the first positive sera. The
prognosis of these patients was sinister; all cases were fatal. Cesaro and colleagues (2004) observed
in 35% of their pediatric SCT patients EBV DNA counts of  300 gekv/100 000 PBMC; the
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immunosuppression was electively reduced in patients who exceeded this cut-off. In that study,
16% of all the recipients showed clinical symptoms of EBV infection (i.e. fever, lymphadenopathy,
hypertrophy of Waldeyer’s ring), and PTLD was diagnosed in one (1%). However, no deaths
caused by PTLD were observed among patients with EBV reactivation. Wagner and colleagues
(2004) studied by qPCR the PBMC of SCT recipients, of whom 11% (9/85) showed single episodes
of a high EBV DNA level (>4000 EBV copies/μg PBMC DNA) and 19% (16/85) showed two or
more episodes. 9.4% (8/85) of all recipients developed symptomatic PTLD and were successfully
treated with EBV-specific cytotoxic T cells (two patients), anti-CD20 antibody (five patients) or
both (one patient). In all the eight patients clinical symptoms associated with increased EBV load
disappeared. With EBV qPCR screening Wagner and colleagues (2004) recommended prompt
rather than pre-emptive treatment, following the onset of PTLD symptoms.
Of our 22 (5.4%) recipients with severe EBV infection, all except one showed EBV DNA very
early, within two months (median) after transplantation. In one patient however, the EBV DNA
appeared after DLI, at ten months post-transplantation. All the patients with excessive amounts of
EBV DNA had an aggressive type of disease: the time from the first EBV-DNA-containing sample
to death was 18 days (median). These observations are in concordance with our earlier studies
(study III). In addition, 16 (3.9%) stem cell recipients showed a low-level EBV-DNA in the last
sample preceding death. Five of these patients showed in post-mortem study histologically
confirmed fatal PTLD; such last samples of these five patients were taken 80 days (median)
preceding death.
By contrast, 19 (4.7%) patients showed only transient EBV-DNA positivity, during the first three
months (median) after transplantation. The EBV DNA copy numbers of this group remained
significantly lower compared to the patients with fatal EBV infection; only one of these patients had
a relatively high level (36 200 copies) of EBV DNA. Importantly, the EBV DNA of all these
patients disappeared without clinical intervention, and none developed EBV PTLD during follow-
up. Our data thereby show that low-level EBV DNA positivity in serum occurs frequently and may
resolve spontaneously.
For identification of the patients with severe EBV infection, we created an algorithm which
distinguished all the patients with a fatal EBV infection from those with a transient EBV
reactivation. In the former patients unlike in the latter, with the EBV DNA levels rising rapidly, the
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mean value of the derivatives of the log-transformed DNA values exceeded the cut-off value of 3.6,
cautioning against life-threatening EBV infection.
In conclusion, low-level EBV-DNA positivity in serum occurs relatively frequently after stem-cell
transplantation and may subside without specific treatment. However, high molecular copy numbers
(>50 000) predict the development of PTLD very strongly, are not spontaneously reversible, and
warrant immediate treatment. Based on the EBV qPCR data, we furthermore created an algorithm
that distinguished the patients with severe EBV infection from those with transient infection.
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